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Abstract 
Ultrasound Sensitive Polymeric Drug Carriers for Treatment of Solid Tumors 
John Eisenbrey 
Margaret A. Wheatley, PhD 
 
 
 
Ultrasound contrast agents (UCA) are comprised of microbubbles stabilized 
by a shell.  The benefits of ultrasound (US) to parenteral drug delivery are well 
documented. In conjunction with US-induced cavitation of co-administered UCA 
they include an increase in drug efficacy due to increases in both vascular gap 
junctions and cellular membrane permeabilities. We have developed a drug-loaded 
UCA which upon reaching the desired site (generally a solid tumor) ruptures under 
the influence of the focused US. UCA cavitation, combined with acoustic radiation 
forces, and the enhanced permeation and retention effect (EPR) are expected to 
increase tumor uptake of the produced fragments, providing a sustained, intratumoral 
release of any associated drug.  
In this thesis, poly (lactic acid) (PLA) UCA have been developed for drug 
delivery utilizing doxorubicin (Dox). These agents provide 15-20 dB of US contrast 
enhancement both in vitro and in vivo.  The agents have been optimized to 
encapsulate Dox while maintaining a high sensitivity to US. Prior to sonication these 
agents have a mean diameter of 1.4-1.8 µm, restricting them to the vasculature until 
rupture.  In vitro data indicate particles reach sizes of 200-400 nm after sonication.  
Electron microscopy of ruptured particles depicts both fragmentation and shriveling 
of shells, resulting in sub-micron, drug loaded particles.  
In vitro these agents become significantly more potent to the human breast 
cancer cell line MDA-MB-231 after sonication, nearly doubling the degree of cell 
 xx
death compared to non-insonated controls (p=0.0272). Microscopy shows that Dox 
from the fragments is transported to the cell nucleus once within the cell. 
Additionally, during US triggered generation, Dox eluting species can be forced 
through a 0.4 µm membrane. These data demonstrate potential for a PLA-Dox UCA 
platform to deliver Dox eluting nanoparticles to the tumor interstitium. Elution 
profiles have been measured, indicating that 76% of drug payload is released over a 
24 day period. 
Studies using VX2 tumors in rabbits show the activated platform is detectable 
within tumor vasculature and results in substantial increases in intratumoral drug 
levels with greater than a 100% increase in delivery efficiency compared to the non-
insonated platform (p=0.004) 
 1
 
1. INTRODUCTION 
 
 
Cancer results from an uncontrolled change in cell differentiation. More than 
85% of cancers involve the formation of solid tumors, nearly half of which 
metastasize and frequently lead to death [1]. Current chemotherapeutic treatments 
lack specificity, resulting in both undesired systemic toxicity and low efficacy. 
Although chemotherapy is one of the most common forms of treatment, it is severely 
dose limited by the need to control side effects. Additionally, direct drug delivery to 
solid tumors is inhibited by their irregular vasculature and uneven blood flow [2]. 
These shortcomings have resulted in a focus on development of efficient “smart” drug 
delivery vehicles which exploit unique properties of the tumor. One such property is 
the formation of larger vascular gap junctions within tumor vasculature, with pores as 
large as 10 times greater than healthy tissue and lack of adequate drainage. This 
results in the propensity of nanoparticles (NP) to aggregate within the tumor 
interstitia through a phenomena well described as the enhanced permeation and 
retention (EPR) effect [3]. 
Ultrasound contrast agents (UCA) generally consist of a gas microbubble 
stabilized by an outer shell. These agents are injected intravenously and are small (<8 
µm) enough to circulate through the capillaries. Recent research has focused on the 
development of drug loaded UCA. Focused ultrasound on an area of interest can be 
used to trigger release, resulting in localized drug delivery. Additionally, UCA 
oscillation and rupture during insonation have been shown to lead to increased cell 
 2
permeability and transport of larger (up to 500 nm) particles out of the vasculature, 
increasing the efficacy of these platforms [4-7].   
Here we describe the development and proof of concept of drug loaded poly 
(lactic acid) (PLA) shelled UCA. The majority of reported research on drug loaded 
UCA focuses on immediate release of the drug upon UCA rupture [8-10], resulting in 
a rapid, transient release of free chemotherapeutic.  While these platforms represent 
an upgrade over the traditional chemotherapy approach, we feel a platform capable of 
delivering encapsulated chemotherapeutics to the tumor interstitia instead of release 
of free drug within the tumor vasculature would represent a substantial improvement 
in drug loaded UCA delivery platforms. This platform would benefit from the 
previously described advantages of both localized delivery and the biophysical effects 
of UCA oscillation and rupture. Additionally, in situ generation of drug loaded NP 
within the tumor would lead to further increased uptake of encapsulated drug through 
the EPR effect, and these fragments could potentially provide a sustained, 
intratumoral chemotherapeutic release during polymer degradation.  
 
1.2 Thesis Objectives: 
 
The overall goal of this research is the development of a doxorubicin (Dox) 
loaded PLA UCA that allows direct, local delivery of encapsulated chemotherapeutic 
to the tumor interstitial. This approach will result in decreased side effects and 
increased efficacy of the encapsulated drug. Towards this goal, we will use a strategy 
comprised of four specific aims. 
 
 3
 
Specific Aim 1: To develop, characterize, and optimize methods of fabricating 
Dox loaded PLA ultrasound sensitive drug carriers. 
Within our laboratory we have previously examined methods of loading poly 
(lactic co glycolic) (PLGA) UCA with drugs and proteins of varying molecular 
weights and hydrophobicities [11]. However, since studies have shown fabrication 
using PLA results in UCA that provide higher levels of enhancement and stability, a 
detailed study of drug-loading capacity of this agent is important. [12]. Two methods 
of Dox surface coating and one method of shell incorporation are investigated in this 
thesis. Choice of loading method and concentration was determined based on drug 
payload, encapsulation efficiency, UCA size, surface morphology, ultrasound 
enhancement, stability, and drug release during UCA destruction.  Additionally, the 
agent must be able to be sterilized without compromising these qualities for in vitro 
and in vivo applications.  The study was based on the hypothesis that using 
modifications of a previously optimized double emulsion method, PLA Dox loaded 
UCA can be fabricated maintaining their smooth surface morphology, small particle 
size (< 8 µm), high degree of ultrasound enhancement (15-20 dB), and stability 
during insonation. Additionally, this agent should incur minimal drug release during 
UCA destruction to avoid bolus release of the toxic chemotherapeutic. 
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Specific Aim 2: To determine the platform’s ability to cause cell death in vitro 
pre and post ultrasound triggering using a human breast cancer cell line.  
 The ultrasound sensitive platform or platforms selected in specific aim one’s 
ability to cause cell death has been investigated in a human breast cancer cell line 
(MDA-MB-231) in vitro. The ideal delivery platform will show minimal cell death 
when combined with ultrasound activation (corresponding to minimal cell death at 
non- targeted areas in future in vivo applications), and maximal cell death after 
ultrasound triggering (corresponding to increased cell death in targeted areas in future 
in vivo applications). Additionally, mechanisms of action have been compared by 
examination of multiple controls, insonation parameters, and cell death over time. 
Mechanisms of drug uptake are examined by microscopy. These studies are based on 
the hypothesis that the selected platform will become significantly more potent when 
combined with ultrasound relative to the uninsonated control. Encapsulation or 
attachment of the Dox within the UCA is beleived to partially shield the drug’s 
bioeffects, limiting cell death prior to triggering. Using the ideal platform, destruction 
of Dox loaded UCA leads to more exposed Dox within the agent, higher cell uptake, 
and ultimately higher cell death rates. It was also expected that the activation of the 
Dox loaded agent through ultrasound triggered rupture would prove more efficacious 
compared to free Dox, due to the well documented bio effects of both ultrasound and 
cavitating UCA increasing cellular uptake. 
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Specific Aim 3: To examine the platform’s ability to reduce in size during 
insonation and to transport encapsulated Dox through a nano-pore membrane 
in vitro.  
 Modes of UCA destruction have been well documented in the literature. It is 
believed that our polymer shelled agent undergoes fragmentation during UCA 
rupture. This thesis explores the hypothesis that ultrasound triggered destruction of 
our drug loaded agent results in PLA-Dox particles on the nano-scale, small enough 
to penetrate leaky tumor vasculature. The potential to produce Dox loaded NP in situ 
enables the platform to exploit the EPR effect within solid tumors, limit 
extravasations within healthy tissue, and take advantage of UCA bioeffects during 
generation. Particle sizing, scanning electron microcopy, and confocal microscopy are 
used to confirm generation of PLA-Dox NP. Effects of insonation pressure and 
insonation time on the agent’s size are also examined. 
 The ability of PLA-Dox NP to pass through membranes in vitro have also 
been investigated as a model for particle extravasation through leaky tumor 
vasculature in vivo. The experimental design is based on the hypothesis that PLA-
Dox NP generated after UCA fragmentation will be small enough to pass through a 
400 nm membrane filter (similar to the pores found in leaky tumor vasculature. 
Acoustic radiation forces and UCA cavitation are believed to aid in the extravasation 
of PLA-Dox NP through both synthetic and endothelial cell-created membranes in 
vitro. While this setup is used primarily as a proof of concept model, ultrasound 
parameters have also been explored for optimization of Dox transport. Additionally, 
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combinations of Dox loaded UCA and Dox loaded solid NP are investigated to 
determine optimal methods of Dox delivery. 
 Finally, drug elution rates are examined in vitro to determine the ability of 
Dox-PLA fragments to provide a sustained release from their location in tumor 
interstitium. This information will is used to determine if the platform is able to 
achieve therapeutic drug levels during NP degradation and the time period to be 
examined during future in vivo efficacy experiments.   
 
Specific Aim 4: To determine the ultrasound sensitive platform’s ability to 
delivery Dox to a VX2 liver tumor model in vivo. 
 Specific aim four examines the platform’s ability to deliver Dox to a liver 
tumor model. Focused ultrasound was used to trigger release within VX2 tumors 
implanted within the livers of rabbits. The ability of ultrasound to detect the platform 
within solid tumors has been confirmed. Combination of the selected Dox loaded 
UCA and insonation are explored and compared to non-insonated controls. This study 
was designed based on the hypothesis that insonation of the platform will lead to 
significant increased delivery of Dox to the tumor model relative to the uninsonated 
controls. Drug levels within select organs were examined and compared among the 
experimental and control group to determine the platform’s potential ability to 
preferentially deliver drug to the tumor, while minimizing Dox delivery to non-
targeted organs. 
Additionally, Dox levels within the blood plasma were monitored in both the 
insonated and non insonated controls to determine concentrations of free Dox in 
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circulation (responsible for systemic toxicity). The hypothesis that encapsulation of 
the drug within the platform significantly reduces the degree of free Dox within the 
blood serum compared to traditional Dox chemotherapy and that insonation of the 
platform did not result in increased serum levels was confirmed. 
 
 
 
 
 
 
  
 8
 
2.  BACKGROUND AND LITERATURE REVIEW  
 
This chapter presents background information along with a review of the 
pertinent literature on (1) cancer, common cancer treatments, and solid tumors, (2) 
ultrasound and UCA imaging and characterization, and (3) a current review of UCA 
being used either as aids or carriers in drug delivery. 
 
2.1 Cancer and Cancer Therapies 
 
Cancer results from a change in cell differentiation, which eventually leads to 
metastasis of the transformed cells causing cancer progression, and possibly death.   
Localized treatments such as surgery and radiation can be used if the malignancy is 
detected early, but after the cells metastasize, a systemic approach must be used. 
Survival rates and treatments depend greatly on time of diagnosis and cancer type. 
 
2.1.1 Breast and Liver Cancer 
 
While the platform discussed in this thesis is expected to be useful in 
treatment of a variety of cancers, both breast and liver cancer models are used for 
proof of principle.  Breast cancer is the second most common type of cancer 
worldwide, accounting for over 10% of all cancer cases [13]. Ten year survival rates 
of breast cancer range from 98 to 10% depending on time of diagnosis and cancer 
type [13]. In 2005, breast cancer deaths totaled 519,000 worldwide, making it the 5th 
most common cancer death, accounting for 7% of all cancer deaths [14].  In 2008 
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within the US alone, there were an estimated 184,450 new cases of breast cancer and 
an estimated 40,930 deaths from breast cancer [15]. 
In contrast to the higher survival rates seen with some breast cancers, liver 
cancer has proven one of the most deadly cancer types. According to the American 
Cancer Society, the current five year survival rate of primary liver cancer is 7%  [16] 
(lower than the 10 year survival rate of even the most aggressive breast cancers). 
According to the American Cancer Society, 21,370 new cases of primary liver cancer 
were diagnosed in the USA and 18,410 people died from primary liver cancer in the 
USA in 2008 alone [16]. Additionally, several cancers eventually metastasize to the 
liver. For example, the colon is one of the primary origins, with more than 118,000 
new cases worldwide each year metastasizing to the liver [17]. The occurrence of 
primary liver cancer has rapidly increased over the last ten years, to the point where 
the World Health Organization predicts it will become the second most common 
cause of cancer death by 2010 [18]. This rise in liver cancer occurrences is mainly 
attributed to increases in Hepatitis B and C infections in the developing world, but is 
also due to increased consumption of alcohol and high fat diets within developed 
nations [19].  
 
2.1.2 Treatment of Solid Tumors 
 
A large percentage of cancers (~85%) involve the formation of solid tumors, 
and roughly 50% of these lead to metastasis and death [20]. Direct drug delivery to 
solid tumors is inhibited by their irregular vasculature and uneven blood flow [2]. 
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Primary options for treatment include surgical removal, chemotherapy, radiation 
treatment, ablation, and chemoembolization. 
Tumor removal through surgery is highly invasive by nature and may not be 
applicable in many cases. For example, surgical tumor removal in liver cancer cases 
is applicable in only 10-20% of cases and are associated with a high recurrence rate 
(82% in one randomized study with cirrhotic patients with hepatocellular carcinoma 
[21] and 75% recurrence within the first two years in a similar study [22]), although 
surgical resection has shown a 28% increase in five year survival rates in cases where 
surgery is possible [23]. 
Chemotherapy relies on the systemic injection and circulation of often toxic 
drugs and is commonly used to treat a variety of cancers. Chemotherapy is most 
effective for rapidly dividing cells such as some forms of cancer cells. Side effects of 
chemotherapy vary greatly by drug, but include alopecia, nausea, pain, anemia, and 
dehydration. Complications from systemic toxicity are also common and include 
heart, liver, and kidney damage.  Efficacy of a drug is often limited due to the low 
delivery efficiency to areas of need and dosage is generally restricted to minimize 
systemic toxicity.  Doxorubicin, one commonly used chemotherapeutic is discussed 
in detail in the proceeding section. 
Radiation therapies have become much improved with developments of 
localized treatments such as 3D confocal radiation therapy. However this treatment is 
still limited by side effects such as damage to healthy tissue, hair loss, nausea, and 
vomiting, and has also shown limited efficacy in some cancer types. For example, 
while radiation therapy of liver cancer has shown the ability to relieve symptoms, it 
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has not been shown to increase survival rates [24]. Similarly, tumor ablation is only 
applicable for very small tumors (generally less than 1 cc) and is also plagued by high 
recurrence rates (for example 45-65% intrahepatic recurrence in a study of liver 
cancer patients [25]). 
Transcatheter arterial chemoembolization involves the surgical blockage of 
tumor blood supply and insertion of drug emitting beads. These beads are relatively 
large (50-500 µm) and provide a sustained release of drug directly towards the tumor 
vasculature as they degrade.  Chemoembolization treatments have become 
increasingly common in the treatment of liver cancers (presumably due to the failures 
of other treatments) and have begun to show substantial improvement in survival 
rates.  Hong et al. surgically placed doxorubicin (Dox) loaded PVA beads within 
VX2 tumors in rabbits and found a 85% decrease in plasma levels (indicating lowered 
systemic toxicity) and over a 1000 fold increase in tumoral drug levels relative to 
intra-arterially administered Dox [26].  Alberti et al. performed chemoembolizations 
using drug emitting beads containing 100-150 mg Dox in patients with unresectable 
intrahepatic cholangiocarcinoma and found that median survival increased from 7 to 
13 months compared to patients who pursued traditional chemotherapy [27].  
However, not all studies using chemoembolization are as promising. Pelletier 
et al. performed chemoembolizations on patients with advanced hepatocellular 
carcinoma using gelfoam and Dox and found no statistically significant increases in 
survival, concluding the particular method was unsuitable for treatment [28].  
Although more concentrated in the tumoral area, chemoembolization is still 
associated with systemic toxicity. Eighty to 90% of patients experience post-
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embolization syndrome, which includes pain, nausea, fever, and vomiting and 4-5% 
of patients experienced serious complications such as embolization to the gut or 
tumor rupture [29].  Additionally, chemoembolization is invasive, expensive, and 
requires highly skilled surgeons, and therefore may not be available for much of the 
world’s population. 
 
2.1.3 Doxorubicin and the Need for Targeted Drug Delivery 
 
Despite the disadvantages of systemic drug delivery discussed above, a large 
variety of chemotherapeutics have been developed for treatment of solid tumors. 
While the platform presented in this thesis is not drug specific (additional drug 
loadings presented in appendix), the main focus is on delivery of doxorubicin (Dox).  
Dox (shown in Fig 2.1) is a hydrophilic, DNA-interacting drug with a molecular 
weight of 543 Daltons.  Dox (Adriamycin®, Rubex®, and liposome entrapped Dox- 
Doxil®) is an anthracycline antibiotic that exerts its effects on cancer cells via two 
different mechanisms. Firstly, intercalation in which the drug wedges between the 
bases of DNA and blocks DNA synthesis and transcription. Secondly, enzyme 
inhibition, in which the drug inhibits the enzyme topoisomerase II, that unwinds DNA 
strands for transcription. As a result of this blockage, Dox prevents the resealing of 
the DNA, stopping all future replication [30]. Dox can be used to treat liver, breast, 
ovarian, and lung cancer [31]. Dox is most commonly administered in dosages of 60-
75 mg/m2 every 21 days when used without other chemotherapeutics [32]. Side 
effects include nausea, leukopenia, alopecia, and heart arrhythmias [31]. Studies have 
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also shown a dramatic risk in congestive heart failure when the cumulative dosage of 
Dox exceeds 550 mg/m2 [31]. 
 
 
Figure 2.1: Chemical structure of doxorubicin 
 
The side effects described above are primarily a result of the lack of 
specificity in chemotherapy treatments. This lack of specificity has led to 
development of targeted or “smart” delivery systems that increase the delivery 
efficiency of chemotherapeutics. Pegylated liposomal Dox is currently FDA approved 
(Doxil ® (Johnson & Johnson, Langhorne, PA)). Encapsulation in a lipid shell has 
shown reduction in cardio toxicity and other systemic side effects while increasing 
survival rates [33], providing preliminary evidence that a platform based on 
encapsulation of the drug may be used to decrease side effects while still providing 
effective delivery.  However despite a lack of cardiotoxicity, acute infusion-related 
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toxicity, stomatitis, myelosuppression, and dermatologic effects such as palmar-
plantar erythrodysesthesia have been reported [34, 35]. 
The tradeoffs associated with Dox and other chemotherapeutics have given 
rise to a great deal of research focusing on targeted or smart delivery options. 
Because systemic toxicity must be taken into account when determining most 
tolerable doses of chemotherapeutics, efficacy of the drug is greatly sacrificed while 
debilitating side effects are still present at these lower doses. The success of treating a 
variety of cancers with Dox combined with its devastating side effects present Dox as 
an ideal candidate for use with a targeted drug delivery platform in which drug could 
be released only within the tumor, minimizing side effects, while increasing the 
overall toxicity within the tumor. 
A wide variety of research has investigated drug loaded microspheres as a 
more efficient form of drug delivery. Muller and Keck have published a thorough 
review of polymer and lipid based delivery platforms, although the majority of 
platforms discussed are passive delivery vehicles [36]. Several groups have 
investigated Dox loaded polymer agents. Tan et al. were able to successfully 
encapsulate Dox within double walled microspheres of both Poly lactic (PLA) and 
Poly lactic-co glycolic acids (PLGA), providing a sustained, controllable release by 
varying both the particle size and shell thickness [37]. Research has also been done 
attempting to trigger drug release from drug loaded microspheres externally, post 
injection.  Liu et al. were able to incorporate Dox in PLGA micelles and trigger the 
drug release thermally using a focused laser [38]. Liu found that PLGA micelles of 
low molecular weight were stable at 37o C, but unstable when heated with laser 
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heating to 39.5 o C, giving a controlled release of Dox within a localized area [38]. 
These examples are just a small sample of the research efforts underway to improve 
delivery of Dox by encapsulation, and show promise for other delivery vehicles such 
as the one presented in this thesis. 
 
2.1.4 Tumor Architecture and the EPR Effect 
 
Tumoral environments both within the vasculature and interstitium vary 
greatly from healthy tissue.  As discussed above, the architecture of a tumor makes it 
difficult for delivery of molecules due to high interstitial pressures and tortuous, 
uneven blood flow [39]. Additionally, the size of vasculature developed by the tumor 
during angiogenesis is highly chaotic, ranging from 10 to 200 µm and lacks 
traditional vasculature features such as arterioles, capillaries and venules [40].  The 
extracellular space within a solid tumor interstitia may also be slightly (as much as 1 
pH unit) acidic. For example, Robinson et al. found the pH of extracellular space 
within the interstitia of a liver hepatoma to vary from 6.4 to 6.8 compared to a pH of 
7.39 to 7.4 of intracellular space within the healthy liver [41]. 
While tumor architecture and vascularity vary greatly by tumor type, tumor 
vasculature is generally “leakier” than healthy tissue vasculature [42]. It has been 
reported that the majority of tumors have a pore cutoff size between 380 and 780 nm 
[43] (significantly larger than those within healthy organs, e.g. sinusoidal liver 
fenestrae average 175 nm [44]) but pore size is dependent on the type of tumor being 
analyzed.  Other studies have indicated a pore cutoff size of about 400 nm [40]. The 
size of these pores also appear to increase with grade and malignancy, with particles 
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as large as 700 nm being reported transported out of the tumor vasculature [45]. 
Additionally, lymphatic drainage within the tumor is minimal, causing particles to 
accumulate within the interstitia [3]. This phenomena is described as the enhanced 
permeation and retention (EPR) effect. 
Several research efforts have focused on exploiting the EPR effect for 
delivery of chemotherapeutics. By encapsulating drug within delivery vehicles small 
enough to pass through the leaky tumor vasculature (< 380-780 nm), but larger than 
healthy tissue fenestrate (> 20-175 nm) drug will passively accumulate within the 
tumor while also minimizing systemic toxicity. This strategy has been widely used to 
deliver Dox to solid tumors. Mitra et al. prepared 100 nm Dox-chitosan nanoparticles 
and found that encapsulation greatly reduced Dox side effects while also yielding a 
25% increase survival rate in J774A.1 tumor bearing mice compared to free Dox [46].  
Yoo et al. conjugated Dox to 200 nm PLGA nanoparticles for sustained, intratumoral 
release delivery by the EPR effect [47]. In mice with subcutaneous EL4 thymoma 
tumors, the group found the Dox particles inhibited tumor growth as effectively as 
free Dox, while substantially lowering systemic toxicity [47]. These results highlight 
just a small sample of reports on exploiting the EPR effect for drug delivery using 
nanoparticles. While only a few such platforms are currently approved for clinical 
use, hundreds of carriers currently being developed have been reported in the 
literature [48]. 
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2.2 Ultrasound 
 
Ultrasound transmits acoustic waves through the body, some of which are 
reflected back to the transducer due to differences in acoustic impedance. Reflected 
waves are then used to generate images. Non reflected waves are either absorbed by 
the body as thermal energy, scattered, or transmitted through the tissue before being 
reflected by a later boundary.  Acoustic impedance (z) is defined as: 
 
,     Eq 1 
 
where ρ is the density of the medium (kg/m3) and c is the speed of sound in the 
medium (m/s). The reflection coefficient (R) is a measure of the degree of reflection 
an ultrasound wave undergoes when passing from one medium to a second medium. 
R = 1 denotes 100% wave reflection, while R = 0 denotes 100% transmission of the 
wave.  R of an acoustic wave passing between two media is given as: 
 
.    Eq 2 
 
Ultrasound is becoming an increasingly popular imaging modality because it 
uses non-ionizing radiation, provides real time imaging, is relatively inexpensive 
compared to competing imaging modalities, and imaging equipment is generally 
lighter and more mobile than other medical imaging technologies [49]. It is estimated 
that there are 75,000 ultrasound machines compared to only 5,000 MRI machines in 
cz  
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the USA [50]. Several parameters can be selected by the operator such as acoustic 
pressure, center frequency, transducer type, and imaging scheme. 
 
2.3 Ultrasound Contrast Agents 
 
The numerous benefits of ultrasound as an imaging modality have resulted in 
a focus on developing technology to expand the range of ultrasound applications, 
while improving the overall quality of imaging. One of these improvements is the 
development of UCA, gas filled micro bubbles that can be injected intravenously and 
provide an impedance mismatch, increasing ultrasound contrast by more than 20 dB 
[51]. Gramiak and Shah first noticed the possibility of UCA while injecting 
indocyanine for an X-ray study of the aorta with the help of ultrasound [52]. During 
injection, bubbles formed at the needle tip that produced large scale ultrasound 
echoes. Later it was discovered that the gas within the microbubbles provided a 
substantial impedance mismatch between the blood to gas interface, reflecting the 
ultrasound waves. For air at atmospheric pressure and 20o C: 
 
zair = 415 Pa·s/m, [53]     Eq 3 
 
while for distilled water (similar to blood and tissue) at 1 atmosphere and 20o C, 
 
zwater = 1.48 x 106 Pa·s/m. [53]  Eq 4 
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Substituting values from Eq 3 and Eq 4 into Eq 2 yields a reflection coefficient 
roughly equal to one.  As a result, air and all other gas bubbles provide a nearly 
perfect reflector of ultrasound waves in blood or tissue, reflecting waves and 
providing additional contrast to ultrasound images. Additionally, the difference in 
compressibility between a gas bubble and surrounding tissue (roughly 20,000 times 
greater than tissue) allow the agents to resonate and reflect acoustic energy at a much 
larger cross sectional area than the actual bubble diameter (often less than 1000 times 
smaller than the ultrasound wavelength). 
 
2.3.1 Existing Ultrasound Contrast Agents 
 
Initial attempts at producing UCA relied on injecting hand agitated saline and 
sugar solutions [54]. However, the free air bubbles produced during agitation were 
highly unstable and easily filtered by the lungs. The difference in pressure (ΔP) 
across the gas to blood interface can be calculated the by the LaPlace equation: 
 
,   Eq 5 
 
where PG is the pressure of the gas within the bubble (N/m2), PF is the hydrostatic 
pressure of the fluid (N/m2), γ is the bubble surface tension (N/m) and r is the bubble 
radius (m). This equation yields a difference in pressure on the order of 1 bar for a 2 
µm free air bubble, making free air bubbles in solution highly unstable [54]. Thus the 
r
PPP FG
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majority of UCA research has focused on gas bubbles having an outer shell for added 
stability and rigidity. 
The ideal UCA should provide a high degree of ultrasound enhancement, be 
injected intravenously, be non-toxic, have a diameter of less than 8 µm in order to 
pass freely though the pulmonary capillary bed, and be stable enough to withstand the 
duration of the ultrasound examination [55]. Over the last 30 years, several 
generations of UCA have been developed using gases such as air, perfluorocarbon 
(PFCs) such as  perfluorobutane and sulfur hexafluoride (SF6), stabilized within shells 
ranging from proteins, various synthetic polymers, phospholipids, and surfactants 
[56]. Table 2.1 below shows a list of current UCA commercially available at one 
time. Optison and Definity are currently the only FDA approved agents. 
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Table 2.1: Commercially Available UCA 
Name Manufacturer Shell Material Core 
Material 
Year Countries 
Albunex Molecular 
Biosystems 
Human 
Albumin 
Air 1994 Off  Market 
Definity Lantheus Medical 
Imaging 
Phospholipid C3F8 2001 USA, Canada 
Echovist Bayer Shering 
Pharma AG 
Glactose Air 1991 Off  Market 
Imagent Alliance 
Pharmaceutical 
Corp 
Phospholipid C6F14 2002 Off  Market 
Levovist Bayer Shering 
Pharma AG 
Glactose Air 1996 Over 60 countries, 
not USA 
Optison GE Healthcare Human 
Albumin 
C3F8 1997 EU, USA 
SonoVue Bracco 
Diagnostics 
Phospholipid SF6 2001 EU, South America, 
China 
Sonazoid GE Healthcare Lipid C4F10 2006 Japan 
 
2.3.2 Polymer Shelled Ultrasound Contrast Agents 
 
Research within our laboratory has focused on producing polymer-stabilized 
UCA out of either poly (lactic acid) (PLA) and poly (lactic-co-glycolide acid) 
(PLGA) polymers using a w/(o/w) double emulsion [12, 57, 58]. This method 
produces air filled UCA with a mean diameter less than 2 µm with shell thickness of 
approximately 10% of the UCA diameter (100-200 nm). Similar PFC-filled agents 
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made from PLGA have also been produced on the commercial scale resulting in 
similar size, morphology, stability and enhancement [59]. These agents have been 
shown to provide up to 25 dB enhancement at 5 and 7.5 MHz in vitro, and are stable 
enough to last the duration of the imaging process (estimated at 20 minutes) [12, 57, 
58]. Table 2.2 below details some polymer UCA currently in commercial 
development, which could potentially join Optison as commercially available 
polymer UCA. 
 
Table 2.2: Polymer UCA in Commercial Development 
Name Company Shell Material Core Material 
AI-700 Acusphere, Inc. PLGA C4F10 
BG1135 Bracco Diagnostics Polymer Air 
PB127/ BiSphere Point Biomedical Human Albumin and 
biodegradable polymer 
Air 
Sonavist Bayer Schering Pharma 
AG 
Cyanoacrylate Air 
 
Lactic acid (shown below in Fig 2.2) is biodegradable and a natural body 
metabolite, making the polymer safe for clinical use as long as the UCA are small 
enough to pass through the capillary bed. It has a glass transition temperature of 45-
65 oC, a Young’s Modulus of 350-2800 MPa, and density of 1210-1430 kg/m3 [60]. 
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Figure 2.2: Chemical Structures of Poly (lactic acid) 
 
Polymer shelled UCA have been shown to behave very differently than lipid-
based UCA.  Bloch found that polymer UCA could not only withstand higher 
pressures (over 0.54 MPa higher peak rarefraction pressure levels than a phospholipid 
based agent), but also exhibited a different method of destruction under the influence 
of ultrasound, first jettisoning their inner gas bubble before undergoing shell 
fragmentation [61]. Additionally, polymer shelled UCA have a much larger shell 
volume than lipid-based UCA, giving them the ability to have potentially larger drug 
payloads within the shell. PLA UCA have also been developed in our lab using 
surface adhesion of tumor specific antibodies on the surface [62], potentially resulting 
in a drug delivery platform with an affinity for diseased tissue. 
 
2.3.3 Ultrasound Contrast Agents for Imaging 
 
Effects of UCA with different ultrasound imaging methods have been well 
studied and are continually being updated as the ultrasound imaging modality 
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evolves. Several of the methods will be briefly discussed. For a more detailed 
description of the imaging methods Szabo’s Diagnostic Ultrasound Imaging is highly 
recommended [63]. 
 
Fundamental Imaging 
UCA were originally applied to B-mode imaging (fundamental imaging) as a 
way to increase signal to noise by enhancing backscattered signal. In this mode, UCA 
have been shown to provide increased scan enhancement and contour detection [64]. 
Although these results do show significant improvements in enhancement, 
fundamental imaging is not ideal for UCA due to the low ratio of blood volume to 
tissue [56]. The low ratio results in an equally low ratio of contrast agent to tissue, 
severely limiting the overall effects of the UCA. Despite the shortcomings with 
fundamental imaging, UCA have made much larger contributions to other imaging 
modes. 
 
Doppler Imaging 
By tracking frequency shifts from a sample volume, relative velocity and 
direction can be calculated. This phenomenon is termed the Doppler effect and is the 
basis for traditional Doppler ultrasound. Traditional Doppler ultrasound can be used 
to track blood velocity by following acoustic reflectors (red blood cells) in the blood 
stream. Alternatively, power Doppler does not convey direction or magnitude of flow, 
but instead gives an indication of the strength of Doppler signal received. The 
addition of UCA significantly increases the signal from both traditional Doppler and 
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power Doppler ultrasound [56]. This increase in contrast greatly improves detection 
of flow in small vessels. Magarelli and coworkers found that the use of power 
Doppler with UCA gave better detection of synovial vessels (a precursor to 
inflammatory disease) than contrast enhanced MRI [65]. 
The increased sensitivity of UCA enhanced Doppler has been applied to a 
wide variety of diagnostic imaging. The ability to detect vessels on the micron scale 
has been applied to a number of imaging and detection applications. UCA enhanced 
Doppler has been used in the detection of several types of cancer [66-70], evaluation 
of cancer therapy [67], and brain imaging [71]. However, despite the expanding uses 
of UCA enhanced Doppler, echocardiography is the most prevalent application, and 
is the only modality for which FDA approval has been received. Echocardiography 
can be performed by either transthoracic or transesophageal ultrasound. UCA 
enhanced Doppler can be used in echocardiography to determine heart chamber walls, 
blood velocity, cardiac output, and ejection fraction. These results can then be used to 
diagnosis a wide variety of cardiac defects including coronary artery disease, 
hypertrophic cardiomyopathy, chest-wall deformities, and the condition of heart 
valves [72-75] 
 
Harmonic Imaging 
Harmonic imaging relies on insonation at a set frequency and signal detection 
at higher harmonic or subharmonic frequencies. Tissue itself has been shown to 
produces lower amplitude harmonic echoes due to the distortion of the ultrasound 
wave as it propagates through the tissue [76]. However, during insonation the 
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oscillations of the UCA can become nonlinear, resulting in nonlinear signals, and 
ultimately significantly higher amplitude harmonic signals (as large as 10 dB greater) 
[77, 78]. The ability of UCA to better scatter at harmonic frequencies compared to 
tissue has resulted in a UCA specific imaging method known as pulse-inversion 
harmonic imaging (PIHI) and greatly increases the signal to noise ratio by removing 
harmonic effects of the tissue. 
In PIHI, multiple inverted signals are emitted after a short time delay.  
Because tissue is a much more linear reflector compared to the UCA, the transmitted 
echo returns relatively unchanged. Due to the signal inversion, when the second pulse 
causes a second, inverted echo, the two emissions are summed, reducing tissue 
harmonics. However, because UCA are nonlinear reflectors (due to their nonlinear 
properties) the summation of sequential echoes does not cancel. This imaging method 
has been shown to be superior to UCA assisted harmonic imaging, which must 
compromise between contrast and spatial resolution [79].  
PIHI has been shown useful in a variety of applications.  Quaia et al. showed 
than PIHI using Levovist to detect liver metastatse was as effective (p=0.9) as helical 
CT [80]. Schmidt et al. compared PIHI to B-mode ultrasound for evaluation of 
inflammatory bowel disease in the small intestine and found an increase of 29.3% in 
‘crucial diagnostic information’ using PIHI without contrast [81]. The technique has 
also been used to predict tumor angiogenesis by determining the degree of 
neovascularity within solid tumors [82]. PIHI imaging has also been shown to be 
possible in Doppler mode, combining the advantages of both imaging techniques 
[83]. 
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Additionally, subharmonic imaging takes advantage of the harmonic 
properties displayed by UCA. The ability of microbubbles to scatter ultrasound at half 
the harmonic frequency is unique and not seen in either blood or tissue. Because this 
phenomenon is unique to UCA and undergoes no nonlinear propagation, it is possible 
to suppress signals from the surrounding tissues [84]. It is expected that this imaging 
mode will become more popular pending further development. 
 
2.3.4 Characterization of Ultrasound Contrast Agents 
 
Several in vitro tests and models have been developed to characterize how an 
UCA will function in vivo.  Understanding how an agent behaves both in circulation 
and under insonation can be important to the type of agent used, overall UCA dosage, 
and ultrasound imaging parameters used. While full characterization of UCA can be 
quite complex, it can be broken down into three main categories: UCA stability, 
backscattering radius, and resonant frequency. 
 
UCA Stability 
As touched on in Eq. 5, a free air bubble requires some form of stabilizing 
shell to remain stable due to the tendency of gas to diffuse into the liquid.  Stability of 
a UCA can be determined through intermittent ultrasound scanning (either in vitro of 
in vivo) over time and comparing the normalized samples. Additionally, a great deal 
of research has been invested in modeling the rate of gas diffusion out of a stabilized 
bubble. The rate of bubble shrinkage through gas diffusion was modeled by Epstein 
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and Plesset and later modified by Borden to include a shell resistance and is given by 
[85],[86]: 
 
,  Eq 6 
 
where L is Ostwald’s coefficient, D is the diffusion coefficient of the gas in liquid, 
Rshell is the resistance of the shell to gas permeation, C is the ratio of dissolved gas 
concentration to saturated concentration, and t is time. 
From equation 6 we see the presence of an outer shell, which is used to both 
reduce surface tension and limit gas diffusion, significantly reduces the rate of bubble 
shrinkage over time, making the UCA much more stable. The resistance to gas 
diffusion by the shell varies from agent to agent and can be determined 
experimentally [87]. Understanding an agent’s stability under circulation is important 
in order to provide contrast for the duration of a scan, as well as for drug delivery 
applications. While polymer shelled agents are generally thought of as being the most 
stable form of agent, Rshell also depends on several other variables such as fabrication 
method and encapsulated gas [87]. 
 
Scattering Cross Section 
As the acoustic wave passes through a UCA, the agent expands and contracts 
according to the pressure rarefaction and compression of the sound wave. Assuming 
that the product of the wavenumber of the ultrasound wave and the value of the radius 
of the scatterer is much less than one, we can say the UCA scattering cross-section is: 
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where, σ is the scattering cross section, I0 is the intensity of the applied wave, IS is the 
scattering intensity, and d is the distance from the transducer to the UCA.  
Backscattering area is a measure of how well a contrast medium reflects 
ultrasound waves and is used as a general indication of how well an UCA can provide 
contrast enhancement. The scattering cross-section of the UCA may be orders of 
magnitude greater than the actual area determined by the diameter of the agent itself 
[87]. While σ may be determined empirically, it can also be calculated by knowing 
the adiabatic compressibility and density of both the surrounding fluid and UCA as: 
 
 , Eq 8 
 
where K is the wavenumber, s is the compressibility of the scatterer , f is the 
compressibility of the fluid, ρs is the density of the scatterer and ρf  is the density of 
the fluid. Notice that the scattering cross-section increases with frequency (through 
the wave number) to the fourth power and radius to the sixth power, making both the 
insonation frequency and size distribution very important to the overall performance 
of the UCA. 
From the bracketed section of  equation 8 we see that an optimal UCA will 
have compressibility as large as possible over the surrounding fluid and a density as 
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small as possible compared to the surrounding fluid.  Additionally, the full 
oscillations of the gas bubble within an UCA may be reduced due to the stiffness of 
the outer shell. Thus a tradeoff exists in shell parameters of a shell being stiff enough 
to provide UCA stability (equation 6), while also provide minimal damping of the 
scattering cross-section of the UCA. 
 
Resonant Frequency 
Under optimum conditions, an UCA can oscillate at harmonics, maximizing 
backscatter and scattering cross section. Several models have been constructed 
examining the resonant frequency of a free gas bubble [88, 89]. The resonant 
frequency of a free bubble can be approximated by: 
  
,  Eq 9 
 
where f0 is the frequency in kHz, and r is the free bubble’s radius in µm [90]. Models 
have also been developed showing the effects of an outer shell on both the motion 
and resonant frequency of the microbubble [91-94]. One of the first models for the 
resonance of an encapsulated bubble was given by de Jong and included the shell 
elasticity as an additional restoring force [94]. From this equation the natural 
frequency, which is significantly higher than a free bubble can be approximated by 
the expression [94]: 
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where ST  is the shell thickness, E is Young’s Modulus and v is Poisson’s ratio. Notice 
that when E increases f0 is also increased.  Resonance can produce a scattering cross 
section in a free bubble of up to three orders of magnitude larger that the cross section 
of the bubble itself [55].  Additionally, the scattering cross section relies heavily on 
insonation frequency, making it important for the UCA to be used at the appropriate 
imaging frequency [55, 87]. The effects of resonance have been examined by 
Anderson and Hampton [95] and described as: 
 
ߪ ൌ ସగ௥మ
൤ቀ೑బ೑ ቁ
మିଵ൨
మ
ା ቀ೑బ೑ ቁ
రఋమ
 ,           Eq 11 
 
 
where δ is the damping coefficient of the bubble’s shell. A method for determining 
the resonant frequency of a UCA empirically has also been well developed [87, 94]. 
Understanding the stability, backscattering radius, and resonant frequency are 
important steps in properly utilizing a UCA for optimal performance. Because of the 
tradeoffs in these properties, the ideal agent may vary on a case by case basis. As 
previously mentioned, while these properties can be estimated theoretically, they are 
often also examined experimentally. 
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2.3.5 Safety of Ultrasound Contrast Agents 
 
Despite the widespread usage of UCA, their safety is still being disputed and 
their use is currently only approved for cardiac use by the food and drug 
administration (FDA). The safety of UCA has been well addressed by Blomley et al., 
who point out that the increased enhancement in endocardial border delineation and 
cardiac perfusion well outweigh the minor side effects (mainly temporary headache 
and altered sensation at the injection site in roughly 2% of patients) [96]. For 
example, a Phase III study of Optison for left ventricular endocardial border 
delineation was able to convert 74% of non diagnostic ultrasound scans to diagnostic, 
thus providing potentially lifesaving information to physicians [97]. 
Adverse reactions are quite rare, but are generally allergic in nature and very 
rarely serious, involving anaphylactoid reactions [98].  A post market study of 157, 
838 patients receiving SonoVue by the European Medicines Agency revealed a 
severe, non fatal reaction rate of 0.012% and a fatal adverse reaction rate of 0.002% 
[98].  Main et al. demonstrate that it is important to put these rates of adverse reaction 
in perspective [99], pointing out the mortality rates of coronary angiography and 
exercise treadmill testing are 0.1% [100] and 0.04% [101] respectively. Both these 
tests are common, clinically accepted, and 20-50 times more likely to cause fatality 
than UCA aided ultrasound based on these figures.  Additionally, unlike X-ray or 
MRI contrast agents, no studies have shown UCA to be nephrotoxic or cardiotoxic 
[96]. 
In spite of these advantages and proven success (estimates of approved UCA 
aided examinations exceed 1 million [96]), the FDA announced a black box warning 
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of UCA in October of 2007 with contraindications of use in patients with serious 
cardiac illness [102]. These contraindications resulted from post market reports of 
four deaths following UCA aided examinations. After scientific rebuttals and 
discussions arose from this ruling [96, 99] the FDA removed the majority of these 
contraindications in July 2008 [102]. However, it is believed this warning from the 
FDA temporarily scared off UCA investment and potentially slowed the development 
of the field.  
Despite these setbacks, the role of UCA is still expected to increase as the 
field moves towards development of both targeted diagnostic UCA and UCA for 
localized, ultrasound triggered drug delivery. Additionally, the need for industry wide 
reform through  increased cost effectiveness for better controlled healthcare costs has 
been well voiced [103], and may eventually lead to increased usage of ultrasound and 
UCA assisted imaging in applications where it has been shown to be better or 
equivalent to more expensive competing technologies. For example, in a follow up 
study of 203 patients receiving Optison during a Phase III trial, Shaw and Dittrich 
noted that the 37.3% increase in diagnostic accuracy using UCA aided ultrasound 
resulted in a 5-33% downstream cost savings of all patients [104]. 
 
2.4 Ultrasound Assisted Chemotherapeutic Delivery 
 
Ultrasound has already been proven as an effective tool for drug delivery with 
and without UCA.  Ultrasound has been shown to lead to increased efficacy at the 
area of insonation through increased drug retention at the tumor site and membrane 
permeability [105]. Studies have also been done showing that systemic administration 
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of Dox combined with low intensity ultrasound (0.25-2 W/cm2) leads to increased 
drug efficacy in vivo [105, 106]. 
The therapeutic benefits of ultrasound with chemotherapy appear to become 
even more significant in the presence of UCA. Several studies have been done 
showing that peptides, genes, and other small molecules can be delivered into the 
intracellular space with the help of ultrasound and UCA cavitation [107-109]. 
Cavitation of a UCA can be described as either stable (repeatable oscillation during 
insonation) or inertial, in which the UCA violently collapses [110]. It has been shown 
that the inertial cavitation of a gas bubble gas produce brief (<1 ms) shockwaves, and 
extreme localized temperatures and pressures (> 5000o C and 500 atm) [111]. 
Several groups have examined modes of UCA destruction for both drug 
delivery and UCA specific imaging modalities. Chatterjee and Sarkar investigated the 
destruction process of commercially available, lipid-based UCA by examining 
decreases in attenuation of ultrasound through a suspended solution and found that 
single-cycle bursts from a 5 MHz transducer resulted in microbubble destruction for 
pressures greater than 1.2 MPa [112].  Bloch et al. performed high speed microscopy 
experiments and found that lipid based UCA destruct at 1.0 MPa, while polymer 
shelled UCA remained intact at pressures up to 1.54 MPa at 2.25 MHz, two cycle 
pulses [61]. Forsberg et al. performed a similar study, investigating the effects of 
mechanical index (MI) displayed on clinical ultrasound scanners on contrast agent 
destruction, but found no direct correlation between the two [113], indicating that 
insonation pressure, despite being a factor of MI, is a better predictor of UCA 
destruction than MI alone. 
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Linear oscillations of UCA alone have been shown to be strong enough to 
rupture lipid based cellular membranes [109].  This phenomenon was documented by 
van Wamel and colleagues. Using high-speed imaging of oscillating microbubbles 
against endothelial cells, the group was able to show uptake of propidium iodide and 
increased membrane permeability as cells became deformed from contact with 
vibrating phospholipid UCA [4]. Additional work using the same high-speed 
photography setup showed that jetting from inertially cavitating gas microbubbles in 
the close vicinity (less than 2 UCA diameters) of a cellular boundary resulted in 
detachment of roughly 5 cells/localized UCA in vitro [114]. 
Cavitation of UCA within the vasculature has also been shown to change the 
tissue transport properties, allowing transport of large (up to 500 nm) particles out of 
the vasculature. For example, Price et al. showed they could delivery 200 and 500 nm 
fluorescent particles out of the capillary vasculature and into the interstitial space 
when combined with phospholipid UCA cavitation by 2.3 MHz, 4 cycle pulses of 
ultrasound at an MI of 0.7 [7].  While the gap junctions within the vasculature are 
quite small (<50 nm) and prevent transport of larger particles, Price was able to show 
these particles could extrasavate in a time window of up to 5 seconds after UCA 
cavitation [7]. Therefore, ultrasound triggered destruction of an UCA may be used to 
temporarily increase vasculature permeability for increased particle transport. 
While these studies demonstrate an added benefit of using ultrasound as a 
trigger for localized delivery on both the cellular and vascular level, the combination 
of intravenously injected, free chemotherapeutic and ultrasound will still involve 
systemic toxicity and the side effects described previously. As a result, research has 
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begun to focus on using UCA not just for increased delivery and uptake, but also as a 
carrier vehicle. 
 
2.4.1 Ultrasound Contrast Agents as Drug Carriers 
 
To overcome systemic toxicity and associated side effects, researchers have 
begun development of drug loaded ultrasound contrast agents, capable of circulating 
through the vasculature before release is triggered at a desired location by external 
ultrasound, focused on the area of need.  One of the first groups to investigate this 
was that of Unger who encapsulated paclitaxel contained in an oil layer inside 
phospholipid-stabilized UCA and insonated with 100 kHz therapeutic ultrasound 
using a pulsed wave with average temporal intensity of 0.8 W/cm2 over 30 mins [8]. 
Huang and MacDonald have created acoustically active liposomes, encapsulating 
calcein in phospholipids. Huang found that calcein could successfully be released 
using a 1 MHz transducer at 2 W/cm2 [10]. Similarly, Dox has been shown to 
successfully be released from stabilized micelles and released upon sonication at 70 
KHz, with a power of 2.8 W/cm2 in vitro [115].  Pong et al. have also shown that it is 
possible to use ultrasound to mediate leakage from large (up to 50 µm), acoustically 
sensitive phospholipid vesicles, again triggering high release amounts in vitro with 
low frequency (kHz range) ultrasound [116]. 
Despite advances in drug delivery with liposomal UCA, drug loaded polymer 
UCA remain largely undeveloped. Kooiman et al. have successfully encapsulated 
Sudan Black (a hydrophobic molecule) as a model drug within an oil/gas core and 
successfully released it using a 10 cycle sine wave generated from a 1 MHz 
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transducer with peak-negative-pressures of 0.51 MPa [9]. This same group has shown 
that paclitaxel (a hydrophobic chemotherapeutic) can successfully be encapsulated 
within the core of this agent and released in vivo using 1 MHz pulsed ultrasound at a 
PRF of 50 Hz and MI of 0.7 within MC-38 mouse colon adenocarcinomas, 
substantially halting tumor growth for 4 days compared to controls [117]. Gao et al. 
showed that Dox loaded, polymeric micelles combined with 30 seconds of 1 MHz 
continuous wave ultrasound with a power density 1.7 W/cm2 resulted in a 34% 
decrease in ovarian cancer tumor growth in mice compared to fee Dox [118]. 
Very few studies of ultrasound triggered drug delivery use polymer shelled 
UCA and lipid agents currently dominate the literature due to their ease of 
fabrication, existing commercially available lipid UCA, and immediate release on 
UCA rupture. However, the potential for increased loading, increased UCA stability, 
and potential for sustained release warrants further investigation into polymer shelled, 
drug loaded UCA. 
 
2.4.2 Acoustic Radiation Force for Drug Delivery 
 
As the acoustic waves generated by an ultrasound transducer travel through a 
medium, they produce a pressure gradient, resulting in directional forces applied to 
particles in solution. UCA in an acoustic field experience both primary and secondary 
forces. The primary radiation force is directed away from the transducer and is 
defined as: 
ܨ௥ ൌ ଶగ௉ೌ
మ௥
ద௖ఋ௪బ ቂ
஽
்ቃ,  Eq 12 
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where Pa is the peak applied acoustic pressure, r is the UCA radius, ߜ is the damping 
coefficient, ߷ is the density of the medium, ݓ଴ is the angular resonance frequency of 
the UCA, and D/T is the duty cycle [119].  Several groups have used primary acoustic 
radiation force to direct microbubbles in vitro. Rychak et al. examined both primary 
and secondary radiation forces on targeted lipid bubbles in vitro using 2 MHz pulses 
at a PRF of 10 Hz [119]. Using equation 10 and a peak pressure of 122 kPa, they 
calculated a maximal bubble velocity of 44 mm/second and saw a 60-80 fold increase 
in attachment in a flow chamber coated with P-selectin (a common cell adhesion 
molecule) [119].  Ferrara’s group examined this effect using high speed photography 
and found that 3 µm diameter phospholipid UCA achieved velocities of up to 0.5 m/s 
during a 20 cycle, 2.25 MHz acoustic pulse at 380 kPa  [120].  This group later used 
radiation force to deposit fluorescent nanoparticles attached to phospholipid UCA on 
the surface of cellulose tubing coated with biotin [121]. The group used lower 
pressure, non destructive radiation force pulses (2.25 MHz, 150 kPa peak negative 
pressure) to position nanoparticle loaded UCA, followed by UCA destructive pulses 
(5 cycle, 1.1 MPa peak negative pressure) to deposit the nanoparticles on the surface, 
increasing nanoparticle attachment by as much as 200% [121]. 
The core of the UCA, responsible for reflecting ultrasound waves for imaging 
appears to be crucial for the particle to be driven by acoustic radiation forces. Yasude 
and Kamakura examined the effects of acoustic radiation forces on solid particles in 
the micron-nanometer size range and found the force to be significantly lower than 
those described above (pN versus nN) [122].  Using a setup with 500 kHz transducer 
and excited with a 50 V peak to peak sine wave, the group found acoustic radiation 
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forces of less than 10 pN for all particles smaller than 10 µm and an acoustic 
radiation force of less than 0.2 pN for all particles less than 600 nm [122].  Thus 
while the radiation forces described by Rychak and Ferrara on UCA are far greater 
than buoyancy or gravitation forces on the particle, radiation forces are far less for 
solid nano and micro particles. 
UCA under insonation also experience secondary forces, termed Bjerknes forces. 
Bjerknes forces result from the oscillation of the UCA during insonation and cause 
attraction between bubbles. These forces are inversely proportional to the separation 
distance of UCA, but generally very small (0.5 pN at a separation distance of 200 µm, 
2 MHz, 122 kPa and PRF=10 Hz) [119]. In comparison, primary radiation forces on a 
UCA under the same condition are roughly 0.9 nN [119]. 
It is also helpful to put these radiation forces in context relative to buoyancy 
forces.  The buoyancy force experienced by the bubble can be calculated by: 
 
ܨ௕ ൌ ସଷ ߨݎଷ݃ሺߩ െ ߩ௎஼஺ሻ,  Eq 13 
 
where g is gravitational acceleration and ߩ௎஼஺ is the overall density of the UCA. For a 
2 µm polymer shelled bubble with 200 nm shell thickness this works out to slightly 
less than 0.1 pN. Both these forces are far lower than the primary acoustic radiation 
force shown in Eq 12, indicating the UCA movement in a static scenario will be 
primarily dominated by radiation forces.  It is believed that these forces can be used 
to improve delivery efficiency of drug loaded, polymer shelled UCA. 
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3.  MATERIALS AND METHODS 
 
 
3.1 Materials 
3.1.1 Polymers 
 
Poly (lactic acid) (PLA), Medisorb 100:0 6E lot # W2297-587 was purchased 
from Lakeshore Biomaterials (Birmingham, AL).  The PLA used for all UCA 
fabrication had a molecular weight (MW) of 88 kDa, inherent viscosity of 0.55 dL/g, 
and contained an ester end capping.  Poly vinyl alcohol (88% mol hydrolyzed, 
MW=25 kDa) was purchased from Polysciences, Inc. (Warrington, PA).  
 
3.1.2 Cells and Culture Material 
 
Human breast adenocarcinoma cells (MDA-MB-231) (passage 5-8) were 
purchased from ATTC (Manassas, VA).  Porcine aortic endothelial cells (PAEC) 
(passage 6-12) were obtained by direct harvest, and received as a gift from the Morss 
Clyne lab (MEM, Drexel University). Penicillin/streptomycin antibiotic was 
purchased from Sigma Chemical Co., St. Louis, MO.  RPMI-1640 medium 
(containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L 
glucose, and 1500 mg/L sodium bicarbonate) was purchased from ATCC (Manassas, 
VA). Dulbecco’s Modification of Eagle’s Medium (DMEM) (1X containing 4500 
mg/L glucose without L-glutamine) was purchased from Mediatech Inc  (Manassas, 
VA). Trypsin EDTA and fetal bovine serum (FBS) were purchased from Fisher 
Scientific (Springfield, NJ).  
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3.1.3 Chemicals for Radiological Assays 
 
Radio-labeled (C14) Doxorubicin (Dox) was purchased from GE Healthcare 
(Pittsburgh, PA) and contained 6.25 µCi/mg Dox-HCl. Tissue solvent (Soluene-350), 
and liquid scintillation cocktail (LSC) (Ultima-Gold) were purchased from Perkin 
Elmer (Waltham, MA). Sodium hydroxide was purchased from Sigma, (St. Louis, 
MO). 
 
3.1.4 Cellular Assays and Fixing Materials 
 
A live/dead reduced biohazard viability/cytotoxicity assay (Kit #1 L-7013) 
containing (SYTO 10 green fluorescent nucleic acid stain) and a cytotoxic stain 
(DEAD Red (ethidium homodimer-2) nucleic acid stain) and CellTracker Blue (a 7-
amino-4-chloromethylcoumarin fluorescent cytoplasm stain) were purchased from 
Molecular Probes (Eugene, OR). Glutaraldehyde and paraformaldehyde were 
purchased from Sigma-Aldrich (St. Louis, MO).  
 
3.1.5 Other Chemicals 
 
Camphor, dimethyl sulfoxide (DMSO) and Dox-HCl were all purchased from 
Sigma-Aldrich (St.Louis, MO). Pharmaceutical grade ammonium carbonate was 
purchased from J.T. Baker (Phillipsburg, NJ).  Phosphate buffered saline (PBS), 
methylene chloride, hexane, acetone, and isopropyl alcohol were all reagent grade 
and purchased from Fisher Scientific (Springfield, NJ). 
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3.2 Methods 
3.2.1 Contrast Agent Fabrication 
 
Agents were prepared based on a previously developed method for producing 
polymer shelled UCA [57]. Using this double emulsion, 0.5 g of PLA and 0.05 g 
camphor were dissolved in 10 ml of methylene chloride. After full dissolving of the 
polymer, 1 ml of 0.4 M ammonium carbonate was added and the mixture sonicated at 
20 kHz using 110 Watts of applied power for 30 seconds at 3 seconds on, 1 second 
off (Misonix Inc. CL4 tapped horn probe with 0.5” tip, Farmingdale, NY) while 
suspended in an ice bath.  The resulting (W/O) emulsion was added to 50 ml of 4oC 
5% PVA and homogenized for 5 minutes at 9500 rpm (Brinkmann Instruments, 
Westbury, NY) and washed with 2% isopropyl alcohol.  Samples were then 
continually stirred for 1 hour to evaporate any organic solvent. Following 
evaporation, UCA were collected using centrifugation and washed with 10 ml 
hexane.  After evaporation of hexane under the fume hood, the capsules were flash 
frozen in liquid nitrogen and lyophilized for 48 hours. As the agent undergoes freeze 
drying, ammonium carbonate and camphor sublime out of the capsule, leaving a void 
in their place. This hollow core then fills with gas (in this case air) when later 
exposed to the atmosphere.  
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3.2.2 Fabrication Modifications for Drug Loading of UCA 
 
Three methods of drug loading have been developed within our laboratory, 
resulting in PLA UCA with drug either adsorbed to the surface or incorporated within 
the shell of the agent. The three loading methods are summarized in Fig 3.1. 
 
Figure 3.1:  Representation of the three drug loading methods explored: I: drug incorporation during 
fabrication (I-Dox-UCA); II: surface adsorption post fabrication (S-Dox-UCA); and III: surface 
adsorption during fabrication (H-Dox-UCA). 
 
The first method (I) involves addition of Dox during the primary emulsion as 
the capsules are fabricated, resulting in drug incorporated within the shell of the agent 
(I-Dox-UCA). The second method (II) of drug loading involved suspension of free 
Dox and pre-fabricated UCA in PBS at 4oC PBS for 24 hours (S-Dox-UCA).  After 
24 hours, the UCA is again collected by centrifugation, washed with deionized water, 
and freeze dried.  This process has been optimized in terms of temperature and 
contact time and results in surface coated Dox-UCA due to the electrostatic attraction 
between the drug and polymer shell [123]. The final method (III) involves addition of 
Dox to the UCA as the agent is washed with hexane during fabrication (H-Dox-
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UCA). The agent is then washed in deionized water before being freeze dried as 
discussed above.  
Varying loading concentrations of Dox between 0.1 to 4% (the point of 
saturation) (weight Dox/weight PLA) were added using each of the three methods 
described above. All samples were prepared in triplicates and stored until use in a 
desicator at 4oC and covered in foil to avoid photo bleaching of Dox.  
 
3.2.3 Fabrication of 200 nm PLA Dox Nanoparticles 
 
Solid 200 nm nanoparticles made from PLA were fabricated with Dox on the 
surface using a single emulsion method followed by Dox surface adsorption. Two 
hundred mg of PLA was dissolved in 5 ml methylene chloride. The mixture was then 
sonicated at 20 kHz using 75 Watts of applied power for 30 seconds at 3 seconds on, 
1 second off (Misonix Inc. CL4 tapped horn probe with 0.5” tip, Farmingdale, NY) 
while suspended in an ice bath.  After sonication the mixture was added to 100 ml of 
1% PVA and homogenized for 7.5 mins at 12,500 rpm (Brinkmann Instruments, 
Westbury, NY). Following homogenization the solution was stirred in the fume hood, 
allowing the organic solvent to evaporate over a period of 12 hours.  Following 
evaporation, particles were collected by ultracentrifugation at 12,500 relative 
centrifugal force (rcf) using a Sorvall WX ultracentrifuge with AH-629 rotor (Thermo 
Electron Corp, Waltham, MA) for 1 hour and freeze dried for 48 hours. Following 
freeze drying, PLA nanoparticles were bathed in 3% Dox/PBS solution at 4oC for 24 
hours while being stirred end over end. Following 24 hours, particles were recollected 
by ultracentrifugation and freeze dried. All samples were prepared in triplicates and 
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stored until use in a desicator at 4oC with the vials covered in foil to avoid photo 
bleaching of Dox.  
 
3.2.4 Characterization of UCA 
3.2.4.1 Size and Zeta Potential Characterization of UCA 
 
Particle sizing and zeta potential measurements were done using a Malvern 
Nano ZetaSizer (Worcestershire, United Kingdom) to assess UCA population sizes 
and surface charges of the agents. For particle sizing, 1 mg of dry agent was 
suspended in PBS and measured in triplicate. Suspensions were pippetted into 1 ml 
plastic cuvettes and analyzed in triplicate at room temperature.  Particle sizes were 
reported as peak % number. The poly dispersity index (PDI) was also referenced as 
an indication of size distribution. For zeta potential measurements 1 mg of agent was 
suspended in 1 ml of DI water and read in triplicate at room temperature using a 
Malvern Zeta Capillary Cuvette.  
 
3.2.4.2 Scanning Electron Microscopy of UCA 
 
UCA were imaged using an environmental scanning electron microscope 
(SEM) (FEI XL30, Hillsboro, OR). Dry agent was gently fixed on carbon tape and 
sputter coated with platinum for 30 seconds using a Denton Desk-II sputtering system 
(Denton Corp, NJ.) prior to imaging. Images were taken at varying magnifications at 
an accelerating voltage of 10.0 kV. All SEM imaging and sample preparation was 
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done at the Drexel University Materials Characterization Facility with assistance from 
Kelleny Oum. 
 
3.2.4.3 Determination of Drug Encapsulation of UCA 
 
Amounts of adsorbed and encapsulated Dox were determined by dissolving 
dry agent in DMSO and measuring fluorescence.  Two mg of dry agent was added to 
2 ml DMSO and vortexed for 30 seconds to dissolve the polymer. Fluorescence of the 
mixture was then read using a Tecan fluorimeter (Männedorf, Switzerland) at an 
excitation wavelength of 495 nm and an emission wavelength of 585 nm. All samples 
were read in triplicate. Dox concentration was then calculated based on a standard 
curve of known amounts of Dox within DMSO. Encapsulation efficiency was defined 
as: 
 
ܧܿܽ݌ݏݑ݈ܽݐ݅݋݊ ݂݂݁݅ܿ݅݁݊ܿݕ ൌ  ி௜௡௔௟ ஽௢௫ ஼௢௡௖௘௡௧௥௔௧௜௢௡௅௢௔ௗ௜௡௚ ஽௢௫ ஼௢௡௖௘௡௧௥௔௧௜௢௡ .   Eq 14 
 
3.2.4.4 Acoustic Testing of UCA in vitro 
 
Acoustic testing was done in vitro to determine the agent’s ability to provide 
ultrasound enhancement as well as to measure the stability of the agent during 
insonation. Ultrasound triggering in vitro was done using the setup shown in Fig. 3.2 
Various frequency transducers (all 12.7 mm diameter, 50.8 mm spherically focused) 
were submersed in a tank containing 18.6 MΩ-cm deionized water at 37ºC. Properties 
of these transducers are listed in Table 3.1. The cover of the tank was fitted with an 
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x–y positioning system (Edmund Scientific, Barrington, NJ) to mount and position 
the ultrasonic transducers.  The transducer was focused through the transparent 
window of a poly-acrylic sample holder containing 50 ml 37oC stirred PBS. The 
transducer/sample holder is shown in Fig 3.3.  A 5072 pulser-receiver (Waltham, 
MA) was used to generate acoustic pressures with a pulse repetition frequency (PRF) 
of 100 Hz. Reflected signal from the UCA was detected by the transducer and 
amplified 40 dB before being read by an oscilloscope (Lecroy 9350 A, Chestnut 
Ridge, NY). Data acquisition and processing was done using LabView 7 Express 
(National Instruments, Austin, TX). 
 
 
Figure 3.2: Diagram of acoustic setup used to test UCA echogenicity, stability under ultrasound, in 
vitro drug release, ultrasound triggered cell death, and particle size after insonation.  
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Table 3.1: Properties of Panametrics Transducers used for Acoustic 
Characterization 
Center 
Freq. 
(MHz) 
Serial 
Number 
-6 dB 
Bandwidth 
(%) 
-6 dB Focal 
Zone (mm) 
Corresponding Time 
Window (µs) (Assuming 
cwater= 1480 m/s) 
2.25 236834 89 5.95 40.2 
5 559846 92 3.19 21.6 
7.5 255112 71 2.25 15.2 
10 228185 65 1.73 11.7 
15 237135 48 1.19 8.3 
 
Table 3.1: Properties of various 12.7 mm diameter, 50.8 mm spherically focused transducers used. 
Serial number and -6 dB bandwidth provided by manufacturer, -6 dB Focal zone calculated by R. 
Basude [124]. 
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Figure 3.3: In vitro setup used for acoustic characterization of agents. Both polyacrylic sample holder 
and transducer were submerged in DI water with the beam of the transducer positioned through the 
acoustic window of the sample holder.  Sample was continually stirred using a stir plate placed beneath 
the tank.  
 
Backscattering enhancement was measured as a function of UCA dosage and 
used to gauge both the agent’s ability to provide enhancement as well as its sensitivity 
to ultrasound for future drug delivery applications. Three mg of dry UCA was 
suspended in 800 µl of PBS by vortexing briefly. Samples were then pipetted into the 
sample holder containing 50 mL of continually stirred PBS (pH 7.4, 37 ºC). UCA was 
allowed to mix for 10 seconds to ensure a homogenous media before measurement. 
Enhancement in relationship to a baseline reading from PBS was then measured for 
each dosage ranging from 0-16 μg/ml.  Enhancement in dB was used by Forsberg et 
al. [125] to quantify a surfactant based UCA in a similar setup, and is defined as:  
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∑ ܧ ൌ 20݈݋ ଵ݃଴ ቂ௥௠௦ሾௌೆ಴ಲሺ௧ሻሿ௥௠௦ሾௌబሺ௧ሻሿ ቃ  Eq 15 
 
where ∑ ܧ is backscattering enhancement, ܵ௎஼஺ሺݐሻ is the rms readings of 60 readings 
with UCA, and ܵ଴ሺݐሻ is the rms readings of 60 readings prior to UCA injection. All 
values were based on an average of three readings from three individual samples (9 
readings, n=3). 
UCA stability during insonation was measured to assess the effect of 
ultrasound on the stability of the UCA and in order to determine whether the agents 
would last for the duration of an imaging session (15 minutes used as a benchmark).  
A dosage on the rise of the dose curve (generally 4 µg/ml) of UCA was added to 50 
ml of 37ºC PBS and continually stirred and insonated with the setup shown in Fig. 
3.2 and discussed above.  Enhancement was measured every minute for 15 minutes 
and the results normalized with respect to initial enhancement. Thus normalized 
enhancement was calculated as: 
 
ܰ݋ݎ݈݉ܽ݅ݖ݁݀ ܧ݄݊ܽ݊ܿ݁݉݁݊ݐ ൌ ∑ ா೟సೣ∑ ா೟సబ  Eq 16 
 
where ∑ ܧ௧ୀ௫  is the enhancement at minute X and ∑ ܧ௧ୀ଴  is the enhancement 
immediately after injection.  
 All values for both dose and time responses were based on an average of 
three readings from three individual samples (9 readings, n=3). 
 
 
 51
3.2.4.5 Determination of UCA enhancement in vivo 
 
Testing was performed on two New Zealand rabbits (3-3.2 kg) at Thomas 
Jefferson University’s Department of Radiology to determine the UCA’s ability to 
provide contrast enhancement in vivo. Rabbits were sedated with 35 mg/kg ketamine 
and 3.5 mg/kg xelozine. Pulsed Doppler ultrasound was used to image the ascending 
aorta using a Sonix RP US platform with L14-5 scanner (Ultrasonix, Richmond BC, 
Canada).  Spectral waveforms were obtained using a center frequency of 5.0 MHz, 
PRF of 6.7 kHz, depth of 2.5 cm, and power of -8 dB.  Dry agent (3% I-Dox-UCA) 
was suspended in PBS at a concentration of 0.04 g/ml by vortexing for 20 seconds. 
UCA was injected through an angiography catheter in the left ear vein and flushed 
with 5 ml of saline. Post injection, the waveform was saved for roughly a 10 second 
period and peak intensities were later converted to dB relative to baseline levels by 
Dr. Flemming Forsberg. Roughly 10 mins were allowed to elapse between injections 
to allow clearance of the UCA.  
Doppler ultrasound images were also obtained from the kidney of Sprague 
Dawley rats. Rats (250 g) were sedated with 2-4% isoflurane. Four mg/kg of UCA 
was injected through the tail vein and flushed with roughly 0.2 cc saline. Pulsed 
Doppler images were recorded using a Toshiba Aplio 80 scanner (Toshiba America 
Medical Systems, Tustin, CA). Imaging was performed at a center frequency of 7.5 
MHz, PRF of 14.1 kHz and MI of 0.2. 
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3.2.4.6 Determination of Drug Burst Effect from Dox-loaded UCA in vitro 
 
Initial drug release from Dox-loaded UCA (burst effect) was measured for 
each agent by suspending 10 mg of agent in 50 ml of PBS at 37oC while stirring. One 
ml of the solution was removed immediately after agent suspension and every two 
minutes for 20 mins while stirring. Immediately after sampling, samples were 
centrifuged at 7500 g for 5 mins to remove polymer and fluorescence of 200 µl of the 
supernatant was read using a Tecan fluorimeter (Männedorf, Switzerland) at an 
excitation wavelength of 495 nm and an emission wavelength of 585 nm. Free Dox 
was then calculated using a calibration curve of Dox in PBS, and expressed as a 
percent of total concentration.  
 
3.2.5 Plasma Sterilization of UCA 
 
Sterilization of UCA was done with oxygen plasma using a Harrick PDC-32G 
Plasma Sterilizer (Ithaca, NY).  Seventy mg of agent was sterilized for t=1, 3, and 6 
minutes on the machine’s low, medium, and high plasma settings. These power 
settings correspond to powers applied to the RF coil of: Low- 10 mA, 6.8 W; 
Medium- 15 mA, 10.5 W; and High- 25 mA, 18W. Three samples were run at a time 
and the results averaged. Each condition is the product of three separate processing 
runs (9 samples total, n=3). A thin (< 1 mm) layer of sample was sterilized on a flat 
surface while in covered well plates 6 cm from the RF coil. Prior to processing, the 
chamber was filled with pure oxygen and sealed. After sealing, the chamber was 
pumped down to a pressure of roughly 200 mTor and the RF coil used to generate 
oxygen plasma. After processing, the chamber was backfilled with unfiltered air and 
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samples immediately transferred to a sterile fume hood using sterile technique. No 
changes in temperature were noticed during plasma processing.   
During optimization, UCA sterility was determined by adding 2 mg of dry 
UCA to 2 ml of RPMI-1640 cell culture media (ATCC, Manassas, VA). Media was 
then incubated at 37oC for 48 hours and presence of bacteria was determined using 
the pH sensitive nature of the media combined with microscopy. Both the opacity and 
color of the media change in the presence of bacteria. Bacteria can also be seen at 
magnifications over 40X.  All values were based on an average of three readings from 
three individual samples (9 total samples). The optimal condition (18 W for 3 mins) 
was also confirmed to be suitable to create sterile UCA by adding 9 separate samples 
each from a separate sterilization run to blood agar cultures (Sigma-Aldrich, St.Louis, 
MO.) and incubating  over a period of 60 hours as outlined by Geze et al. [126]. 
Additionally, sterility within the core of the UCA using optimal settings was 
demonstrated by ultrasonic rupture of the agent (post plasma processing) in culture 
media within an Opticell (Thermo Fisher Scientific, Rochester, NY) with no detection 
of bacteria after 60 hours  by which time the capsules had started to disintegrate. 
After initial optimization studies, all sterilizations were performed using the 
machine’s high setting (25 mA, 18W) for 3 mins. 
 
3.2.6 Ultrasound Triggering Cell Death of MDA-MB-231 Cells 
3.2.6.1 Ultrasound Triggering of Dox Loaded UCA 
 
MDA-MB-231 cells (passage 6) were cultured to 70% confluency within 
Opticell® culture systems (Fisher Scientific, Springfield, NJ) in media containing 
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94% RPMI 1640, 5% FBS, and 1% penicillin/streptomycin antibiotic. Prior to 
treatment, medium was removed and replaced with 10 ml of fresh medium containing 
the desired Dox-loaded agent. I-Dox-UCA and S-Dox-UCA experimental groups 
both contained 2 mg of drug loaded agent, for a total Dox concentration of roughly 10 
µM assuming complete release of drug into the cell media (0.055 mg Dox). Each arm 
of the study included controls of ultrasound alone, ultrasound plus 10 µM of free 
Dox, ultrasound with 2 mg of UCA containing no drug, uninsonated drug loaded 
UCA, uninsonated UCA containing no drug, no treatment, and 10 µM free Dox with 
2 mg UCA and ultrasound. 
Opticell® cassettes were held in a 20 gallon tank of 18.6 MΩ-cm, 37ºC 
deionized water using the setup shown in Fig 3.4. The 5 MHz focused transducer 
discussed in the acoustic testing section was focused on one quadrant of the 
Opticell® surface. A pulser/receiver (5072 PR Panametrics, Waltham, MA) was used 
to generate pressure amplitudes with pulse repetition frequency equal to 100 Hz. 
Pressure amplitude levels were varied using the pulser/receiver’s energy level setting 
and later determined using a 0.5 mm polyvinylidene fluoride (PVDF) needle 
hydrophone (Precision Acoustics, Dorset, UK). These values are shown below in 
Table 3.2.  All given pressure amplitudes shown in the results section correspond to 
the peak positive values of the asymmetrical pulses at the focal plane. 
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Figure 3.4: In vitro setup used to insonated MDA-MB-231 cells and Dox loaded UCA. Cells were 
grown in Opticells and each quadrant insonated at varying pressure amplitudes at 5 MHz. 
 
Table 3.2: Properties of 5 MHz Acoustic Pressure Amplitudes generated in vitro 
Energy 
level 
Peak positive pressure 
amplitude (MPa) 
Peak negative pressure 
amplitude (MPa) 
Pulse 
Length (us) 
E=1 0.69 0.45 0.85 
E=2 0.92 0.57 0.95 
E=3 1.26 0.74 1.0 
E=4 1.65 0.94 1.0 
 
Table 3.2: Properties of 5 MHz acoustic pressure amplitudes generated by varying the energy level on 
the pulser/reciever’s energy settings. Pressure amplitudes were measured using a 0.5 mm PVDF needle 
hydrophone (Precision Acoustics, Dorset, UK). Pulse length was determined with assistance from 
Piyush Arora and Michael Cochran.  
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Each quadrant of the Opticell® was insonated for 5 mins for a total of 20 
minutes of insonation. After insonation, cells were returned to the incubator incubator 
(370C, 5% CO2) until determination of cell death was performed. Orientation of cells 
in the incubator after treatment (face up and separated from the floating UCA vs. face 
down with the floating UCA in direct contact with the cells) did not result in any 
differences of cell death for either the insonated group or uninsonated controls.  
Future work will focused on media replacement post insonation to remove drug/UCA 
not uptaken by cells, for a more realistic simulation of in vivo conditions. However, 
this may prove difficult due to the possibility of temporary, but substantial cell 
detachment in the presence of inertial and transiently cavitating bubbles, as shown by 
Ohl et al. who used a single finite wave of 2.5 µs and -4MPa amplitude to induce 
microbubble rupture and cell detachment [114]. 
 
3.2.6.2 Determination of Cell Death after Ultrasound Triggering 
 
Cell death was calculated as the percentage of dead or cytotoxic cells to the 
total number of cells. For viability after treatment a Live/Dead Reduced Biohazard 
Viability/Cytotoxicity Kit #1 (Molecular Probes, Eugene, OR) was used. Cells were 
incubated for 15 mins at room temperature with a live stain (SYTO 10 green 
fluorescent nucleic acid stain) and a cytotoxic stain (DEAD Red (ethidium 
homodimer-2) nucleic acid stain). After staining, cells were fixed with 4 % 
glutaraldehyde (Sigma, St. Louis, MO) for 1 hour at room temperature. Fluorescent 
images were then obtained using an Olympus IX71 fluorescence microscope. Live 
cells (SYTO stain) were read using a 510-540 nm wavelength filter, while dead 
 57
(DEAD stain) cells were read using a 570-630 nm filter. Images were processed using 
SPOT image software to adjust intensity levels. Images of stained cells in 10 adjacent 
fields were then counted blindly for each marker after the images and had been 
overlaid. 
 
3.2.6.3 Imaging of MDA-MB-231 Cells after Uptake of Ruptured UCA Shards 
Using Confocal Microscopy 
 
 MDA-MB-231 cells were imaged post insonation to show cellular uptake of 
UCA shards containing Dox. Cells were grown to 70-80% confluency within 
Opticell® culture systems (Fisher Scientific, Springfield, NJ) in medium containing 
94% RPMI 1640, 5% FBS, and 1% penicillin/streptomycin antibiotic. After removal 
of medium, 6 mg of 3% I-Dox-UCA within 10 ml of medium was added and the 
Opticells®  insonated as discussed in the previous section at a peak positive pressure 
amplitude of 1.68 MPa. Cells were incubated in solution for 12 hours to allow uptake 
and reattachment before the cell medium was removed and cells washed twice with 
PBS. Cell cytoplasm was then stained using CellTracker Blue stain (Molecular 
Probes, State) and fixed within the Opticell® with 4% paraformaldehyde prior to 
imaging. Uninsonated cells incubated with 6 mg of 3% I-Dox-UCA within 10 ml of 
medium were used as a control.  
 Confocal imaging was done with assistance from Steve Kemeny (Drexel 
MEM).  Images were obtained using an Olympus IX81 microscope run by Olympus 
Fluorview version 1.7b. A DAPI filter was used to image the CellTracker Blue 
cytoplasm dye. Dox was simultaneously imaged by excitation using a FITC filter and 
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emission using a TRITC filter. Proper gain levels were determined automatically 
using the Fluorview software.   
 
3.2.7 Measurement of UCA Size Reduction in vitro during Insonation 
 
Ultrasound triggering in vitro was done using the setup shown in Fig 3.2.  Ten 
mg of agent was suspended in 50 ml PBS at 37oC and continually stirred. The sample 
was insonated at 5 MHz at a PRF=100Hz using the focused transducer discussed 
above. Pressure values corresponding to the pressure amplitudes used in cell death 
experiments were varied using the output energy settings on the pulser-receiver and 
are described in Table 3.2.  One ml of solution was sampled every 5 mins and read 
using the Zeatsizer as discussed in the particle sizing section.  All experiments were 
repeated in triplicate and are reported as peak particle size.  A negative control with 
no insonation (0.00 MPa) was also performed for each sample. 
 
3.2.8 Measurement of Dox Release Profiles from Dox-PLA UCA 
 
Dox release profiles from Dox-PLA shards were measured to gauge the 
potential of the ruptured agent to provide a sustained, intratumoral delivery after 
exiting the tumor vasculature. Twenty mg of 3% I-Dox-UCA was suspended in 50 ml 
of PBS at 37oC and continually stirred while insonated using the setup described in 
Fig. 3.2.  Samples were insonated at 5 MHz at a PRF of 1 kHz at a peak positive 
pressure amplitude of 1.65 MPa for 30 mins. After insonation, samples were 
transferred to 50 ml centrifuge tubes and continually turned end over end at 37 oC. 
 59
One ml of solution was then sampled on a daily basis and centrifuged at 12.6 rcf for 
20 mins to separate free Dox in solution from nano sized fragments generated during 
insonation. After centrifugation, supernatant was removed and the pellet dissolved by 
the addition of one ml DMSO followed by 30 seconds of vortexing.  Fluorescence of 
the mixture was then read using a Tecan fluorimeter (Männedorf, Switzerland) at an 
excitation wavelength of 495 nm and an emission wavelength of 585 nm. All samples 
were read in triplicate. Dox concentration was then calculated based on a standard 
curve of known amounts of Dox within DMSO. Free Dox was then calculated using a 
mass balance. Readings of three samples were repeated in triplicate (9 readings, n=3) 
and results were compared to a uninsonated negative control.  
 
3.2.9 UCA Shard Penetration in vitro 
3.2.9.1 UCA Shard Penetration through a 400 nm Polyester Membrane 
 
 The ability of the agent to fracture and pass through leaky vasculature within 
the tumor into the tumor interstitium was examined using Corning Transwell 
Permeable Inserts (Corning Inc, Lowell MA).  Inserts were made of 24 mm diameter 
polyester membranes with a 400 nm pore density of 4 x 106 pores/cm2.  Inserts were 
modified slightly in that side slits were covered with double sided tape to allow for 
higher fluid levels, thus reducing the chances of creating a standing wave when 
insonated from the bottom.  
Transwell inserts were placed in 6 well plates (Corning Inc, Lowell MA) 
containing 3 ml of PBS at 37oC and experimental/control agent. Three ml of PBS was 
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then added to the upper compartment of the setup. A schematic of this arrangement 
(with and without cells) is shown in Fig. 3.5.  
 
 
Figure 3.5: Diagram of Transwell Insert/Well Plate assembly used for in vitro shard penetration 
without a cellular layer (a) and with a PAEC layer above the 400 nm pore membrane. 
 
 The setup containing both 6 well plate and Transwell insert were held on the 
surface of the water. Transducers listed in Table 3.1 were positioned facing upwards 
at a length of 50.8 mm from the membrane surface, providing focus at the membrane 
surface. An acoustic absorber made from a rubber stopper was also placed at the 
upper level of the fluid of the insert to minimize reflected energy at the liquid-air 
interface. A schematic of this setup is shown in Fig 3.6 Care was taken to ensure air 
was not entrapped below or within the cell plate setup to minimize reflected energy 
beneath the plate. Rahim et al. used a similar setup with a 6 well polystyrene plate 
(without Transwell inserts) for ultrasound assisted gene transfection, generating an 
acoustic wave at 1 MHz and 0.5 MPa peak-to-peak pressure amplitude for gene 
transfection and found that only 10% of the signal was attenuated [127]. Thus, while 
more attenuation may take place in our setup with higher frequencies, it is still 
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believed a majority of the acoustic pressure transmits through the 1 mm thick 
polystyrene plate and reached the membrane.  
 
Figure 3.6: Diagram of Transwell Insert/Well Plate assembly combined with ultrasound setup. A 
pulser/receiver is used to generate acoustic pressure amplitudes vertically using the transducer, focused 
50.8 mm on the cell/pore membrane. 
 
 Acoustic pressure amplitudes were generated with the transducer using the 
setup shown in Fig 3.7.  Pressures and PRF were varied using the system’s 
pulser/receiver settings. Membranes were insonated and 200 µl were samples at t=0, 
5, 10, 15, and 20 mins. After sampling, fluorescence of the mixture was then read 
using a Tecan fluorimeter (Männedorf, Switzerland) at an excitation wavelength of 
495 nm and an emission wavelength of 585 nm. Dox concentration was then 
calculated based on a standard curve and expressed as a percentage of total Dox 
added beneath the membrane. Experimental groups consisted of 5 mg of 3% I-Dox-
UCA suspended in 3 ml of PBS at 37oC. Control groups consisted of 5 mg of 3% I-
Dox-UCA without ultrasound, 200 nm, solid Dox loaded nanoparticles with and 
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without insonation, and 200 nm solid Dox loaded nanoparticles combined with 
unloaded PLA UCA with and without ultrasound.  
 
 
Figure 3.7: Photograph of Transwell Insert/Well Plate assembly combined with ultrasound setup. A 
pulser/receiver is used to generate acoustic pressure amplitudes vertically using the transducer, focused 
50.8 mm on the cell/pore membrane. Multiple transducers are in place to allow quick changing of 
insonation frequency.  
 
3.2.9.2 UCA Shard Penetration through a 400 nm Polyester/PAEC Membrane 
 
Experiments described in the previous section were repeated with membranes 
layered with porcine aortic endothelial cells (PAEC). Cells were grown on 
membranes to 100% confluency in DMEM media containing 5% FBS and 1% 
penicillin/streptomycin. At confluency, it is estimated that cells covered 
approximately 80% of pores on the membranes. Fig 3.8 shows a micrograph of PAEC 
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grown on polyester Transwell membrane inserts. While it is acknowledged that this 
system varies greatly from the leaky tumoral gap junctions UCA will be required to 
penetrate though in vivo, it serves a basic membrane model with a UCA-cell 
interaction in which to optimize delivery strategies.  
 
 
Figure 3.8: Porcine aortic endothelial cells grown to 100% confluency on 400 nm pore, polyester 
Transwell insert membranes.  Outlines of PAEC can be seen covering pores (appearing as white dots). 
Magnification = 40X, size bar= 50 µm. 
 
 
3.2.9 Acute Study of Delivery of I-Dox-PLA UCA to a VX2 Tumor in Rabbits 
 
Drug delivery in vivo was performed using a VX2 liver tumor model in New 
Zealand rabbits. New Zealand rabbits were anesthetized using ketamine (35 mg/kg), 
xlazine (2mg/kg), and glycopyrolate (0.01mg/kg). After sedation, 2-3 mm cubes of 
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VX2 tumor harvested from the thigh of a carrier rabbit were implanted into the left 
lobe of the liver. Tumors were then allowed to grow for 3 weeks, reaching sizes of 
roughly 2-3 cm3 in both experimental and control rabbits. All implantations were 
done by Dr. Michael Soulen with the assistance of Marion Knaus (Hospital of the 
University of Pennsylvania).  
 
3.2.9.1 Ultrasound Triggered Delivery of I-Dox-PLA UCA to a VX2 Tumor in 
Rabbits 
 
I-Dox-UCA were prepared as described in the methods section above at a 
loading concentration 3% (g PLA/ g UCA) of C-14 Dox in accordance with the 
radiation safety approved protocol. Rabbits were anesthetized using ketamine (35 
mg/kg), xylazine (2mg/kg), and glycopyrrolate (0.01mg/kg). Three control rabbits 
received an injection of 70 mg of agent (1.47 uCi, 2 mg Dox) suspended in 5 ml of 
physiological saline through an auricular line, then flushed with an additional 5 ml of 
saline.  Four rabbits in the experimental group received an equivalent injection of 70 
mg of agent, combined with 20 minutes of non-directional Doppler ultrasound 
focused on the tumor (ATL/Philips HDI-5000, Bothel, WA). Ultrasound was 
performed at 5 MHz, PRF = 1000 Hz, with a MI of 1.0 and continually swept over 
the tumor by Susan Schultz (Hospital of the University of Pennsylvania). Images 
were stored and digitized for later use. 
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3.2.9.2 Determination of Blood Plasma Drug Levels 
 
Blood was sampled over a 4 hour period through an auricular arterial line in 
the second ear in each rabbit.  One ml of blood was drawn at t= 0, 5, 15, 30 mins and 
t= 1, 2, and 4 hours. After sampling blood samples were spun at 7000 rcf for 5 mins 
to separate blood plasma. Two hundred µL were removed from the supernatant 
(blood plasma) and added to 0.5 ml tissue solvent and 0.5 ml isopropyl alcohol and 
incubated at 60 ºC for 2 hours. After incubation, 0.2 ml hydrogen peroxide was added 
and shaken for 30 mins, followed by 30 mins of incubation at 60 ºC.  Finally, 10 ml 
of LSC cocktail was added and scintillation vials read after one hour of light 
adaptation in a scintillation counter (Packard 1900CA, Meriden, CT). Disintegrations 
per minute (DPM) were converted to µCi (1 Ci = 2.22 x 1012 DPM), which were then 
converted to ng Dox. 
 
3.2.9.3 Determination of Organ and Tumoral Drug Levels 
 
After 4 hours, rabbits were sacrificed and tumors, healthy liver, heart and 
spleen were harvested. Harvested organs and tumors were cut into 50-100 mg 
sections and read in triplicates. The necrotic center of the tumor was defined as the 
inner 33% of the cross section diameter, and was easily distinguishable in appearance 
from the peripheral tissue of the tumor. Tissue and tumor samples were added to 2 ml 
of tissue solvent and incubated at 60 ºC for 3 hours. After incubation 0.2 ml of 
hydrogen peroxide was added and incubated for 30 mins followed by the addition of 
10 ml of LSC cocktail. Scintillation was then read after one hour of light adaptation in 
a scintillation counter (Packard 1900CA, Meriden, CT). DPM were converted to µCi, 
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which were then converted to ng Dox. Results were then expressed as ng Dox/ g 
tissue. 
 
3.2.10 Statistical Methods 
 
 Statistically significant differences for multiple groups were determined using 
a one way ANOVA with a Newman-Keuls post test. Statistical significance between 
individual groups was determined using a Student’s t-test. All testing was done using 
Prism 3.0 (GraphPad, San Diego, CA). Statistical significance was determined using 
α = 0.05. Error bars were displayed as standard error about the mean (SEAM). 
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4. RESULTS AND DISCUSSION 
 
4.1 Development and Optimization of a Dox Loaded UCA 
 
Three different techniques have been developed for adding chemotherapeutics 
to our PLA UCA.  Our initial drug loading technique consisted of a “dry absorption” 
method in which dry samples were bathed in solutions of varying Dox concentration 
in PBS with a pH (7.4) between the isoelectric point of the polymer and the drug.  
The UCA resulting from this loading method were termed S-Dox-UCA because the 
drug is adsorbed to the surface post fabrication of the UCA.  The second loading 
method also involved surface adsorption of Dox to the surface but Dox was contacted 
with the UCA during the fabrication process while washing with hexane and the 
resulting UCA were termed (H-Dox-UCA).  The third and final loading method 
involved incorporating Dox within the shell of the agent (I-Dox-UCA). Loading 
methods and drug payload were optimized to provide an UCA with a maximal drug 
payload with minimal burst effect, show a tight size distribution preferably in the 1-2 
µm range, provide strong acoustic enhancement both in vitro and in vivo and show a 
smooth surface morphology for future targeting applications. Method selection and 
optimization are discussed in terms of these properties over the remainder of the 
subsection.  
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4.1.1 Optimization of a Surface Adsorption Loading Method Post Fabrication 
 
 Effects of both temperature and loading time were first examined to optimize 
the method of Dox surface adsorption post UCA fabrication (S-Dox-UCA). 
Optimization was necessary to both maximize drug loading (through longer exposure 
times) while minimizing hydrolysis of the agent (through shorter exposure times and 
lower temperatures). Hydrolysis of the PLA results in destruction of the UCA shell, 
hindering ultrasound triggering during drug delivery. Samples were incubated with 
3% Dox (w/v) solution for varying time increments before being washed and freeze 
dried. A standard curve of Dox suspended in DMSO was constructed as described in 
the methods section and used to calculate encapsulation efficiency. This curve is 
shown in Fig 4.1.  
 
 
Figure 4.1: Standard curve of Dox in DMSO used to calculate encapsulation efficiencies (n=3, error 
bars = SEAM, Ex=495 nm, Em=585, Gain=100 dB). 
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Effects of contact time were first examined in terms of drug-loading 
efficiency, at 4oC. These results are shown below in Fig 4.2.  Increased time of UCA 
in Dox solution resulted in an increased overall encapsulation efficiency. A 
statistically significant increase in efficiency occurred between 12 and 24 hours (* 
p=0.0323) reaching a maximal saturation point after which no significant additional 
increases in drug attachment were seen (p > 0.05). Thus, the ideal surface loading 
technique would be done over a period of 24 hours to maximize encapsulation 
efficiency and drug payload. 
 
 
 
Figure 4.2: Effects of increased incubation time of UCA in Dox solution. Attachment efficiency 
increased with time, reaching maximal point after 24 hours incubation (T=4oC, *p=0.0323, n=3, error 
bars = SEAM). 
  
 
Effects of loading time on the UCA’s ability to provide ultrasound contrast in 
vitro were then examined to determine if the drug loaded agent was still a viable 
contrast agent. Dry agent was suspended in 3% (w/v) at 4oC for varying time intervals 
prior to washing and freeze drying solution as discussed in the methods section. In 
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vitro enhancement was then measured as discussed in the methods section. Results of 
this study are shown in Fig 4.3. 
 
Figure 4.3: Effects of loading time on in vitro ultrasound enhancement of the UCA at 4oC (n=3, error 
bars= SEAM).  
 
  
A gradual decrease in ultrasound enhancement at a given dose was seen with 
increased Dox loading time in solution. After 24 hours of incubation followed by 
freeze drying, samples maintained 13 dB of enhancement (roughly 65% of their 
original). The use of shorter incubation times (which result in lower drug payloads 
based off Fig 4.2) would be useful in preserving the agent’s echogenicity.  
Loading temperature was briefly examined to increase the rate of Dox 
attachment to the UCA shell. The previous experiment was repeated at 20oC and in 
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vitro ultrasound enhancement for the various loaded agents compared. These results 
are shown below in Fig 4.4. 
 
 
Figure 4.4: Effects of loading time on in vitro ultrasound enhancement of the S-Dox-UCA at 20oC 
(n=3, error bars= SEAM) .  
 
 
 A major drop off in in vitro ultrasound enhancement is seen for samples 
exposed to aqueous solution at room temperature for over 5 mins (p<0.0001). After 
24 hours of loading (the ideal loading time to maximize drug attachment at 4oC) the 
resultant UCA provides less than 2 dB of enhancement. This level of enhancement is 
believed to be far too low for an ultrasound triggered delivery vehicle and 
significantly less than samples bathed in Dox solution at 4oC (p<0.0001). 
Additionally, incubation temperature did not significantly change drug attachment 
efficiency (data not shown).  The smaller drop off in enhancement of samples loaded 
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at 4oC is believed to be due to a reduced rate of hydrolysis at lower temperatures and 
is consistent with the Arrhenius equation, which predicts the rate of a chemical 
reaction (in this case hydrolysis) to nearly double with every temperature increase of 
10oC. As a result of these studies all future work using surface adsorption of Dox to 
prefabricated UCA (S-Dox-UCA) were done for a period of 24 hours at 4oC.  
 
4.1.2 Effects of Dox Loading on UCA Size and Surface Morphology 
 
Effects of drug loading methodologies on both the surface morphology and 
particle size were examined to determine if the UCA’s properties were altered during 
drug loading. As discussed in the background section, the ideal agent will remain 
small enough to pass across the capillary beds (< 8µm), and maintain a tight size 
distribution. Additionally, future work incorporating targeting ligands to the surface 
may require a smooth morphology for adequate attachment. All three methods 
resulted in smooth, spherical particles. After sonication and freeze drying, ruptured 
particles displayed a hollow core and shell thickness of roughly 10% of the particle 
diameter. An example of these SEM findings is shown in Fig 4.5 for I-Dox-UCA. 
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Figure 4.5: SEM Images of drug loaded agents a) after fabrication (Mag. = 9000x, Size bar = 2 µm) 
and b) post sonication and re-freeze drying (Mag. = 50000X, Size bar = 500 nm).  Agent shown is a 
PLA agent with 3% (g Dox/g PLA) loaded within the shell of the agent.  Morphology, core, and shell 
thicknesses were consistent with all three loading methods and all drug payloads (Accelerating voltage 
= 10.0 kV, Spot Size=3.0, Working Distance=8.9 mm) [128]. 
 
 Particle size and polydispersity index (PDI) were both measured to determine 
if Dox loading in the shell of UCA surface significantly altered the size 
characteristics of the sample, specifically to ensure they did not exceed the maximum 
size to pass unimpeded through the vasculature.  These findings are summarized in 
Table 4.1 for 3% (g Dox/G PLA) loading and are consistent with all loading 
concentrations tested.  
 
Table 4.1: Effects of Dox Loading Method on Particle Size and PDI 
 Unloaded UCA H-Dox-UCA I-Dox-UCA S-Dox-UCA 
Particle Size (nm) 1692 +/- 779 1734 +/- 1403 1865 +/- 1074 2206 +/- 2039 
PDI 0.212 +/-0.051 0.254 +/-0.104 0.309 +/- 0.102 * 0.412 +/-0.108 
  
No statistically significant changes in particle size were detected among 
loading groups with peak particle sizes ranging from 1.7 µm to 2.2 µm.  Both the H-
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Dox-UCA and I-Dox-UCA groups showed a PDI similar to that of the unloaded 
agent, indicating no changes in the size distribution had taken place. However, the S-
Dox-UCA agent did show a significantly higher PDI (*p=0.0441 relative to the 
unloaded control).  These findings are attributed to the secondary freeze drying of the 
S-Dox-UCA samples, which may lead to swelling and destruction of the agents due to 
hydrolysis and exposure to low atmospheric pressures. The possibility of inter-bubble 
cross linking with Dox as a linker was examined using microscopy, but bubbles 
remained unattached after resuspension for all three loading methods. There was also 
no visible distress upon injection into rabbits (discussed in 4.1.8), indicating that the 
mean bubble size did not increase beyond the limits of the pulmonary bed (6-8µm). 
Confocal fluorescence microscopy was used for visualization of Dox within 
larger UCA.  While only larger UCA were able to be viewed ( > 3 µm), UCA 
appeared spherical when viewed at a cross section of the UCA. Additionally, the 
presence of Dox was only detected around the perimeter of the agent, indicating 
attachment within or on the shell. The outer location of Dox only within the outer 
shell region also confirms the SEM findings that the UCA are hollow. An example of 
these findings is shown in Fig 4.6. 
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Figure 4.6: Fluorescent confocal micrograph showing Dox within the agent’s shell (Mag=100X, Size 
bar= 5 µ, (only larger UCA are visible using fluorescent microscopy)). Agent shown is a PLA agent 
with 3% (g Dox/g PLA) loaded within the shell of the agent [128].   
 
 
4.1.3 Effects of Dox Loading Strategies on UCA Acoustic Properties 
 
 Effects of Dox loading strategies on in vitro enhancement were compared at 
varying insonation frequencies. All results shown are from 3% loading (as discussed 
in the following subsection. Figure 4.7 shows in vitro enhancement at varying 
frequencies of S-Dox-UCA.  
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Figure 4.7: In vitro enhancement of S-Dox-UCA at varying frequencies. (3% w/v loading, n=3, error 
bars= SEAM, 24 hour loading time at 4oC). 
 
 
 
 A statistically significant variation (p=0.0024) was seen in S-Dox-UCA 
sample enhancement when insonated at various frequencies. Five MHz insonation 
resulted in maximal enhancement (13.1 dB) followed closely by 7.5 MHz insonation 
(12.1 dB), although no significant difference was seen between these two groups 
(p=0.75). However, a significant drop off in enhancement (*) was seen at other 
frequencies as shown in Fig 4.7. These results indicate the resonance frequency of the 
UCA to be within bandwidth of the 5 and 7.5 MHz transducers, at which point the 
agent would demonstrate optimal enhancement. Additionally, a previous study 
examining an unloaded PLGA agent made from the same technique showed a 
resonance frequency between 3.09 and 3.49 MHz [58]. As a result of these findings 
future work will focus on ultrasound triggering at 5 MHz.  
Figure 4.8 shows in vitro enhancement at varying frequencies of H-Dox-UCA. 
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Figure 4.8: In vitro enhancement of H-Dox-UCA at varying frequencies. (3%  Dox/g PLA loading, 
n=3, error bars= SEAM). 
 
As seen with S-Dox-UCA, a statistically significant variation (p=0.0009) was 
seen in H-Dox-UCA sample enhancement when insonated at varying frequencies. 
Similar to S-Dox-UCA, insonation at 5.0 and 7.5 MHz resulted in maximal 
enhancement (18.3 dB and 17.6 dB respectively) with no statistically significant 
difference between the two insonation groups (p=0.79). However, a significant drop 
off in enhancement (*) was seen at other frequencies as shown in Fig 4.8. Again, 
these results indicate the resonance frequency of the UCA to be within the bandwidth 
of the 5 and 7.5 MHz transducers, at which point the agent would demonstrate 
optimal enhancement. Consistent with S-Dox-UCA, future work will focus on 
triggering and imaging at 5 MHz. 
Figure 4.9 shows in vitro enhancement at varying frequencies of I-Dox-UCA.   
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Figure 4.9: In vitro enhancement of I-Dox-UCA at varying frequencies. (3%  Dox/g PLA loading, 
n=3, error bars= SEAM). 
 
As seen with previous loading methods, a statistically significant variation 
(p=0.0030) was seen in I-Dox-UCA sample enhancement when insonated at varying 
frequencies. Similar to previous loading methods, insonation at 5.0 MHz resulted in 
maximal enhancement (17.9 dB) followed closely by insonation at 7.5 MHz (17.4 
dB). Unlike previous samples however, no statistically significant differences in 
enhancement were seen in I-Dox-UCA insonated at 2.25, 5.0, 7.5, and 10.0 MHz 
(p=0.39). A significant drop off in enhancement (*) was seen using insonation at 15 
MHz. These results are unexpected in that Dox incorporation resulted in a tighter size 
distribution (PDI) than S-Dox-UCA samples (Table 4.1) and thus due to the highly 
size dependant equation for resonance frequency (Equation 9-10), it would be 
expected that a tighter size distribution would result in more pronounced 
enhancement at a particular frequency.  This may be indicative that Dox placement in 
the UCA shells may be changing the shell properties of some individual UCA more 
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than others, thus varying the resonance frequency of UCA population over a wider 
range.  
Stability under insonation was examined for each loading method at the 
frequencies discussed above. These results are shown below in Figs 4.10-4.12. No 
significant variation in normalized enhancement over time between varying 
insonation frequencies was observed for any of the three loading methods.  These 
results are somewhat unexpected in light of the previous data showing the importance 
of insonation at or near the resonance frequency of the UCA for optimal 
enhancement. However, it is believed that the acoustic pressure amplitudes (0.68 MPa 
and below) are still below the rupturing threshold of the polymer bubbles, and thus 
cause minimal decreases in enhancement over time.  
 
Figure 4.10: In vitro stability of S-Dox-UCA at varying frequencies. (3%  w/v loading, n=3, error 
bars= SEAM). 
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Figure 4.11: In vitro enhancement of H-Dox-UCA at varying frequencies. (3%  Dox/g PLA loading, 
n=3, error bars= SEAM). 
 
 
 
Figure 4.12: In vitro enhancement of I-Dox-UCA at varying frequencies. (3%  Dox/g PLA loading, 
n=3, error bars= SEAM). 
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 Dose response data at optimal frequency (5.0 MHz) is reproduced from Figs 
4.7-4.9 and compared below in Fig 4.13 and also compared to unloaded UCA.   
 
 
Figure 4.13: Effects of loading method on in vitro enhancement at 5.0 MHz, 0.68 MPa peak positive 
pressure amplitude (*p=0.0062, 3% loading, n=3, error bars= SEAM). 
 
No statistically significant changes in backscattering were measured for either 
H-Dox-UCA or I-Dox-UCA relative to the unloaded control, with all three agents 
reaching enhancements of roughly 19 dB at doses of 7.5 µg/ml and above.  However 
a significant decrease in enhancement was seen in S-Dox-UCA loaded at 4oC relative 
to the unloaded control (* p=0.0062), with samples reaching a maximal enhancement 
of 13.1 dB at a dose of 9.0 µg/ml. This drop off in enhancement with S-Dox-UCA is 
believed to be the result of the second freeze drying process. Freeze drying is 
believed to destroy some UCA resulting in lower overall enhancement. Additionally, 
the 24 hour contact period in which the UCA are suspended in buffer may result in 
hydrolysis of the PLA shell, destroying a portion of the agent’s population.  
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Corresponding time response data at 5.0 MHz was reproduced for each 
loading method from Figs 4.10-4.12 and compared in Fig 4.14. 
 
 
Figure 4.14: Effects of loading method on in vitro stability during insonation at 5.0 MHz, peak 
positive pressure amplitude = 0.68 MPa (**p<0.0001, 3% loading, n=3, error bars= SEAM). 
 
Effects of drug loading on the agent’s stability during insonation were 
measured and are shown in Fig 4.14. No significant decreases in stability were seen 
for either surface adsorption method relative to the unloaded control, only losing 
roughly 15% of the agent’s original enhancement after 15 mins. However, a 
statistically significant (** p<0.0001) decrease was seen in stability of the I-Dox-
UCA  relative to the unloaded control, with the incorporated agent losing roughly 
40% of its original enhancement after 15 mins of insonation. This decrease in UCA 
stability is believed to be due to the induction of weaknesses into the shell of the 
UCA, making it more susceptible to both hydrolysis and UCA destruction by 
increasing the number of point defects on the surface of the agent. While this 
decrease in stability during insonation may inhibit the agent’s ability to provide 
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contrast for the duration of an ultrasound scan, it may also prove advantageous in 
future drug delivery situations. 
 
4.1.4 Effects of Dox Concentration on UCA Properties 
 
 Dox concentrations were varied from 0.1% to 4.0% (g Dox/g PLA) were 
varied for all three loading methods and loading effects on the UCA’s acoustic 
properties were examined. Figures 4.15-4.16 show the effects of varying Dox loading 
concentration on in vitro enhancement.  
 
 
Figure 4.15: Effects of Dox loading concentration (0.1-4.0 % g Dox/g PLA) on H-Dox-UCA in vitro 
enhancement at 5.0 MHz (P=0.68 MPa, n=3, error bars= SEAM). 
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Figure 4.16: Effects of Dox loading concentration (0.1-4.0 % g Dox/g PLA) on I-Dox-UCA in vitro 
enhancement at 5.0 MHz (P=0.68 MPa, n=3, error bars= SEAM). 
 
 
 
Figure 4.17: Effects of Dox loading concentration (0.1-4.0 % Dox w/v) on S-Dox-UCA in vitro 
enhancement at 5.0 MHz (P=0.68 MPa, n=3, error bars= SEAM). 
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 No significant variation in in vitro enhancement was seen for Dox loading 
concentrations between 0.1 to 4.0% Dox loading for H-Dox-UCA (p=0.50), I-Dox-
UCA (p=0.86), or S-Dox-UCA (p=0.30). This lack of a trend in enhancement is 
presumed to be due to the relatively small size of the drug (less than 1% molecular 
weight of the polymer) and the relatively low quantities of drug that were used.  
 Effects of varying Dox concentration were also examined for each of the three 
loading methods on the agent’s stability during insonation. These results are shown in 
figures 4.18-4.20. Similar to dose response results, Dox loading concentration did not 
result in any statistically significant variations in stability during insonation for H-
Dox-UCA (p=0.89), I-Dox-UCA (p=0.56), or S-Dox-UCA (p=0.34). This is again 
believed to be due to the relatively small size of the Dox particles relative to the 
polymer (over two orders of magnitude smaller) as well as the low concentrations of 
drug used.  
 
Figure 4.18: Effects of loading concentration (0.1-4.0 % g Dox/g PLA) on in vitro stability of H-Dox-
UCA during insonation at 5.0 MHz, peak positive pressure amplitude = 0.68 MPa (n=3, error bars= 
SEAM). 
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Figure 4.19: Effects of loading concentration (0.1-4.0 % g Dox/g PLA) on in vitro stability of I-Dox-
UCA during insonation at 5.0 MHz, peak positive pressure amplitude= 0.68 MPa (n=3, error bars= 
SEAM). 
 
 
Figure 4.20: Effects of loading concentration (0.1-4.0 % Dox w/v) on in vitro stability of S-Dox-UCA 
during insonation at 5.0 MHz, peak positive pressure amplitude = 0.68 MPa ( n=3, error bars= SEAM). 
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4.1.5 Encapsulation Efficiency and Payload Optimization of Dox-UCA 
 
Both final drug payload and encapsulation efficiency were measured for each 
of the three loading methods over a range of loading concentrations (1.0-40.0 mg 
Dox/g PLA).  These results are shown in Fig 4.21. 
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Figure 4.21:  Final drug payload as a function of loading method and initial concentration (a), and 
corresponding encapsulation efficiency (b). H-Dox-UCA = , I-Dox-UCA = , S-Dox-
UCA = . H-Dox-UCA approached a maximal drug load of 24.1 mg Dox/g PLA (encapsulation 
efficiency of 60.2%) at an initial loading concentration of 40.0 mg Dox/g PLA. Both the I-Dox-UCA 
and S-Dox-UCA samples reached peak drug payloads of 6.2 and 6.5 mg Dox/g PLA (encapsulation 
efficiencies of 20.5 and 21.9%) respectively at an initial loading concentration of 30.0 mg Dox/g PLA 
[128]. 
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UCA with Dox loaded during the hexane washing process showed 
significantly higher drug payload and encapsulation efficiency (p=0.0038). H-Dox-
UCA showed a maximal drug payload of 24.1 mg Dox/g PLA at the highest initial 
loading concentration (40 mg Dox/g PLA). This corresponds to an encapsulation 
efficiency of 60.2%.  Alternatively, both I-Dox-UCA and S-Dox-UCA samples 
reached a peak drug payload of 6.2 and 6.5 mg Dox/g PLA respectively, with 
corresponding encapsulation efficiencies of 20.5 and 21.9%. Thus, in terms of a drug 
carrier, H-Dox-UCA samples proved superior in both payload and encapsulation 
efficiency. However, this is not the only requirement of the drug delivery vehicle.   
 
4.1.6 Effect of Loading Method on Drug Release during Ultrasound Triggered 
UCA Destruction 
 
  Prior to determining the extent of drug release during ultrasound triggered 
destruction, a Dox standard curve was constructed as described in the methods 
section to determine the relationship between amount of free Dox in PBS and 
fluorescence intensity. This curve is shown below in Fig. 4.22. 
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Figure 4.22: Standard curve of Dox in PBS used to calculate encapsulation efficiencies (n=3, error 
bars = SEAM, Samples centrifuged at 12.6 rcf for 20 mins prior to reading, Ex=495 nm, Em=585, 
Gain=100 dB). 
 
Dox loaded UCA were suspended in stirred PBS to determine the effect of 
loading method on the degree of release during UCA destruction. After an initial 
burst upon introduction into the release medium, all samples showed no statistically 
significant release of Dox during UCA destruction (p>0.05 relative to the 
corresponding uninsonated controls). These results are shown in Fig 4.23. While 
ultrasound triggered release may be desirable for some delivery applications, this lack 
of release is ideal for a platform designed to deposit sustained release drug-polymer 
fragments at a desired release site.  
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Figure 4.23: Effects of  loading method and insonation on drug release (-■- H-Dox-UCA, -▲- S-Dox-
UCA, -▼-  I-Dox-UCA, -□- H-Dox-UCA + US, - - S-Dox-UCA + US, - - I-Dox-UCA + US,) . H-
Dox-UCA samples showed significantly more burst (*p<0.0001) relative to the S-Dox-UCA or I-Dox-
UCA samples (78% vs. 27% of the total Dox within the UCA). No samples showed any significant 
release when insonated (p>0.05). Data shown is for 3% Dox loading, but results were consistent for all 
drug loading concentrations (P=1.65 MPa, 5 MHz, n=3, error bars=SEAM) [128]. 
 
All the loading methods resulted in a burst of drug release upon suspension in 
37oC PBS.  Since the various preparations were all washed extensively prior to freeze 
drying, this burst must be caused by movement of the drug towards the surface of the 
capsule as the various components (water camphor and ammonium carbonate) 
sublime off under vacuum.  Both S-Dox-UCA and I-Dox-UCA showed an immediate 
burst of roughly 27% of the total encapsulated Dox and no further release was 
detected over the 20 minute insonation period.  However, the H-Dox-UCA showed a 
significantly higher burst release (*p<0.0001) than the incorporated or cold-adsorbed 
samples, immediately releasing 78% of the total Dox and remaining constant.   
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As a result of these studies, incorporation of Dox within the shell of the UCA 
was selected for future work because it results in highly echogenic, drug loaded 
capsules that maintains the drug payload for future ultrasound triggered studies. 
 
4.1.7 Ultrasound Enhancement in vivo with I-Dox-UCA 
 
The I-Dox-UCA agent was chosen for in vivo imaging experiments due to its 
high enhancement (19 dB) and relatively low burst effect (27 %) in vitro. Figure 4.24 
shows an example of a Doppler image of a rat kidney prior to (a) and 8 sec post 
injection (b) of 0.1 ml/kg of I-Dox-UCA. The agent is clearly detectable and provides 
adequate contrast of the rat kidney using Doppler US for roughly 45 seconds post 
injection. Results of in vivo dose response curves monitored over the ascending aorta 
of a New Zealand rabbit are shown in Fig 4.25. 
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Figure 4.24: Doppler US scans of a rat kidney (a) pre injection, and (b) 8 sec post injection of 0.1 
ml/kg of I-Dox-UCA (3% Dox loading).  The agent was clearly detectable in vivo and provides image 
contrast enhancement for roughly 45 seconds [128].  
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 Figure 4.25: In vivo dose response of 3% I-Dox-UCA in the ascending aorta. The agent showed 
marked enhancement at all dosages, with a peak US enhancement of 15.5 dB at a dose of 0.1 ml/kg 
and lasted roughly 5 mins (n=3, error bars= SEAM) [128]. 
 
 UCA with Dox incorporated within the shell showed improved enhancement 
within the ascending aorta of a New Zealand rabbit at all doses, with a peak 
enhancement of 15.5 dB at a dosage of 4.0 mg/kg. Peak enhancement in vivo was 2.5 
dB lower than in vitro results (Fig. 4.13), but these differences were not found to be 
statistically significant (p=0.13).  Additionally, peak enhancement was roughly 4 dB 
lower than a comparative study in which in vivo enhancement of unloaded PLA UCA 
were measured in the distal aorta below the renal arteries in New Zealand rabbits 
[12].  This slight decrease in enhancement is believed to be due to agent’s decreased 
stability shown in Fig 4.14. Decreased stability of the agent due to creation of shell 
weaknesses and point defects results in an agent more susceptible to destruction by in 
vivo forces during circulation. Thus as a result of this loss in stability, fewer UCA 
may reach the imaging location intact, reducing overall contrast enhancement. 
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However, it is important to note that the agent is still clearly detectable at all dosages 
and reactive to ultrasound for future triggering applications.  
 
4.1.8 Investigation of Strategies to Increase Drug Load 
 
 Investigations were conducted into a strategy that could create an agent that 
contained Dox within the shell (I-Dox-UCA) followed by surface adsorption after 
freeze drying (S-Dox-UCA). The double method of 3% Dox Incorporation followed 
by Dox surface adsorption from a 3% solution resulted in roughly a 70% increase in 
drug payload relative to the individual loading methods (although this change was not 
statistically significant, but did show a trend towards significance with p=0.07). 
Results from this study are shown in Fig 4.26. 
 
 
Figure 4.26: UCA Dox payload of I-Dox-UCA, S-Dox-UCA, and a combination method S-I-Dox-
UCA. Roughly a 70% increase in drug payload was seen using a combination of the two methods. 
(n=3, error bars= SEAM) 
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 This method of using two separate drug loading methodologies at first 
appeared promising for developing a UCA containing a higher concentration of 
chemotherapeutics. However, an examination of the double loaded agent’s (S-I-Dox-
UCA) in vitro enhancement showed the agent had lost a great deal (over 10 dB) of its 
ability to provide contrast. These results are shown in Fig 4.27. 
 
 
Figure 4.27: In vitro ultrasound enhancement of I-Dox-UCA, S-Dox-UCA, and a combination method 
S-I-Dox-UCA. (3% Dox loading for each drug loading step) (*p=0.0021, n=3, error bars= SEAM) 
 
 A statistically significant decreases in in vitro enhancement was seen between 
the S-Dox-UCA and double loaded (S-I-Dox-UCA) agents (*p=0.0021). The double 
loaded agent yielded a peak enhancement of 7.6 dB at a dosage of 10 µg/ml. This 
drop off in enhancement is believed to be due to the increased instability of the 
prefabricated agent when Dox is incorporated within the shell of the agent. As seen 
previously in Fig 4.14, incorporation of Dox within the shell results in a substantially 
less stable agent relative to an unloaded control. This change in stability may be 
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amplified during the surface adsorption process that includes contact with an aqueous 
solution and a second freeze drying. As a result of these findings, efforts to develop a 
multiple loaded agent were halted, although additional investigation into multi-
loading strategies are suggested in the future works section of this thesis.  
 
4.1.9 Conclusions on the Development of Dox Loaded UCA 
 
Several methods of loading polymer shelled UCA with Dox have been 
developed. These methods include two forms of surface coating, and one form of 
drug incorporation within the shell of the agent.  The agent with Dox incorporated 
within the shell of the agent (I-Dox-UCA) was selected for further study due to its 
optimal combination of high in vitro enhancement (18 dB),  tighter size distribution 
(PDI=0.309), and low burst effect (27%) relative to the alternative methods. While 
this agent does show significantly less stability relative to the alternative methods 
(p<0.0001), this may be ideal for future drug delivery use.  This study also paves the 
way for investigation of other drugs, some preliminary data of which is shown in the 
appendix. 
 
4.2 Plasma Sterilization of Dox Loaded UCA 
 
No techniques for sterilizing polymer UCA post fabrication have been 
reported, making long term in vitro and in vivo studies difficult, especially on a 
laboratory scale. While polymer UCA have successfully been fabricated in clean 
facilities [59], this solution is cost intensive and may not be feasible for research 
efforts. Previous sterilization attempts in our laboratory using autoclave, dry heat, 
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ethylene oxide, ultraviolet light, filtering, and washing with diluted isopropyl alcohol 
were all unsuccessful at either sterilizing the agent or maintaining the UCA’s 
response to ultrasound. This failure is attributed to the need for the thin-walled, gas-
filled capsules to remain intact combined with the agent’s susceptibility to alcohol 
dissolution and a high sensitivity to heat and pressure.   
 The following section will investigate the effects of both exposure time and 
power on generating sterile PLA UCA using an RF- generated O2-plasma as 
described in the methods section. Effects of these procedures on the acoustic 
performance of the agent are discussed. Surface modification and changes in 
morphology are examined through zeta potential, differential scanning calorimetry 
(DSC) and SEM. Finally, surface adsorption of Dox is used as an example of how 
surface modification of an existing UCA through plasma treatment can be used to 
provide an improved vehicle for US-triggered, drug delivery. The following results 
have been published in the journal Ultrasound Medicine and Biology [129]. 
 
4.2.1 Effects of Oxygen Plasma on UCA Sterility 
 
Effects of both plasma exposure time (1, 3 and 6 minutes) and power level 
(unsterilized, i.e.  0 W and 6.8, 10.5 and 18.0 W), on the UCA sterility were 
examined. These results are summarized in Fig. 4.28 Samples treated on high power 
(18.0 W) for times of 3 and 6 minutes showed complete sterilization of all three 
samples determined in both culture media and on blood agar. Samples treated for 
shorter time periods or using lesser power levels showed either no or inconsistent 
sterilizations. Samples treated using 18 W power at all time points and samples 
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sterilized with 10.5 W power for times of 3 and 6 minutes showed statistically 
significant higher chances of sterility than the unsterilized samples (p<0.001, 9 
samples/condition, n=3). 
 
 
Figure 4.28: Effects of plasma power and exposure time on UCA sterility. One hundred percent of 
samples were determined sterile after plasma sterilization of 18.0 W at 3 and 6 mins. (9 
samples/condition, n=3, error bars= SEAM) [129]. 
 
 
4.2.2 Effects of Oxygen Plasma on UCA Acoustic Properties 
 
In vitro ultrasound enhancement of plasma processed UCA was examined to 
determine how well the sterilized UCA would provide contrast during an ultrasound 
scan, and how sensitive the agent was to ultrasound for potential triggered and drug 
delivery applications. Surprisingly, processing power (unsterilized or 0 W, 6.8, 10.5 
and 18.0 W) had no differential effect on the measured profiles (data not shown), 
whereas time did. This suggests that even at the lowest power, the energy was enough 
to overcome the activation energy to cause damage to the polymer, even though it 
was not necessarily enough to cause damage to the microorganisms. As a 
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consequence, only 18 W data are presented.  Fig. 4.29 shows the effects of plasma 
processing time using 18.0 W on ultrasound enhancement in vitro. Even though no 
significant effects on enhancement were seen between UCA sterilized at varying 
plasma powers, a statistically significant (p = 0.0045) drop off in acoustic 
enhancement was seen in samples sterilized for t=6 mins compared with 0 and 3 mins 
(18.0 W data shown). 
 
 
Figure 4.29: In vitro ultrasound enhancement of PLA UCA prior to and post varying exposure times 
to plasma at 18.0 W. A statistically significant drop off was seen for sterilization times over three 
minutes (p=0.0045). This measurement is used to determine the UCA’s ability to provide contrast 
(P=0.68 MPa, 5MHz, n=3, error bars= SEAM) [129]. 
 
Enhancement over a 15 min period of insonation was measured to determine 
if the plasma sterilization significantly affected the agent’s stability or ability to 
provide contrast over the course of a typical ultrasound scan. As with dose response 
curves, the processing power (unsterilized or 0 W, 6.8, 10.5 and 18.0 W) had no 
differential effect on the stability of the agent for a given sterilization time (data not 
shown). For a power of 18.0 W, the effects on stability are shown in Fig. 4.30 for 
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various processing times. Unsterilized samples and samples processed for 1 and 3 
min lost a relative enhancement of 10% after 15 mins of insonation. However, 
samples sterilized for 6 mins were significantly less stable, losing roughly 35% of 
their original enhancement.  
 
 
Figure 4.30: In vitro normalized ultrasound enhancement over time of PLA UCA prior to and post 
varying exposure times to plasma at a power of 18.0 W. A statistically significant drop off in stability 
was seen for sterilization times over three minutes (p< 0.0001) (P=0.68 MPa, 5MHz, n=3, error bars= 
SEAM) [129]. 
 
While sterilization power did not affect either the agent’s ability to provide 
contrast or its acoustic stability, exposure times of over 3 minutes did reduce these 
properties and thus the agent’s overall function as a UCA. These findings are 
consistent with our SEM findings discussed in the next subsection, in which surface 
pitting was seen to greatly increase with increased plasma exposure time, while only 
moderately increasing with increases in plasma power. While increased shell pitting 
was noticed with increased plasma power, this increase was not detectable in terms of 
acoustic performance, indicating a potential threshold of shell integrity. It is believed 
that as extensive and deeper pitting occurs, the shell becomes more porous and is 
 102
eventually breached, at which point the UCA loses the ability to entrap gas for 
extended periods of time. This decrease in shell integrity explains both decreases in in 
vitro enhancement and stability during insonation. In future studies these observations 
could be used to develop agents with increased sensitivity to ultrasound, and with an 
increased surface area.  
 
4.2.3 Effects of Oxygen Plasma on UCA Surface Morphology 
 
UCA samples were examined using SEM to determine changes in 
morphology or noticeable deformation of the UCA surface.  It was noticed that 
increases in exposure time resulted in a more dramatic increase in surface pitting than 
increases in plasma power. An example of pre and post processing SEM images is 
shown in Fig. 4.31 for 0, 3 and 6 minute treatments at 18 watts.   
 
 103
 
Figure 4.31: Scanning electron micrographs of contrast agents (A) pre-plasma sterilization 
(magnification=9000X, size bar= 2 µm), (B) post-sterilization at 18.0 W for 3 mins 
(magnification=2500X, size bar= 2 µm), and (C) post-sterilization at 18.0W for 6 mins 
(magnification=2500X, size bar= 2 µm) [129]. 
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In light of changes to the UCA surface morphology, differential scanning 
calorimetry (DSC) was performed with the help of Dr. Chris Li (Drexel University, 
MSE) on samples to study the effect on bulk properties of the PLA during plasma 
exposure. The glass transition temperature (Tg) was used as an indication of bulk 
change in polymer. Although all samples also showed hysteresis, presumably due to 
the UCA fabrication process, all samples showed a consistent Tg of 59.8 +/- 0.9 oC 
with no trends among plasma power or exposure time. 
According to Menczel et al., amorphous polymers exhibit a hysteresis in heat 
capacity at the glass transition when the samples are heated much more rapidly than 
they had previously been cooled [130]. This is attributed to the fact that the change in 
the actual number of high-energy conformations is a function of the heating rate and 
the relaxation time.  Our results suggest that the w/o/w emulsion process used to 
fabricate the UCA produces capsules with an amorphous shell.   
 
4.2.4 Surface Modification of UCA Using Oxygen Plasma 
 
Zeta potential of plasma treated UCA was measured in order to judge changes 
in surface chemistry due to surface modification of the agent while interacting with 
plasma. Zeta potential was seen to increase with both plasma sterilization power and 
exposure time. These trends are counterintuitive to what would be expected from 
generation of -COOH groups and are summarized in Fig. 4.32. These results show 
that exposure to plasma has significantly altered the surface chemistry of UCA. 
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Figure 4.32:  Changes in zeta potential of UCA treated with plasma at varying powers and exposure 
times.  Both increases in power and exposure time increased the zeta potential of the UCA. Statistically 
significant increases relative to unsterilized samples were seen for both 10.5 and 18.0 W powers at 
processing times of 3 and 6 mins [129]. 
 
Both increased sterilization power and exposure time lead to increased zeta 
potential (less negative) of the agent, although no changes in the agent’s ability to re-
disperse were noticed. As mentioned above, this is somewhat surprising if the 
proposed interaction between the plasma and the PLA is the breaking of the polymer 
backbone and production of –COOH groups.  Generation of a carboxyl groups, with 
pKa’s below 4.0 would normally result in an increase in negative surface charge. It is 
still unclear why the zeta potential of treated UCA becomes less negative, but this is 
consistent with the proposed mechanism of Inagaki et al. [131], and to their 
observation that the surface hydrophilicity of plasma treated PLA surfaces did not 
increase as originally expected.  We have reported on anomalous zeta potential data 
of PLGA UCA in an earlier study in which fabrication of PLGA UCA using polymer 
with lauryl ester end-capped groups resulted in UCA with an average zeta potential of 
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-36.06 mV, while agents fabricated using PLGA with free –COOH end groups 
resulted in UCA with an average zeta potential of -28.49 mV (an increase of 7.57 
mV) [132] (Results shown in appendix).  However, this is more likely to do with 
forces that affect the actual conformation of the polymer at the surface of the capsule 
during fabrication, than with any post fabrication modification.  At this point in time, 
the exact mechanisms of shifts in zeta potential are not well understood and may 
equally well be from changes in surface morphology altering the particles’ 
electrophoretic mobility. 
A method of loading Dox to the surface of the UCA post fabrication (S-Dox-
UCA discussed in the previous section) was used as an example of how modification 
of the agent’s surface during sterilization can be used to alter potential drug and 
surface ligand attachment for targeted drug delivery applications. UCA sterilized with 
varying plasma power levels and exposure times were drug loaded as described in the 
methods section using a 4% Dox solution. A positive correlation between 
encapsulation efficiency with both plasma exposure time and sterilization power was 
seen. These results are summarized below in Fig. 4.33. 
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Figure 4.33: Loading efficiency of S-Dox-UCA using UCA processed with varying plasma powers 
and exposure times.  Surface modification during plasma sterilization resulted in significantly higher 
encapsulation efficiencies for high powered (18W) sterilizations of t=3 mins (5% increase, p=0.023) 
and t= 6 mins (10% increase, p=0.025)  (4% Dox loading for 24 hours at 4oC) [129]. 
 
A general trend of increasing drug attachment is seen for both increases in 
sterilization power and plasma exposure times. Samples sterilized using 18W showed 
a statistically significant increase in encapsulation efficiency for exposure times of 3 
mins (5% increase, p=0.023) and 6 mins (10% increase, p=0.023). 
Modification at the UCA surface provides increased options for surface 
attachment in both drug delivery applications, as was demonstrated by a 10% increase 
in encapsulation efficiency using a surface adsorption technique and future targeting 
applications. This process of surface modification is also expected to increase ligand 
attachment for targeting applications (more active groups are available for ligand 
conjugation).  This later property is significant in our application of tumor-targeted 
UCA. The plasma sterilization process is therefore ideal for our agents, enabling 
UCA fabrication using an end-capped polymer, followed by surface modification 
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during sterilization for potential drug delivery and targeting applications, without 
sacrificing the acoustic properties of the agent.   
 
4.2.5 Conclusions of Plasma Sterilization of UCA 
 
It has been shown that exposure to oxygen plasma reliably sterilizes PLA 
UCA without sacrificing their ultrasonic properties as long as the parameters are 
chosen with care. Additionally, surface modification during this process can be used 
to improve drug loading for ultrasound triggered drug delivery.  Parameters have 
been identified (18.0 W sterilization for t=3 mins) that reliably sterilizes the UCA, do 
not affect the agent’s sensitivity to ultrasound, and result in significant surface 
modification that can be used to increase drug adsorption. These conditions have been 
repeated 9 times and the resulting UCA are shown to also be sterile in blood agar 
cultures. Surface modification could well prove to be highly significant, firstly in 
improving targeting potential of ligated UCA, and secondly facilitating use of end-
capped PLGA, a polymer that produces more stable UCA, but which to date had 
generated few active groups on the UCA surface.  These possibilities are being 
actively pursued by us.  While numerous methods of sterilization have been proven to 
destroy PLA UCA, plasma sterilization appears to both sterilize and beneficially 
modify the agent for increased Dox adsorption using the S-Dox-UCA loading 
method. These results provide opportunities for future targeting and drug delivery 
applications, while also making long term cellular and in vivo studies feasible without 
the need for production within a clean facility.  
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4.3 Ultrasound Triggered Cell Death in vitro 
 
 Ultrasound triggered cell death using both the incorporated agent (I-Dox-
UCA) and surface adsorbed agent (S-Dox-UCA) were examined in in vitro. The 
success of each agent was judged in terms of the agent’s ability to trigger cell death 
after activation by ultrasound, while also minimizing cell death when uninsonated. 
Thus a platform would be developed in which ultrasound triggered cell death could 
be localized to diseased tissue, while minimizing cell death in healthy, non-targeted 
regions. Insonation parameters and the rate of cell death were also briefly studied to 
determine potential mechanisms of cell death and optimal conditions for future in 
vivo applications. The following work has been published in the journal Ultrasonics 
[133]. 
 
4.3.1 Cell Death using S-Dox-UCA 
 
The S-Dox-UCA was first examined as an ultrasound sensitive drug carrier. 
Dox adsorbed microbubbles were insonated at 5 MHz, 1.65 MPa in the presence of 
MDA-MB-231 cells as described in the methods section and cell death measured after 
48 hours. These results are shown in Figure 4.34. 
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Figure 4.34: Percent cell death of MDA-MB-231 cells 48 hours after insonation at 5 MHz (P=1.65 
MPa) in the presence of 2 mg of S-Dox-UCA (10µM total Dox). No significant differences were seen 
between the insonated S-Dox-UCA and uninsonated S-Dox-UCA indicating minimal cell death 
triggered by ultrasound [133].  
 
As expected, little cell death was seen in untreated cells (2.1 +/- 1.5%), and by 
introducing ultrasound alone (5.6 +/- 6.0 %), UCA alone (10.7 +/- 16.8 %) or 
ultrasound with unloaded UCA (7.2 +/- 4.3%). When Dox with and without 
ultrasound was introduced into the system cell death became significantly different 
from controls (p < 0.01).  However, no significant difference was found between 
treatment with free Dox accompanied by ultrasound (23.8 +/- 9.9 %), S-Dox-UCA 
without ultrasound (25.5 +/- 11.7 %), and S-Dox-UCA with ultrasound (29.23 +/- 
12.2). The most dramatic, and statistically significant (p = 0 0.0274 relative to S-Dox-
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UCA with ultrasound) increase was achieved when cells were treated with free Dox, 
blank UCA and ultrasound (38.3 +/- 12.2 %).   
The S-Doc-UCA results suggest that although Dox is initially adsorbed to the 
polymer shell, this does not prevent drug action, possibly due to release of Dox by 
polymer degradation at the surface. However, if free Dox and UCA are administered, 
the interaction of ultrasound with the UCA translates into an increase in susceptibility 
of the cells to the free Dox.  Increased cellular membrane permeability in the 
presence of insonated UCA has been observed by other groups at slightly lower 
frequencies (1 MHz) and varying acoustic pressure amplitudes (0.15-1.39 MPa peak-
negative-pressure), and is attributed to interactions between the inertial or transiently 
cavitating bubble and the cell membrane [4, 5, 134, 135]. While a strategy of free 
drug, free UCA and ultrasound may lead to optimal cell death and has been 
frequently reported in the literature [107-109], this approach does not address the 
main concern of reducing systemic toxicity in the healthy (uninsonated) areas unless 
the dose can be drastically reduced by this procedure. 
 
4.3.2 Cell Death using I-Dox-UCA 
 
The above investigation was repeated using UCA with incorporated Dox (I-
Dox-UCA). The results are shown in Fig 4.35. No significant difference was 
measured among the control samples and introduction of Dox in all forms induced the 
expected statically significant increase in cell death (p <0.01).  
However, with I-Dox-UCA, there was a statistically significant difference 
between the insonated drug loaded agent (25.78%) relative to the uninsonated agent 
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(16.12 %) (p=0.0272). The experimental group of insonated drug loaded agent 
showed equivalent efficacy as the 10µM free Dox combined with ultrasound. This is 
important since, unlike the free Dox, the incorporated Dox is not available to cause 
systemic toxicity.  While the free Dox, ultrasound and blank UCA still showed 
significantly more cell death (p=0.0124), again this strategy does not limit systemic 
toxicity. 
 
 
Figure 4.35: Percent cell death of MDA-MB-231 cells 48 hours after insonation (5 MHz, P=1.65 
MPa) of 2 mg (10µM total Dox) of UCA with Dox incorporated within the shell. A 9.66% increase in 
cell death was seen between the insonated drug loaded agent relative to the uninsonated agent 
(p=0.0272) [133].   
 
 
4.3.3 Cell Death Comparison of S-Dox-UCA with I-Dox-UCA 
 
Figure 4.36 shows a comparison of the two loading methodologies in the 
presence and absence of insonation (Data reproduced from figures 4.34-4.35). 
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Figure 4.36: Cell death comparison of insonated and uninsonated groups for S-Dox-UCA and I-Dox-
UCA. Significantly less cell death (p=0.0336) was seen between the uninsonated UCA with 
incorporated drug relative to the surface coated agent, while no difference was seen in efficacy 
between the insonated (activated) groups [133].  
 
 
Both platforms showed statistically equivalent efficacy post insonation, 
however the I-Dox-UCA showed roughly 10% less cell death compared the S-Dox-
UCA samples when not insonated (p=0.0336). These results indicate the incorporated 
platform is a better choice for targeted cancer therapy as the two platforms show 
relatively the same efficacy once insonated, but the I-Dox-UCA platform 
significantly reduces toxicity prior to activation (p=0.0272 compared to the 
uninsonated control). By using a platform with lowered systemic toxicity, overall 
treatment dosage may be increased, both minimizing side effects and increasing drug 
efficacy. 
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4.3.4 Effects of Insonation Pressure Amplitude on Cell Death  
 
Insonation pressure amplitudes were varied for both S-Dox-UCA and I-Dox-
UCA. Cell death for each of these groups at 48 hours is shown in Fig 4.37. 
 
 
 
Figure 4.37: Effects of insonation pressure amplitude with both S-Dox-UCA and I-Dox-UCA after 48 
hours. Significant increases in cell death were seen for shell incorporated agents for pressure 
amplitudes of 1.26 MPa and above [133]. 
 
 
Varying insonation pressure amplitude showed no statistically significant 
differences in cell death for all S-Dox-UCA. These findings are consistent with our 
previous findings and reinforce the hypothesis that all available drug is exposed with 
or without UCA destruction, resulting in limited additional cell death with sonication. 
A statistically significant increase in cell death was seen for I-Dox-UCA for 
all pressure amplitudes larger than 0.92 MPa (p=0.0346). Cell populations insonated 
at a pressure amplitude of 1.26 MPa showed an 8.11 % increases in total cell death (a 
48% increase in drug efficacy) compared to insonation at 0.92 MPa. Several groups 
have examined the cavitation thresholds of similar polymeric UCA with reports of 
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thresholds as low as 0.96 to over 1.54 MPa depending on UCA shell thickness and 
insonation frequency [61, 136]. These findings provide evidence that the incorporated 
agent is becoming significantly more toxic after sonication due to rupture of the 
agent.  
 
4.3.5 Cell Death over Time with I-Dox-UCA  
 
The rate of cell death using I-Dox-UCA was investigated by observing cell 
death over time. Cell populations were combined with the platform and insonated at 
1.65 MPa for 20 mins. Results were compared to a non-insonated control. These 
results are shown in Fig 4.38.  
 
 
Figure 4.38: Cell death over 48 hours of cells insonated at 5MHz in the precence of 2 mg of  the I-
Dox-UCA (3%)  platform. The insonated and uninsonated groups show similar cell death over the first 
8 hours, but become significantly different (*p=0.0093) at 24 hours and for all time points afterwards 
[133]. 
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 No statistically significant differences were seen between the insonated and 
uninsonated groups over the first eight hours, although cell death was 3.6 and 5.3% 
higher at 4 and 8 hours respectively. Between 8 and 24 hours cell death for insonated 
cells relative to the uninsonated control increased, resulting in significantly higher 
cell death starting at 24 hours (*p=0.0093). This increase in cell death after 8 hours in 
insonated populations is believed to be a result of apoptosis, not physical stresses 
associated with UCA cavitation, which would present immediate signs of cell death. 
For example, in a study examining Dox triggered apoptotic cell death in Jurkat cells 
(a T cell leukemia model) Blankenberg et al found only 2% apoptosis after 12 hours, 
but 57% after 24 hours [137]. The low levels of cell death prior to 24 hours is 
consistent with the low level of cell death seen with insonated, unloaded UCA 
(7.15%) in Fig 4.34-4.35. Images showing differences of cell death at the 48 hour 
time point between non-treated controls and insonated I-Dox-UCA are shown below 
in Fig 4.39. 
 
 
Figure 4.39: Differences in cell death in populations with a) non-treated cells and b) insonated I-Dox-
UCA at a pressure amplitude of 1.65 MPa (Green = live cells, Red = dead cells, size bar = 100 µm, 
time = 48 hours). The decrease in cell population size with drug loaded agent is due to Dox halting cell 
reproduction, eventually leading to cell apoptosis [133]. 
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4.3.6 Cellular Uptake of PLA-Dox Shards after Insonation 
 
Fluorescent and confocal microscopy was performed on cells 12 hours after 
insonation to identify the location of Dox within the cell as described in the methods 
section. Fig 4.40-4.41 shows merged images of fluorescent and bright field images of 
MDA-MB-231 cells 12 hours after insonation with I-Dox-UCA 
 
 
Figure 4.40: MDA-MB-231 cells 12 hours after 20 mins of 5 MHz insonation with I-Dox-UCA (3%) 
at a pressure amplitude of 1.65 MPa  (size bar = 100 µm) 
 
.   
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Figure 4.41: MDA-MB-231 cells 12 hours after 20 mins of 5 MHz insonation with I-Dox-UCA (3%) 
at a pressure amplitude of 1.65 MPa (size bar = 10 µm). 
 
 Fluorescence from Dox was clearly visible within the MDA-MB-231 cells 12 
hours after 20 minutes of insonation at 5 MHz, indicating that Dox initially 
introduced within the UCA is transported into the cell, eventually leading to the cell 
death discussed previously. Additionally, fluorescence appeared to be centralized 
within the nucleus of the cell. This locality would be ideal in inducing cell death, as 
Dox leads to cell death by DNA intercalation interference as discussed in the 
background section.  As a result of these preliminary findings, confocal microscopy 
was used to investigate Dox location within the cell after ultrasound triggering. These 
results are shown in Fig 4.42-4.43. 
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Figure 4.42: MDA-MB-231 cells 12 hours after 5 MHz insonation with I-Dox-UCA (3%) at a 
pressure amplitude of 1.65 MPa  imaged using confocal microscopy (size bar = 20 µm).  
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Figure 4.43: MDA-MB-231 cells 12 hours after incubation with I-Dox-UCA (3%) with no insonation 
imaged using confocal microscopy (size bar = 20 µm).  
 
 Fig 4.42 shows MDA-MB-231 cells 12 hours after insonation with I-Dox-
UCA.  Dox fluorescence is clearly centralized within the nucleus, indicating that after 
ultrasound triggering, Dox not only transports into the cell, but into the nucleus where 
it can trigger cell death.  While the presence of Dox within the nucleus is expected 
and consistent with cell death experiments, the lack of Dox within the cytoplasm is 
surprising. This is believed to be due to the physical attraction forces between the 
Dox-PLA fragments and DNA, causing Dox within the cell to bind to DNA and 
eventually aggregate within the nucleus. Fig 4.43 shows MDA-MB-231 cells 12 
 121
hours after incubation with I-Dox-UCA (no insonation). Uninsonated cells showed 
minimal Dox within the nucleus, indicating that this uptake may be ultrasound 
dependant. It is believed that insonation may cause UCA to rupture resulting in a 
smaller particle suspension more prone to endocytosis and cell uptake.  
 The phenomena of UCA delivered encapsulated Dox appearing centralized 
within the nucleus has begun to be documented in the literature, as has the importance 
of the drug remaining encapsulated post release. Lentacker et al. formulated Dox-
liposome loaded UCA and showed increased melanoma cell nucleic uptake and cell 
death when insonated with 1 MHz, 50% duty cycle, ultrasound with an intensity of 2 
W/cm2 in vitro compared to Dox-liposomes alone [138].  While insonation of Dox-
liposome loaded UCA resulted in higher Dox concentrations within the nucleus, 
insonation of both free Dox with lipid UCA and lipid UCA containing Dox resulted 
in lower nucleic uptake. This study shows both the feasibility of UCA delivered 
chemotherapy, as well as the importance and advantage of maintaining drug 
encapsulation post UCA destruction [138].   
Additionally, several groups have shown that cells in close proximity to 
cavitating contrast agents become temporarily more permeable, potentially leading to 
an increase if PLA-Dox shard uptake [4, 139, 140]. The addition of ultrasound is also 
expected to lead to increased interaction between the UCA and cells as radiation 
forces are generated, pushing the UCA towards the cells and forcing interaction 
between the two.  Thus, the addition of ultrasound provides a three-fold advantage for 
drug delivery in vitro; 1: decreased size of the particles due to UCA rupture, 2: 
temporarily increased cellular membranes, and 3: increased interaction of the Dox-
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UCA and cells due to acoustic radiation forces. These factors explain both the 
increased intracellular Dox shown in Fig 4.42 relative to Fig 4.43, as well as the 
increased rate of cellular death discussed in the previous subsection. These 
advantages are also expected to translate well into in vivo applications.  
 
4.3.7 In vitro Ultrasound Triggered Cell Death Conclusions 
 
  A PLA UCA with drug incorporated within the shell (I-Dox-UCA) has been 
shown superior in triggering cell death in vitro compared to a surface adsorbed agent 
(S-Dox-UCA). I-Dox-UCA has shown equivalent potency in MDA-MB cancer cells 
to free Dox combined with ultrasound. Without activation from ultrasound, the agent 
approaches half the platform’s potency. These differences have been linked to UCA 
rupture and are believed to be due to both an increase in exposed drug and uptake of 
Dox-UCA shell fragments. This platform shows promise for an in vivo platform in 
which a systemic dose of drug loaded UCA can be used with external ultrasound to 
provide localized cell death at an area of need, while minimizing cytotoxicity of 
healthy tissue. 
 
4.4 In vitro Ultrasound Triggered Size Reduction and Membrane Penetration 
 
 It is believed that when insonated, the Dox loaded carrier I-Dox-UCA 
ruptures, resulting in polymer shards on the nano-scale with Dox encapsulated within 
the shell. These resulting particles (which could be generated in situ may be capable 
of penetrating through the leaky tumor gap junctions discussed in the background and 
entering the tumor interstitia. From the interstitium these particles could then provide 
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a sustained, intratumoral release during degradation. Delivery of drug eluting 
nanoparticles directly to the tumor interstitium may potentially avoid the systemic 
toxicity seen with current chemoembolizations where drug elution from larger, 
surgically implanted beads is often circulated throughout the vasculature after release. 
The following subsections will examine I-Dox-UCA’s ability to reduce in size when 
insonated as well as pass through several in vitro permeable membrane models.  
 
4.4.1 In vitro Size Reduction of I-Dox-UCA during Insonation 
 
Particle size during periods of insonation in vitro was examined to determine 
the ability to reduce I-Dox-UCA’s size in situ.  Results from this study are shown in 
Fig. 4.44. Uninsonated controls (0.00 MPa) showed a trend in increasing size (27% 
size increase over 20 mins, p=0.66809), presumably due to UCA swelling or 
aggregation. Size reduction within the UCA population was seen for all insonated 
populations, becoming statistically significant after 15 minutes for all pressures 
(p<0.05).  For each insonation group, suspensions showed an average size of less than 
350 nm after 15 minutes. These resulting particles are thus small enough to pass 
through gap junctions within the tumor vasculature, entering the tumor interstitia 
where they may potentially provide a sustained chemotherapeutic release during 
degradation.  Additionally, this level of size reduction was reached in 5 mins (10 mins 
quicker) for suspensions insonated at 1.26 and 1.65 MPa. Crum’s group has shown 
that a fragmentation threshold for similar, thick shelled polymer UCA was found at 
0.96 MPa at 3.5 MHz pulses [136]. Thus, this increased rate of size reduction may be 
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due to insonation at pressures above the fragmentation threshold, while the size 
reduction at lower pressures is due to gradual fragmentation due to shell fatigue.   
 
 
Figure 4.44: Effects of varying insonation pressure amplitude and exposure time on average particle 
size of I-Dox-UCA. After 15 mins all insonated suspensions showed statistically significant size 
reduction (p < 0.05). The resulting particle suspension showed an average size capable of passing 
through gap junctions within solid tumors [141]. 
 
 These results have led us to believe that our platform (I-Dox-UCA) may 
potentially be capable of ultrasound triggered size reduction in situ. Upon reaching 
the desired site (a solid tumor), the platform could be activated using ultrasound to 
create a Dox-PLA nanoparticle small enough to pass through the leaky tumor 
vasculature to the tumor interstitia. Once in the tumor interstitia these particles induce 
cell death as examined in the ultrasound triggered cell death section, or provide a 
sustained release as the particles degrade. 
 SEM micrographs were obtained of 3% I-Dox-UCA post insonation and 
freeze drying to provide additional evidence of ultrasound triggered size reduction 
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and explore possible mechanisms. Figure 4.45 shows a sample prior to insonation and 
freeze drying, Fig. 4.46 shows the sample suspended in PBS without insonation, then 
freeze dried, and Fig 4.47-4.49 show example micrographs of the sample suspended 
in PBS, insonated for 20 mins, then freeze dried. 
 
 
Figure 4.45: SEM of 3% I-Dox-UCA prior to resuspension, insonation, and freeze drying. 
Accelerating voltage = 3 kV, Magnification = 2.94 kX, Size Bar= 5 µm. Incorporated samples showed 
smooth, spherical particles consistent with previous studies. 
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Figure 4.46: SEM of 3% I-Dox-UCA after resuspension and  freeze drying (no insonation) . 
Accelerating voltage = 3 kV, Magnification  = 3.00 kX, Size Bar = 10 µm. The majority of UCA 
remained intact, smooth and spherical. Larger particles appeared to have been smashed and some 
larger debris was also detected. 
 
 
Figure 4.47: SEM of 3% I-Dox-UCA after resuspension, 20 minutes insonation at 5 MHz 1.65 MPa, 
and  freeze drying. Accelerating voltage = 3 kV, Magnification  = 5.34 kX, Size Bar = 2 µm. The 
presence of both shattered UCA, shell fragments, and ‘shriveled’ UCA were observed.  
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Figure 4.48: SEM of 3% I-Dox-UCA after resuspension, 20 minutes insonation at 5 MHz 1.65 MPa, 
and  freeze drying. Accelerating voltage = 3 kV, Magnification  = 8.00 kX, Size Bar = 500 nm. The 
micrograph shows the presence of fragmented UCA shells. 
 
 
Figure 4.49: SEM of 3% I-Dox-UCA after resuspension, 20 minutes insonation at 5 MHz 1.65 MPa, 
and  freeze drying. Accelerating voltage = 3 kV, Magnification  = 4.00 kX, Size Bar = 10 µm.  A large 
population of smaller nanoparticles (50-150 nm)  was detected and believed to be created during 
ultrasound triggered destruction of the UCA. 
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 The results of two different potential mechanisms of particle population size 
reduction were noticed in SEM micrographs of insonated, freeze dried samples that 
were not detected in either the original, or uninsonated control groups. These include 
the ‘shriveling’ of UCA shell or skins after rupture and the fragmentation of shells 
resulting in the apparent generation of smaller particles during fragmentation.  
Polymer shelled UCA have been shown to oscillate about shell defects when 
insonated [61] (See appendix B). It is believed that both the fragmentation of UCA 
and generation of smaller, previously undetected particles may result from these 
oscillations, which can lead to inertial cavitation at higher pressure amplitudes (>1 
MPa). Ferrara’s group examined the destruction of polymer shelled UCA and found 
they sometimes jettison the core gas bubble through surface defects prior to 
destruction, often leaving the shell intact [61]. Expulsion of the gas core without 
sacrificing shell integrity may result in the shriveled shell ‘skins’ seen in the images 
above. While the exact mechanism of destruction cannot be pinpointed without high 
speed microscopy, it is clear from the images that ultrasound mediated destruction 
does result in significant size and morphological changes to the agent, potentially 
allowing the resultant particles to transport out of the vasculature. A brief study of 
using high speed microscopy to investigate oscillations of I-Dox-UCA is shown in 
Appendix B. 
 
4.4.2 In vitro Penetration of I-Dox-UCA through a 400 nm Membrane 
 
 Corning 400 nm transwell inserts were used as a model of leaky tumor 
vascualutre to determine if fragments generated in situ from I-Dox-UCA were small 
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enough to pass out of the tumor vasculature through leaky gap juntions. Solid 200 nm 
Dox-loaded NP, free Dox, and uninsonated I-Dox-UCA were compared to insonated 
I-Dox-UCA using the setup desribed in the methods section. Results of this study are 
shown in Fig 4.50. 
 
Figure 4.50: Dox transport through a 400 nm membrane using I-Dox-UCA and ultrasound. After 20 
mins of insonation (5 MHz, 1.68 MPa, PRF=100 Hz) transport of Dox became significantly higher 
(p=0.0036) than the uninsonated control, Dox loaded nanoparticles with ultrasound, Dox loaded 
nanoparticles with ultrasound and unloaded UCA, and equivalent to free Dox in solution (n=3, Error 
bars= SEAM). 
 
 
 A significant increase (p=0.0036) was seen in Dox transport through the 
membrane after 20 mins using I-Dox-UCA when combined with ultrasound. 
Uninsonated I-Dox-UCA, insonated Dox nanoparticles, and the combination of Dox 
nanoparticles with unloaded UCA showed no increase in transport over a 20 min 
span. Uninsonated I-Dox-UCA was not expected to pass through the membrane due 
to the size restriction (400 nm pores vs 1.2-1.8 µm UCA).  The lack of transport using 
solid 200 nm Dox nanoparticles was somewhat surprising. However, as touched on in 
the background section, the acoustic radiation forces on solid nanoparticles are 
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relatively small (<0.1 pN) and not large enough to overcome the graviational focres 
opposing transport [122]. This is also consistent with the insonated nanoparticle/ 
UCA group. While cavitatating UCA has proven to increase transport of solid 
nanoparticles [7], this appears to be a biological based phenomena and may not be 
replicable with a polyester membrane.  
To understand how these forces lead to a greater level of transport it is usefull 
to calculate peak particle velocities. Using equations 12 and 13 from the background 
section acoustic radiation and buoyancy forcess can be calculated as 2.02 nN and 
0.035 pN respectivly. Summing these forces and equating them to the Stoke’s drag 
force of small Reynolds numbers: 
 
ܨ஽ ൌ 6ߤߨݎܸ,  Eq 17 
 
where V is the particle velocity (m/s) and ߤ is the fluid’s dynamic viscosity (Pa s), we 
find the UCA achieve peak velocities of up to 77 mm/s.  To put these velocites in 
perspective, Brownian motion velocity can be calculated by: 
 
஻ܸ௥௢௪௡௜௔௡ ൌ ௄ಳ்/ଶ௥଺ఓగ௥ , Eq 18  
 
where KB is Boltzman’s constant and T is the temperature in oK. Brownian motion on 
the UCA equates to roughly 0.2µm/s.  
 Repeating these calculations, the Dox loaded nanparticles experince acoustic 
radiation forces of only 0.2 pN and a buoyancy force of -0.038 pN, which result in 
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peak velocities of only 0.02 mm/s. However, due to their smaller size, these particles 
reach velocities due to Brownian motion of up to 0.027 mm/s, negating acoustic 
radiation velocities. Differences in membrane transport are most likely attributed to 
this variation in velocity between the two platforms.  
Peak Dox transport using the I-Dox-UCA was observed after 20 mins of 
insonation at 18% with no statistical significant difference from free Dox.  It is 
somewhat unexpected that free Dox would transport at such a rapid rate when 
generally dependant on diffusion through the membrane. However, because roughly 
10% of the sample volume is removed from the top of the setup at each time sampling 
point, removal of media is believed to create suction through the membrane, possibly 
increasing speed of transport. 
 Within the setup described, the transport of PLA-Dox shards through a 
membrane is believed to be a two part process. First, the micron-sized UCA must be 
moved to the membrane surface using acoustic radiation forces (Eq 12). NP were not 
seen to be influenced by radiation force. Secondly, the I-Dox-UCA must rupture near 
the pores, resulting in a significant size reduction to allow transport through the 400 
nm membrane pores. Evidence of size reduction is shown below in Fig 4.51, examing 
the size of Dox particles before and after membrane transport. 
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Figure 4.51: PLA-Dox particle size before and after transport through a 400 nm membrane with 20 
mins of insonation (5 MHz, 1.68 MPa, PRF=100 Hz). I-Dox-UCA prior to insonation showed a size 
distribution between 1 and 1.2 µm, while insonated particles that passed through the membrane 
showed a size distribution between 200-400 nm. 
 
 Figure 4.51 demonstrates that PLA-Dox particles that transport through a 
membrane are substanitally smaller (~600 nm smaller) than the uninsonated control. 
These results confirm a size reduction takes place in insonated populations capable of 
passing through the membrane.  
 After proof of concept, transport optimzation was attempted based on a two-
tired approach. In the first tier of insonation, acoustic raditation forces were optimized 
without causing UCA rupture (Eq 12) to position UCA at the surface of the 
membrane. Acoustic parameters included a lower insonation frequency (2.25 MHz), 
and lower pressure amplitude (313 kPa) to avoid UCA rupture. After positioning 
using acoustic radiation forces, a destructive, higher freuqency, higher pressure (5 
MHz, 1.68 MPa) pressure amplitude is generated to rupture UCA and allow 
membrane transport. This approach was attempted at varying time ratios and shown 
in Fig 4.52. 
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Figure 4.52: Dox transport through a 400 nm membrane using I-Dox-UCA and ultrasound.  Total 
insonation was performed for 20 mins, while varying 2.25 MHz insonation intervals, followed by 5 
MHz insonation for the remainder of the 20 mins. Twenty minutes of insonation at 5 MHz (no 
insonation at 2.25 MHz) resulted in maximal transport, although no significant differences were 
detected (p=0.6624) (n=3, Error bars=SEAM). 
 
 
 Consistent with the previous study, maximal Dox transport reached roughly 
18% after 20 mins of insonation. No statistical differences were observed between 
groups (p=0.6624).  However, a noticeable trend was seen, with transport decreasing 
with increased 2.25 MHz insonation intervals. While it was originally thought that 
positioning using non-destructive acoustic radiation forces may result in increased 
delivery, higher pressure amplitudes at 5 MHz insonation appears to be more 
beneficial for transport. Longer insonation intervals at 5 MHz (near the resonance 
frequency of the UCA) and at higher pressures may result in a larger proportion of 
fragmented UCA, resulting in more sub-micron particles capable of passing through 
the membrane. While this in vitro model is useful in understanding some of UCA 
behavior during insonation, it is acknowledged that this is done under static 
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conditions and lacks the bio-physical effects of UCA cavitation described in the 
background section.  
 
4.4.3 In vitro Penetration of I-Dox-UCA through a 400 nm/ Cellular Membrane 
 
Similar experiments as above were conducted using Corning 400 nm transwell 
inserts with porcine aortic endothelial cells (PAEC) grown on the top surface. The 
addition of a cell layer above the membrane was used to study potential biophysical 
effects of UCA rupture and shard generartion in the leaky tumor vasculature model. 
Solid 200 nm nanoparticles, free Dox, and uninsonated I-DocUCA were compared to 
insonated I-Dox-UCA using the setup desribed in the methods section. Results of this 
preliminary study are shown in Fig 4.53.  
 
 
Figure 4.53: Dox transport through a 400 nm membrane with PAEC layer using I-Dox-UCA and 
ultrasound.  Total insonation was performed for 20 mins, at 5 MHz with a peak pressure amplitude of 
1.68 MPa (n=3, Error bars=SEAM). 
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  As seen in Fig 4.53, no changes in Dox transport using I-Dox-UCA were seen 
over 20 minutes of insonation at 5 MHz, PRF of 100 Hz, and peak postivie pressure 
amplitude of 1.68 MPa. No statisitcally significant variation was seen between the 
insonated I-Dox-UCA platform and any of the encapsulated controls (p=0.5716). Free 
Dox combined with ultrasound showed no statistically significant difference in 
tranport through the PAEC layered membrane compared to the polyester membrane 
alone (Fig 4.50) (p=0.1899), indicating the presence of a cellular layer did not alter 
transport of free drug across the membrane. Free Dox did show significantly higher 
transport than the I-Dox-UCA platform when combined with ultraosund (p=0.0341), 
demonstrating the failure of the drug loaded UCA to penetrate the polyester-PAEC 
layered membrane as efficiently as free drug alone. It was initially believed that 
rupturing of UCA at the surface of the membrane may induce an increase in 
membrane permeability through detachment of cells. This theory would be consistent 
with examples in the literature, such as de Jong’s group who showed that jetting from 
inertial cavitating gas microbubbles in the vicinity of a cellular boundary resulted in 
detachment of roughly 5 cells/localized bubble in vitro [114].  However, the thickness 
of the polyester membrane (10 µm) may be too large for any UCA-cell interaction, 
preventing PAEC detachment.  
 Using the same insonation strategy as Fig 4.52, lower frequency (2.25 MHz), 
and lower pressure amplitude (313 kPa) insonation was used to posittion UCA at the 
membrane surface before triggering the 5 MHz destructive pressure amplitudes (5 
MHz, 1.68 MPa). Results from this approach are shown in Fig 4.54. 
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Figure 4.54: Dox transport through a 400 nm polyester membrane with PAEC layers using I-Dox-
UCA and ultrasound.  Total insonation was performed for 20 mins, while varying 2.25 MHz insonation 
intervals. Consistent with Fig 4.53, no changes in transport were seen and no significant transport 
differences between insonation combinations were detected (p=0.6129) (n=3, Error bars=SEAM). 
 
 Consistent with Fig 4.53, no changes in Dox transport were detected for any 
insonation regime over the 20 minute period. No significant differnces (p=0.6129) 
were measured among variations of 2.25 and 5.0 MHz insonation schemes. These 
results reinforce the previous thought that while UCA may be rupturing at or near the 
membrane surface, the thickness of the polyester membrane may be preventing any 
cellular detachment. Without this detachment transport of larger PLA-Dox shards 
(350 nm relative to <1 nm of free Dox) is greatly inhibited. Post insonation, 
membranes were examined by light micropscopy and no major evidence of cellular 
detachment was detected, reinforcing this theory.  Future work focusing on creation 
of a similar based model but with more UCA-cell interaction would provide a far 
superior platform for both proof of concept and optimization in vitro. 
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4.4.4 In vitro Size Reduction and Membrane Penetration Conclusions 
 
 The ability of the I-Dox-UCA to reduce in size after ultrasound triggered 
rupture has been demonstrated in vitro. It is believed that after triggering, the 
resulting PLA-Dox shell fragments are small enough to pass through leaky tumor 
vasculature, aggregate within the tumor interstitia, and provide a sustained release 
during degradation. While final particle size was found to be independent of 
insonation pressure amplitude at 5 MHz, increased pressure amplitudes (0.92 MPa 
and above) led to a quicker size reduction of the I-Dox-UCA population.   
 Electron microscopy was used to confirm this behavior and determine 
potential mechanisms of UCA size reduction. Insonated samples clearly showed 
evidence of UCA destruction, while non-insonated controls showed minimal damage. 
Both fragmentation of smaller (<1.5 µm) UCA and the ‘shriveling’ of larger (> 3 µm) 
was detected, indicated multiple modes of UCA destruction and size reduction may 
be at play. 
 Finally, two in vitro models using 400 nm polyester membranes were 
constructed to examine the Dox loaded agent’s ability to pass through leaky 
membranes post ultrasound triggering. The I-Dox-UCA platform proved as efficient 
in Dox transport across a 400 nm polyester membrane as free Dox, and significantly 
more efficient (p=0.0036) than the uninsonated platform, Dox nanoparticles, and a 
combination of Dox nanoparticles with unloaded UCA. This performance is 
attributed to buoyancy forces of the UCA, the ability of the agent to reduce to sizes 
small enough to pass through the 400 nm membrane, and acoustic radiation forces. A 
similar model was constructed consisting of a 400 nm polyester membrane with 
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PAEC layer in an attempt to examine potential bio-physical effects on Dox transport 
during UCA rupture. However, the insonated I-Dox-UCA platform showed 
significantly less transport in this model compared to Free Dox alone (p=0.0341) and 
no statistically significant improvement in transport over the uninsonated or 
nanoparticle controls (p=0.5716).  Lack of Dox transport in the polyester-PAEC 
layered model is believed to be due to a decrease in pore size and an inability of the 
UCA to interact with the cell layer. Ideally, in future in vivo applications the UCA 
will be in closer proximity to vasculature wall, resulting in a larger cellular disruption 
and ultimately higher vascular permeability.  
 
4.5 Dox Release Profile from I-Dox-UCA over Time 
 
 Release of free Dox over time was examined to determine if the delivered 
PLA-Dox nanoshards could provide a sustained release of drug once in the tumor 
interstitium and if this effect was ultrasound dependant. Twenty mg of 3% I-Dox-
UCA was insonated for 30 minutes (the point at which no backscattering 
enhancement was detected) and free Dox release with time compared to a 
uninsonated control as described in the methods section. Release profiles over a three 
week period are shown in Fig. 4.55. 
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Figure 4.55: Dox elution from insonated and uninsonated 3% I-Dox-UCA. Gradual, sustained release 
was seen with 75% release achieved after 22 days of incubation. No differences were seen between 
insonated and uninsonated samples (p=0.1841) (n=3, Error bars= SEAM).   
 
 Dox elution gradually increased over time, reaching 75% release after 22 days 
of incubation.  No statistical differences (p=0.1841) were detected between the 
insonated and uninsonated groups. Originally, it was believed that UCA rupture 
would lead to a greater exposed surface area and therefore quicker polymer 
degradation though hydrolysis and in turn a faster rate of Dox elution. However, this 
does not appear to be true. While the polymer itself has a longer time of degradation 
(up to 1 month), diffusion of the gas core occurs much more rapidly (1-6 hours), after 
which the integrity of the shell is breached and its gaseous interior is replaced by the 
suspending media. As a result, both destroyed (insonated) and intact (uninsonated) 
UCA show similar release profiles over the long term as the PLA degrades. 
 While it has been shown that this platform is capable of providing a sustained 
release in vitro, it is important to note that this release may not be necessary for the 
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treatment of solid tumors.  As was shown in section 4.3, once insonated, the Dox-
UCA ruptures into small ‘nanoshards’, capable of being uptaken by cells, possibly 
being trafficked through the acid lysosomes where polymer degradation would 
accelerate,  and eventually reach the nucleus inducing cell death. Thus, Dox-PLA 
particles that are transported into the tumor interstitium should lead to tumor 
shrinkage by both cell uptake and by providing a sustained release during 
degradation. While cell uptake is expected to occur much more rapidly, ability to 
provide a sustained release is also a potential benefit and may prove advantageous for 
other applications.   
 
4.6 In vivo Delivery of I-Dox-UCA to a VX2 Tumor Model  
 
 The ability of the I-Dox-UCA platform to delivery chemotherapeutic to a 
solid tumor was first examined in a VX2 liver tumor model in New Zealand rabbits, 
due to the tumor’s high vascularity and growth rate. Ability to detect the agent, Dox 
blood levels over a 4 hour window, organ toxicity and tumor toxicity were all 
compared with and without insonation to determine if the platform could be used to 
locally delivery chemotherapeutic.  
 
4.6.1 Ultrasound Image Enhancement of a VX2 Tumor Using I-Dox-UCA 
 
In vivo imaging was conducted showing the agent’s potential to both provide 
enhancement during ultrasound scans, and penetrate into the vasculature of a solid 
tumor. Doppler ultrasound was used to image the solid tumor at a frequency of 5 
MHz at a MI of 1.0 (the highest possible power output), believed to result in  
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pressures above what have been shown to cause destruction of polymer shelled UCA 
[61], a potential mode of triggering drug release. This MI was selected for maximal 
output power from the transducer, ensuring maximal UCA rupture and fragment 
generation. Figure 4.56 shows Doppler images of the tumor pre and post injection of 
the UCA. 
 
 
Figure 4.56: Power Doppler image of an implanted VX2 tumor within the liver of a 2-3 kg New 
Zealand Rabbit, a) pre injection, b) post injection of I-Dox-UCA. The upper left oval shows the solid 
tumor within the liver. Notice that after injection, UCA penetrates well into the tumor as well as in the 
tumor feeding vessels surrounding it [123].  
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Results from imaging studies with our agent show that the UCA penetrates 
well into the solid tumor and the in vitro studies indicate that focused ultrasound can 
be used to cause destruction of the microbubbles in an isolated region.  For drug 
release studies in vivo, the ultrasound beam can be focused entirely on the solid tumor 
(1-2 cm2 surface area), initiating destruction of UCA within this region.  
 
4.6.2 Dox Blood Serum Levels During Delivery of I-Dox-UCA to a VX2 Tumor 
 
Dox levels were measured within the blood serum to quantify free drug in 
circulation. Peak serum levels were detected 5 minutes after injection with 3.90 pM 
and 3.75 pM for the non-insonated and insonated groups respectively. No statistically 
significant differences were seen between groups (p=0.4340) and serum levels 
became undetectable 15 minutes after injection (sensitivity cutoff less than 1.85 pM).  
As expected, encapsulation of the drug within the UCA dramatically reduced the 
level of free Dox within circulation. Compared to a reference study and normalizing 
the amount of Dox (2 mg versus 11.25 mg) I-Dox-UCA resulted in a decrease in over 
35,000 pM/mg serum concentration compared to free Dox, and a nearly 400 pM/mg 
reduction in serum concentration compared to Dox loaded PVA beads used in 
transcatheter arterial chemoembolization [142]. Additionally as expected, the addition 
of ultrasound did not result in an increase in Dox serum levels, indicating that free 
drug was not released during UCA destruction.  These results are similar to in vitro 
results, showing insonation of Dox loaded agents using all three drug loading 
methods resulted in minimal drug release after UCA rupture. Although free Dox will 
eventually be released during degradation of the PLA, this gradual release at the 
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tumor site avoids any bolus systemic circulation of chemotherapeutic, greatly 
minimizing side effects from drug toxicity. 
 
4.6.3 Organ and Tumor Dox Levels using I-Dox-UCA 
 
Organs of specific interest (heart, spleen, and healthy liver) and VX2 tumors 
were harvested post treatment and drug levels determined as described in the methods 
section. These results are shown in Fig. 4.56.  No significant differences in drug 
levels were detected between any organs in the non-insonated groups. Heart and 
spleen showed no significant differences in drug levels between the insonated 
(experimental) and uninsonated (control) groups. Heart (1.08 ng/g, 0.89 ng/g), spleen 
(1.10 ng/g, 1.20 ng/g), and liver (1.48 ng/g, 0.75 ng/g) tissue (control, experimental) 
all had more drug than the VX2 tumor. It is believed that the higher presence of Dox 
within the organs relative to the tumor is due to the higher vascularity of these three 
organs. This ratio is consistent with drug levels in the healthy liver versus VX2 in a 
reference study using free Dox [143].   
A significant decrease (*p=0.0094) was detected within the healthy liver when 
insonation of the tumor took place. This corresponded to a total Dox decrease of 0.64 
ng Dox per gram of tissue.  While we have not yet elucidated the reason for this 
decrease, it is believed to partially be a result of increased drug accumulation within 
the tumor. Additionally, the significant size reduction of the UCA during insonation 
discussed in the previous subsections may result in a drug loaded particle more able 
to freely pass through the liver vasculature, resulting in lower drug levels at the time 
of harvest.  
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 Tumor drug levels were measured for both the central and peripheral tumor 
and are also shown in Fig. 4.57.  The center portion of the tumor was highly necrotic 
and showed low drug levels (0.14-0.15 ng/g tissue) with no significant differences 
between groups. This is consistent with the lack of vasculature within the region of 
the tumor and thus a lack of delivery of agent. The peripheral, outer portion of the 
tumor (generally responsible for the spread of the disease and roughly 66% of the 
tumor cross sectional area) showed significantly (**p=0.0036) more Dox levels when 
insonated relative to the uninsonated control. This increase of 0.26 ng Dox/ g tissue 
corresponds to an increase of 110% in Dox delivery efficiency relative to the non-
insonated control.  This increase in delivery is presumed to be due to localized size 
reduction of the agent within the vasculature, enabling the resulting particles to travel 
out of the tumor vasculature and accumulate in the interstitia.  
 
 
 
 145
 
Figure 4.57: Organ and tumoral Dox levels using the platform with and without ultrasound. 
Significantly less drug was accumulated within the liver when combined with tumor insonation 
(*p=0.0094). The peripheral (vascular) region of the tumor showed an increase of 110% in Dox 
delivery (**p=0.0036) when insonated relative to the non-insonated control [141]. 
 
 While these drug levels within the peripheral of the tumor are still believed to 
be below therapeutic levels (1-10 µM), the increase in delivery efficiency does show 
promise for the delivery vehicle itself. The maximal tolerable dosage of PLA UCA is 
still unknown, although no distress was observed within either animal population, 
indicating larger injection volumes may be achievable. Additionally, metronomic 
dosages may provide opportunity for multiple staged injections, building tumoral 
drug levels over time. Finally it is anticipated that tumoral drug levels will increase 
over time as Dox-PLA fragments and smaller particles accumulate within the 
interstitium due to the EPR effect.  
 Although these factors may all result in increased levels of Dox delivery, 
these levels may still be below therapeutic levels. The loading of more potent 
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chemotherapeutics may prove useful in overcoming this obstacle. For example, initial 
work using 3-Bromo-Pyruvate, a highly toxic, but also highly effective 
chemotherapeutic has been experimented with and preliminary results are shown in 
Appendix A. Finally, additional strategies for increasing drug payload are briefly 
discussed in the future works section of this thesis.  
 
4.6.4 Conclusions of in vivo Delivery to a VX2 Tumor Model 
 
Results from this acute in vivo delivery study show that the platform is 
capable of delivering drug to a focused region using ultrasound, while reducing blood 
plasma levels and decreasing systemic toxicity through microencapsulation of the 
drug. In vivo studies using VX2 tumors showed the platform combined with US 
resulted in nearly a 50% decrease in drug levels within the healthy, non-targeted areas 
of the liver, and a 110% increase in drug levels within the peripheral of the tumor. In 
addition the levels of Dox in the heart and other measured organs were attributed to 
unruptured capsules or large fragments (there was no measurable serum level after 10 
mins) effectively protecting the sensitive cardiomyocytes and particularly keeping the 
Dox away from the cardiac mitochondria, the acknowledged site of cardiotoxicity 
[144]. 
These studies show promise for a delivery vehicle for creating drug loaded NP 
in situ using external, focused ultrasound. However, further biodistribution and 
survival studies are needed examining the mechanisms of particle penetration to the 
tumor interstitial and their ability to provide a sustained release during degradation to 
determine if the Dox loaded platform can successfully used to treat solid tumor 
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5. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
 
 
5.1 Conclusions and Contributions to Science 
 
The overall objective of this thesis was the development and verification of a 
chemotherapeutic loaded UCA capable of locally delivering Dox to a solid tumor 
while minimizing systemic toxicity.  
 Three PLA UCA have been developed containing Dox either within the shell 
or on the surface of the agent. A method of encapsulating Dox within the shell of the 
agent has been selected due to the agent’s superior in vitro enhancement, minimal 
burst effect upon resuspension, and minimal cell death in vitro prior to ultrasound 
activation. Additionally, the agent has proven to be as efficacious as Dox after 
ultrasound activation in a human breast cancer cell line in vivo.  
A method of sterilization using oxygen plasma has been developed and 
optimized allowing investigation of these agents in vivo. The described method is the 
first documented method for sterilization of UCA post fabrication that does not 
compromise the acoustic properties of the agent and represents a highly significant 
breakthrough for small scale in vivo studies.  Additionally, surface modification of the 
agent during plasma sterilization creates possibilities of surface modification for 
future drug delivery and targeting applications.  
Mechanisms of delivery have been investigated both in vitro and in vivo. 
Upon sonication, the Dox loaded agent has been shown to rupture, resulting in Dox 
loaded PLA fragments small enough to pass through tumor vasculature. This is a 
novel concept in ultrasound triggered drug delivery. Effects of insonation time and 
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pressure have been examined on particle fragmentation and confirmed using electron 
microscopy. Additionally PLA-Dox fragments appear to be preferentially transported 
to the cell nucleus (the location of Dox action) after cell uptake. While competing 
drug loaded UCA platforms result in immediate release of free drug within the 
vasculature which may be washed out during blood replenishment, fragmentation of 
our agent is believed to transport encapsulated drug into the tumor interstitium. This 
approach would represent a significant improvement by providing a sustained, 
intratumoral release of drug over a three week period (confirmed by in vitro elution 
studies). Further, the “nano shards’ have been shown in vitro to be readily taken up 
and processed by cells, resulting in high nuclear Dox levels. 
In vivo transport of Dox to a VX2 tumor model using the platform is increased 
by 110% when combined with ultrasound relative to the uninsonated controls. As 
expected, encapsulation of Dox results in a significant reduction of a bolus release of 
free Dox within the serum, an important factor when limiting systemic toxicity. In 
addition the levels of Dox in the heart were attributed to unruptured capsules or large 
fragments (there was no measurable serum level after 10 mins) effectively protecting 
the sensitive healthy tissue by restricting drug to the vascular system.  
These results represent major advances in the field of ultrasound triggered 
drug delivery. The platform has demonstrated how polymeric UCA can be used for 
localized, ultrasound triggered cancer therapy. Future work is expected to combine 
targeting as well incorporation of alternative drugs for a more targeted, potent 
therapy.   
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5.2 Future Recommendations 
 Several opportunities for future research using the discussed delivery platform 
exist. While the current platform has proven to be a major improvement over 
traditional chemotherapy, the platform still relies on a systemic, non-targeted 
distribution of agent prior to activation. The addition of targeting ligands, discussed in 
the literature, may allow development of agents with a greater affinity for the area of 
need, improving delivery efficiency. Additionally, future work should investigate 
delivery of alternative drugs (discussed briefly in Appendix A). Future work 
examining the platform’s ability to deliver a variety of therapeutics or genetic 
material may prove invaluable for future applications.  
 Within the thesis itself, several areas of future improvement exist. Within 
specific aim 1, future research on increasing Dox loading may be beneficial. 
Combination of methods, drug layering, loading within the core of the agent, or 
addition of drug loaded NP to the UCA may all potentially be used for increasing 
payload. Fabrication of an agent with higher drug payloads still capable of delivering 
encapsulated drug to a tumor interstitial would constitute an important improvement 
for the delivery platform. 
 Within specific aim 3 we initiated the attempt to create a successful biological 
in vitro model to demonstrate Dox-PLA transport across an endothelial cell-polyester 
membrane. The described model involves covering 400 nm pores with cells rather 
than creation of vascular gap junctions similar to those seen in tumor vasculature. 
Creation of a more realistic, dynamic model would provide an opportunity for in vitro 
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optimization of shard delivery as well as means for future studies in transport 
mechanisms. 
 Finally, within specific aim 4, longer trial times, larger sample sizes, and 
varying tumor and animal models will all help to better demonstrate the platform’s 
efficacy, leading to future translation to the clinic. A current study using a Morris 
Liver Hepatoma model is being conducted with hopes of showing the platform’s 
efficacy and further evidence of PLA nanoshards delivery. 
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Appendix A: Fabrication of PLA UCA with Alternate 
Chemotherapeutics 
 
 
Oxaliplatin, irinotecan, 5-FU (also known as flurouracil), and 3-
bromopyruvate were briefly investigated as potential chemotherapeutics to be 
delivery via delivery platform proposed in this thesis. All four compounds are 
hydrophilic chemotherapeutics with molecular weights from 130-677 g/mol, and are 
used to treat a wide variety of cancers. Drug loading was performed using the 
incorporation method (I-Dox-UCA) described in this thesis at a loading concentration 
of 2% (g drug / g polymer).  Acoustic testing and encapsulation efficiency were 
performed as described in the methods section of this thesis. Samples and testing 
were performed with assistance from Rekha Kambhampati, Jen Hsu, Phyllis Huang, 
and Nicole Cohen.  
 Effects of drug loading on in vitro ultrasound enhancement were investigated 
for all five chemotherapeutics. These results are shown in Fig. AA.1. Dox, 
oxaliplatin, irinotecan, 5-FU, and 3-bromopyruvate all showed similar in vitro 
enhancement with no significant statistical variance (p>0.05).  While Dox loaded 
samples provided peak enhancement, all drug loaded samples showed enhancement 
of over 16 dB. 
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Figure AA.1: Effects of 2% drug loading on in vitro ultrasound enhancement. Do x, 
Oxaliplatin, Irinotecan, 5-FU, and 3-Bromopyruvate all showed similar enhancement (p>0.05) (n=3, 
error bars= SEAM). 
 
Stability of each agent during continuous insonation was measured and 
compared to Dox loaded samples. These results are shown in Fig. AA.2. No 
significant changes in UCA stability were seen between Dox, oxaliplatin, irinotecan, 
5-FU, and 3-bromopyruvate loaded samples. All samples lost between 37-41% of 
their original enhancement, consistent with the Dox incorporation results discussed in 
this thesis.  
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Figure AA.2: Effects of 2% drug loading on in vitro stability during insonation. Dox, 
Oxaliplatin, Irinotecan, 5-FU, and 3-Bromopyruvate all showed similar normalized enhancements, 
losing between 37-41% of their original enhancement over 15 mins (n=3, error bars= SEAM). 
 
 Encapsulation efficiency of 2% loading (g drug/ g polymer) was measured for 
Dox, irinotecan, and 5-FU were measured and compared. These molecules are 
naturally fluorescent and can be measure with a standard fluorimeter. Oxaliplatin and 
3-bromopyruvate were omitted due to their need for additional high performance 
liquid chromatography columns for accurate measurement.  Results of measured 
encapsulation efficiency are shown in Fig. AA.3. Dox, irinotecan, and 5-FU all 
showed similar encapsulation efficiencies, within a range of 23.7 to 26.3%.  
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Figure AA.3: Effects of choice of chemotherapeutic using 2% drug loading incorporation (I-
Dox-UCA) on encapsulation efficiency. Dox, irinotecan, and 5-FU all showed similar encapsulation 
efficiencies (p>0.05), ranging from 23.7 to 26.3% (n=3, error bars= SEAM). 
 
 While this brief fabrication study has not gone into the full detail as the 
development of a Dox loaded agent described in this thesis as a model drug, it 
reinforces the belief that the delivery platform described can be used for multiple 
chemotherapeutics. In the future, the platform may be used for delivery of 
chemotherapeutics other than Dox, or potentially combinations of multiple drugs as 
needed. 
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Appendix B: Visualization of I-Dox-UCA Destruction using Real-
time and High Speed Microscopy 
 
 Preliminary studies confirming I-Dox-UCA destruction and investigating 
potential modes of rupture were performed at Erasmus Medical College, Rotterdam, 
The Netherlands with generous assistance from Klazina Kooiman, Marcia Emmer, 
and Nico de Jong. Two mg of UCA were suspended in 1 ml PBS before being 
injected into an Opticell cassette containing 10 ml of room temperature PBS.  The 
Opticell was held on the surface of a water bath. A 5MHz focused transducer 
connected to a function generator was used submerged beneath the Opticell and 
focused on the film’s surface.  A camera collecting images at 30 frames per second 
(fbs) was focused about the focal region of the transducer. Fluorescent images were 
also obtained using the same setup in combination with a fluorescent bulb and FITC 
filter.  
 Fig. AB.1 shows brightfield images of 3% I-Dox-UCA prior to (top picture) 
and post (bottom picture) insonation by a 10 cycle, 5 MHz pressure wave with peak 
negative amplitude of 520 kPa.  From these images, the exact mechanisms of UCA 
destruction are not clear, although they are clearly sensitive to the ultrasound wave.  
Ultrasound triggered destruction of the agent is clearly present; roughly 50% of the 
UCA appear to destruct, either through shriveling or disappearing completely.   
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Figure AB.1: Brightfield image of 3% I-Dox-UCA prior to insonation (top) and immediately after a 
10 cycle, 5 MHz pulse with peak negative amplitude of 520 kPa (bottom). Frame rate= 30 fps, 
magnification= 60X. 
  
Figure AB.2 shows fluorescent images of 3% I-Dox-UCA prior to (top 
picture) and post (bottom picture) insonation by a 10 cycle, 5 MHz pulse with peak 
negative amplitude of 520 kPa (bottom). The white regions within the images show 
the naturally fluorescent Dox on and within the shell. Prior to insonation, two UCA 
appear (both roughly 2 µm in diameter). However, post ultrasound triggering only 
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one of the UCA remained.  Similar to the brightfield image, the modes of UCA are 
still unclear. However, the sensitivity of the agent to ultrasound is again 
demonstrated.  
 
 
 
 
Figure AB.2: Fluorescent image of 3% I-Dox-UCA prior to insonation (top) and immediately after 10 
cycle, 5 MHz pulse with peak negative amplitude of 520 kPa (bottom). Frame rate= 30 fps, 
magnification= 60X, fluorescence imaged with a FITC filter. 
 
 High speed imaging (20 Mfps) was used to detect possible mechanisms of I-
Dox-UCA destruction using the Brandaris 128 digital camera. Imaging with the 
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Brandaris allows collection of up to 25 million fps with a resolution of 36 lp/mm 
using a customized rotating mirror camera which is well described in the literature 
and has previously been used to image UCA destruction [145, 146].  One mg of 3% I-
Dox-UCA was suspended in 10 ml of room temperature PBS within an Opticell 
cassette. The Opticell was held on the surface of a water bath. A 2.25 MHz focused 
transducer connected to a function generator was used submerged beneath the 
Opticell and focused on the film’s surface. A function generator connected to the 
transducer was used to produce 2.25 MHz, 16 cycle pulse with peak negative pressure 
amplitudes of 250 kPa. High speed images were taken during insonation, stored and 
later analyzed using NIH’s ImageJ. While UCA rupture could not be achieved due to 
the systems lower acoustic output settings, microbubble oscillation was observed for 
greater than 50% of agents.  Figure AB.3 shows a time sequence of an oscillating I-
Dox-UCA. Each step between images represents 6 frames, equating to roughly a 0.3 
µs time step. The bubble diameter was found to be 2.6 µm using ImageJ software. 
Unlike lipid UCA oscillations described in the literature [61, 146], the I-Dox-UCA 
shell appeared to flex about surface defects within the shell. It is believed that this 
flexing eventually leads to shell fragmentation, Dox loaded PLA fragments on the 
nano scale.  
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Figure AB.3: Micrographs of 3% I-Dox-UCA in 0.3 µs increments during a 2.25 MHz, 16 cycle pulse 
with peak negative pressure amplitudes of 250 kPa. Oscillations about a point on the shell (top of 
UCA) were seen showing the sensitivity of the agent to ultrasound as well as a potential mode of UCA 
fragmentation. Frame rate= 20 Mfps, magnification= 60X, UCA diameter= 2.6 µm. 
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Appendix C: Effect of Polymer Molecular Weight and End Capping 
on Poly Lactic-co Glycolic Acid UCA 
 
Poly lactic-co-glycolic UCA have previously been developed in our 
laboratory [57, 147] using the UCA fabrication method described in the methods 
section of this thesis. While PLGA provides a less stable UCA to work with due to its 
lower glass transition temperature, the polymer’s lower hydrophobicity can results in 
higher Dox payloads compared to PLA. Additionally, previous studies in our 
laboratory have indicated rough surface morphology may be better for targeting 
applications. 
Optimization of polymer choice provides a potentially superior UCA for 
imaging purposes (in terms of enhancement and stability) as well as an alternative 
potential drug loading and delivery platform. The ability to custom surface 
morphology may also be useful for future targeting studies. Particle sizing, zeta 
potential measurements, electron microscopy, and acoustic testing were all performed 
as described in the methods section of this thesis.  The following results have been 
published in Polymer Engineering & Science [132]. 
All 50:50 poly (lactic-co-glycolic acids) were purchased from Lakeshore 
Biomaterials (Birmingham, Al). Non-end capped polymers (molecular weights = 
12.4, 53.5, 66.0, 73.8, 84.8 kDa) had a free carboxylic acid terminal group, and end 
capped polymers (molecular weights = 9.1, 35.4, 47.8, 82.6 kDa) had an ester (lauryl) 
terminal end group. Poly (vinyl alcohol), 88% mole hydrolyzed, with a MW of 25 
kDa and camphor were purchased from Sigma-Aldrich (St.Louis, MO). Ammonium 
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carbonate was purchased from J.T. Baker (Phillipsburg, NJ). All other chemicals 
were reagent grade from Sigma Chemical Company (St.Louis, MO). 
 
Effect of PLGA Molecular Weight on Ultrasound Enhancement and Stability 
 Differences in molecular weight of PLGA used in the shell preparation were 
investigated in order to determine the effects on UCA enhancement and stability. 
Figures AC.1 and AC.2 show the enhancement and stability of the non-end capped 
PLGA varying the polymer molecular weight. 
 
Figure AC.1: Backscattering enhancement as a function of sample dosage for each of 5 samples of 
varying molecular weight, non-end capped PLGA. Samples reached a maximum enhancement of 19 
dB at a molecular weight of 66.0 kDa and a dose of 10 µg/ml. 
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Figure AC.2: Normalized enhancement over time for each of 5 samples of varying molecular weight, 
non-end capped PLGA. Samples reached a maximum stability at 66.0 kDa, losing roughly 38% of 
signal enhancement over 15 minutes of insonation.  
 
 Similar experiments were performed for PLGA polymers of varying weight 
with an ester (lauryl) end capping.  Only four different molecular weights were used 
consistent with the availability of polymers. These results are shown in Figures AC.3 
and AC.4. 
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Figure AC.3: Backscattering enhancement as a function of sample dosage for each of 4 samples of 
varying molecular weight, end capped PLGA. Samples reached a maximum enhancement of 20 dB at a 
molecular weight of 82.6 kDa (the highest molecular weight available) and a dose of 14 ug/ml. 
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Figure AC.4: Normalized enhancement over time for each of 4 samples of varying molecular weight, 
end capped PLGA. Samples reached a maximum stability at 82.6 kDa, the highest available molecular 
weight, losing roughly 20% of signal enhancement over 15 minutes of insonation.  
 
Both enhancement and stability for each set of polymer varied with polymer 
molecular weight. These variations were seen to be statistically significant with α 
=0.05. While both polymer types gave similar enhancements at high molecular 
weights (19 dB above 80 kDa), the esterified polymer produced less echogenic 
capsules at low molecular weights (6 dB for 9.1 kDa compared with ~11 dB for 12 
kDa) although direct comparison at exactly equal molecular weights was not possible.  
As would be expected, a direct correlation was seen between contrast agent 
enhancement and stability under constant insonation.  For example the least 
echogenic preparation was found for the capsules prepared using non-end capped 
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polymer of molecular weight 12.4 kDa, which was found to have a half life of only 2 
minutes (figure AC.2) when insonated at 5 MHz.  Microbubbles with smooth, 
spherical morphology are expected to provide optimal enhancement due to their 
ability to oscillate uniformly under pressure waves. Smooth, spherical agents will also 
have minimum surface area exposed to the aqueous environment and are therefore 
less susceptible to both hydrolysis and rupture. Therefore this correlation is expected 
and confirmed later by SEM imaging of agent morphology. 
In order to better gauge the trends amongst polymer type and the differences 
between end capped and non-end capped groups, maximum enhancement was 
graphed with sample molecular weight. These results are shown in figure AC.5 and 
were found to be statistically different.  
 
Figure AC.5:  Maximum enhancement as a function of polymer molecular weight, end capped vs. 
non-end capped PLGA.  Non-end capped PLGA peaked at 66.0 kDa with an enhancement of 19 dB, 
while the end capped samples a linear relationship, peaking at 20 dB. (Dosages taken from maximum 
enhancements determined in Figures AC.1 and AC.3) 
 179
 
While each polymer set reached similar maximum enhancement at a given 
molecular weight as shown in Figures AC.1 and AC.3, the non-end capped samples 
rose to a maximum enhancement of 19 dB at the highest commercially available 
molecular weight of 82.4 kDa.  A positive, linear relationship was seen between 
molecular weight and maximum enhancement for end capped PLGA, indicating that 
enhancement of greater than 20 dB may be achievable. However, lack of availability 
of polymers prevented samples from being made from polymer with molecular 
weight greater than 82.6 kDa.   
Separately, the non-end capped PLGA peaked at an enhancement of 19 dB, 
then rapidly declined for higher molecular weights.  This may be explained by 
stronger interactions between non-end capped monomers at higher molecular weight 
either prohibiting the formation of fully spherical capsules or damping shell 
oscillations under pressure. The end capped polymer’s lack of a peak at these 
molecular weights may be indicative of weaker monomer interactions, allowing for a 
more fully formed shell. These results are confirmed by SEM images later. 
 
Effect of PLGA Molecular Weight on Surface Morphology 
A set of SEM images for non-end capped PLGA varying molecular weights 
are shown in figure AC.6, and a corresponding set of end capped PLGA samples are 
shown in figure AC.7. 
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Figure AC.6: SEM images for four molecular weight non-end capped PLGA samples. (a) 12.4 kDa, 
(b) 53.5 kDa, (c) 66.0 kDa, (d) 84.8 kDa. Smoothest surface morphology was seen for the molecular 
weight giving optimum ultrasound enhancement and highest level of stability (66.0 kDa). (Size bar = 
10 µm) 
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Figure AC.7: SEM images for four molecular weight end capped PLGA samples. (a) 9.1 kDa, (b) 
35.4 kDa, (c) 47.8 kDa, (d) 82.6 kDa. Perfectly smooth surface morphology was never reached, but 
was closest at the highest molecular weight sample (82.6 kDa). These results indicate higher molecular 
weight polymer may be optimal. (Size bar = 10 µm) 
  
A strong connection between polymer molecular weight and surface 
morphology was seen. In both cases the low molecular weight polymer (9.1 kDa 
AND 12.4 kDa) produced highly crenellated capsules.  The smoothest surface 
morphology was obtained with non-end capped polymer at 66 kDa.  Similarly, 
molecular weight appears to influence the range in size of the capsules, for example 
comparing end capped samples made from 35.4 kDa and 47.8 kDa polymer, there is 
visual evidence of a sizable population of sub micron capsules in the higher 
molecular weight sample than in the 35.4 kDa sample.   Each sample set (end capped 
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and non-end capped) showed morphologies trending toward a peak surface 
smoothness at the same molecular weights that gave both optimal UCA enhancement 
and stability.  Spherical particles will allow a greater degree of resonance under 
ultrasound pressure waves without destruction, yielding greater ultrasound 
enhancement. Additionally, smoother particles will have fewer surface defects and a 
smaller exposed surface area, making them less susceptible to ultrasonic rupture and 
to hydrolysis, rendering them more stable. 
 
Effect of PLGA Molecular Weight on Particle Size and Zeta Potential  
 Particle size was measured to ensure clinically acceptable particle sizes and to 
examine possible trends among and between polymer molecular weight and end 
capping.  For either polymer type, contrast agent mean number size was not seen to 
depend on molecular weight.  Non-end capped samples showed a mean number size 
at 1.62 +/- 0.52 µm, while end capped samples showed a mean number size at 1.45 
+/- 0.38. These sizes were not found to be statistically different. However, molecular 
weight was seen to have a large influence on the polydispersity index (PDI) of the 
sample as was noted in the SEM images in figures AC.6-7.  PDI results for each 
polymer and molecular weight are listed in Table AC.1. 
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Table AC.1: Summary of Maximum Enhancement, Polydispersity, and Zeta 
Potential of End Capped PLGA 
Molecular Weight 
(kDa) 
Maximum 
Enhancement (dB)
Polydispersity 
Index 
Zeta Potential 
(mV) 
9.1 8.1 +/- 1.20 0.95 +/- 0.03 -32.97 +/- 1.05 
35.4 12.95 +/- 0.97 0.63 +/- 0.03 -38.70 +/- 0.36 
47.8 15.53 +/- 0.94 0.47 +/-  0.03 -40.83 +/- 3.36 
82.6 * 19.83 +/- 0.46 0.26 +/- 0.02 - 31.73 +/- 1.80 
Non-End Capped PLGA 
Molecular Weight 
(kDa) 
Maximum 
Enhancement (dB)
Polydispersity 
Index 
Zeta Potential 
(mV) 
12.4 11.49 +/- 1.64 0.81 +/- 0.11 -29.93 +/- 1.72 
53.6 15.15 +/- 1.13 0.72 +/- 0.04 -26.07 +/- 1.54 
66.0 * 19.03 +/- 0.54 0.60 +/- 0.09 -22.37 +/- 2.00 
73.8 17.52 +/- 1.70 0.31 +/- 0.07 -30.43 +/- 3.06 
84.8 15.63 +/- 0.39 0.55 +/- 0.05 -33.63 +/- 2.25 
 
Table AC.1: Results of maximum attainable enhancement (dB), PDI, and zeta potential (mV) for each 
polymer set of molecular weights.  (* = molecular weight resulting in maximum ultrasound enhancing 
UCA) 
 
 
As the molecular weight of the sample approaches the point for highest 
ultrasound enhancement and smoothest surface morphology, the PDI reaches its 
maximum value, indicating the tightest size distribution.  The two polymer sets show 
identical slopes, but the end capped set ultimately reaches a much tighter distribution 
than the non-end capped sample set. Therefore, although molecular weight and end 
capping do not affect the peak number size of the UCA, they do play a significant 
role in the overall size distribution.  It is also important to note that all these 
distributions are still within the size requirements discussed in the introduction. 
 Zeta potential was initially measured to determine the aggregation properties 
of the contrast agents in solution. These results are also tabulated in table 1. Non-end 
capped PLGA UCA showed a statistically significant higher zeta potential, indicating 
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a more hydrophobic sample set, more prone towards flocculation. This may be 
explained by the orientation of the polymer strands and the ability of a non-end 
capped microbubble to have an exposed carboxyl group. 
 Unexpectedly, each polymer set showed a peak zeta potential at the same 
molecular weight that yielded a peak acoustic enhancement. This behavior may be 
explained by the surface morphology results. Each set of polymers showed very 
smooth morphology at the molecular weight exhibiting peak enhancement. This 
results in a minimal exposed surface area and a potentially larger electrical double 
layer, yielding zeta potentials closer to zero. Additionally, fuller formed microbubbles 
may be slightly more buoyant, influencing zeta potential measurements.  
 
Conclusions 
Effects of PLGA molecular weight and end capping have been documented 
for UCA formulated with a double emulsion method. A strong correlation was 
noticed between UCA enhancement, stability, surface morphology and zeta potential.  
Optimum molecular weight for non-end capped PLGA was found to be 66.0 kDa, 
after which ultrasound parameters were seen to decrease. Optimum molecular weight 
for end capped PLGA was not determined, but peaked at the highest commercially 
available polymer molecular weight of 82.6 kDa, giving rise to the possibility of 
higher performance UCA with higher molecular weight polymers.  This study has 
shown that these parameters can be influenced by polymer molecular weight and end 
capping and can be tailored to suit a particular application. 
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Appendix D: Standard Operating Procedures 
 
I: Protocol for Fabrication of PLA Ultrasound Contrast Agents  
The following protocol is used for production of plain, PLA UCA. It has been 
reproduced by permission from Kelleny Oum.[148]. Modifications have been made 
for fabrication of drug loaded PLA UCA and are detailed in the methods section of 
this thesis.  
1. Weight out the following chemicals: polymer (0.5g, record lot number as 
well), and porogens ammonium carbamate (0.78g) or ammonium carbonate 
(0.4g) and camphor  (0.05g-if used)  
a. Note: Polymer should always be brought to room temp. before 
opening so that condensation does not form on the beads and cause 
degradation. For convenience you should take ~5g out of the stock 
solution and place it in a sealed glass vial in the refrigerator.  
2. Combine the polymer and 10ml of methylene chloride in a beaker (40ml max 
volume) with a stir bar and stir on a magnetic stir plate, cover with a layer of 
wax paper topped by a layer of parafilm, until camphor and polymer are 
dissolved (~15min). 
a. Note: The ratio of polymer to solvent is important. If the cover opens 
during stirring, some methylene chloride may evaporate. You should 
be careful, but if needed you can add more methylene chloride to bring 
the level to 10ml after stirring. Also, remember to wear gloves when 
using methylene chloride.   
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3. Combine porogen with 10ml of deionized water in a beaker (40ml max 
volume) with a stir bar and stir on a magnetic stir plate. 
4. Measure out 50ml of 5% poly vinyl alcohol (PVA) and put it in a beaker 
(600ml max volume) and place it in the refrigerator. 
5. Measure out 100ml of 2% isopropyl alcohol (IPA) and keep it in the 
graduated cylinder. 
6. When the camphor and polymer are dissolved, remove stir bar and put in 1ml 
of the porogen solution and sonicate with Misonix probe sonicator at 110W 
for 30 seconds. Sonicate in an ice bath 3 seconds on 1 second off. 
7. After sonication, pour the solution into the cold PVA and homogenize with 
Brinkmann PT 3100 homogenizer with attached Polytron PT-DA 3020/2 
generator for 5 minutes at 9,500 rpm. 
8. After homogenization, pour the 100ml of IPA in the solution, add a larger stir 
bar, and stir on a magnetic stir plate for 1 hour.  Make sure the vortex spans 
the diameter of the beaker so the solvent can fully evaporate. 
a. After homogenization remove the blade and pour the IPA over it into 
the beaker to prevent the loss of yield. 
9. After an hour, combine the solution in at least 4 centrifuge tubes (50ml max 
volume) and then centrifuge for 5 minutes at 5,000 rpm (the equivalent of 
approximately 5,000 g). 
10. Decant the liquid and combine the microcapsules into 1 tube and recentrifuge 
for 5 minutes at 5,000 rpm. 
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11. Decant the liquid and wash the microcapsules three times with hexane. Lay 
the centrifuge tube under the hood and let excess solvent evaporate for about 
30 min. 
12. When the microcapsules appear to be thick and pasty, add water and 
recentrifuge for 5 minutes at 5,000 rpm.  
13. Decant the water, mix (fluff) the microcapsules, put a kimwipe on top of the 
tube with a rubber band, and flash freeze using nitrogen (swirling the tube in 
nitrogen to create a cone shaped pellet). 
14. Put the frozen microcapsules in a freeze dryer vessel and on the freeze dryer 
for at least 48 hours. 
 
II: Protocol for Conducting Dose and Time Responses 
The following protocol is used for acoustic characterization of the UCA. It has 
been reproduced by permission from Kelleny Oum [148]. Measurements include 
contrast enhancement as a function of UCA dosage (Dose Response), and stability of 
the agent during continuous insonation (Time Response).  
 
For Dose Response: 
1. Weigh out 3mg of contrast agent and suspend it in 200µl of Phosphate 
Buffered Saline (PBS pH 7.4).  This is your stock solution. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser/receiver, and focus the sample vessel.  
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3. For each dose, starting with 0.003mg/ml, inject 20µl of stock solution into the 
sample vessel and begin the LabView computer program. 
4. Run the program. 
5. For the next dose, 0.006mg/ml, inject another 20µl of stock solution into the 
sample vessel.  Do not remove the original contents if this is a cumulative 
dose response. 
6. Continue dose response up to 0.03mg/ml or until shadowing is evident. 
 
Computer Operation for Dose Response: 
1. Create a folder with appropriate subfolders. 
2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
3. Using the open file program, choose a directory path in which the data should 
be saved by opening the folder path, selecting which folder to save the data in, 
and hitting select current directory. 
4. To begin taking the dose response, push the Run button. 
5. When completed, to view the results, first under the Analyze Data tab, push 
Export Calculated Text and chose a folder to save the data to. 
6. To view results, open up the dose data file using Excel and the enhancement 
in will be displayed for each dose in mV and dB.  
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For Time Response: 
1. Choose dose on the dose response curve that is not the maximum (it should be 
on the linear (rising) part of the curve) and prepare a solution of that 
concentration, using procedure described above in the dose response section. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser, and focus the sample vessel.  
3. Inject dose into the sample vessel and begin the LabView computer program 
(Main Ultrasound Program.vi). 
4. Run the program for 15 minutes. 
 
Computer Operation for Time Response: 
1. Create a folder with appropriate subfolders. 
2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
3. Using the open file program, choose a directory path in which the data should 
be saved by opening the folder path, selecting which folder to save the data in, 
and hitting select current directory. 
4. To active Time Response, select button next to “Capture waveform on set 
time interval” and set the interval and number of time points to acquire. 
5. Hit run button to begin Time Response. 
6. To view the results when completed, go to the Analyze Data tab, select Export 
Calculated Text and chose a folder to save the data to. 
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7. To view results, open up the time data file using Excel and for each minute the 
enhancement will be given in mV and dB.  
 
III: Protocol for Measuring UCA Size and Zeta Potential 
 The following protocol is used to measure size distributions and zeta potential 
of UCA in solution using Malven’s Zetasizer Nano ZS. Size distribution is important 
in understanding an UCA size and safety, while zeta potential is useful in 
understanding the agent’s surface charge and tendency to flocculate in suspension 
1. Ensure Malvern Zetasizer is connected to CPU via USB cable, turn machine 
on and open software program DTS (Nano). 
2. Create a new data file by selecting ‘File -> New Measurement File’. 
3. Suspend 1 ml of dry agent in 1 ml of solution (PBS for size measurements, DI 
water or a low ionic strength buffer for zeta potential measurements). 
For Size Measurements: 
1. Pipette 1 ml of suspended UCA solution into clear plastic rectangular Malvern 
cuvette. 
2. Select measurement protocol by selecting Measure-> SOPs -> Size-> PLA 
Microspheres. 
3. Click “Start” in protocol window. 
4. Data will be saved in data measurement file and can be exported using File -> 
Export. 
5. Size cuvettes can be reused between samples, but are disposable and should 
be thrown away after days use. 
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For Zeta Potential Measurements: 
1. Pipette 1 ml of suspended UCA solution into clear plastic Malvern Zeta 
Potential Capillary cuvette. 
2. Select measurement protocol by selecting Measure-> SOPs -> Zeta-> PLA 
Microspheres. 
3. Click “Start” in protocol window. 
4. Data will be saved in data measurement file and can be exported using File -> 
Export. 
5. Zeta potential capillaries are reusable and can be rinsed with DI water for 
future use. 
 
IV: Protocol for Plasma Sterilization of PLA UCA 
 Plasma sterilization of UCA is necessary for and in vitro work with cells to 
avoid cell contamination or any long term animal studies. The plasma sterilizer is 
located in Dr.Sun’s laboratory (Mechanical Engineering) on the 3’rd floor of 
Bossone. 
1. Ensure oxygen tank is connected to sterilizer 
2. Clean our sterilization chamber using alcohol and a Kim wipe.   
3. Check oil level on front of vacuum pump. If low, fill to oil line. 
4. Turn on oxygen and fill chamber for 3 minutes. 
5. Insert 0-40 mg of dry agent enclosed within a 1” Petri dish covered and held 
closed with masking tape into sterilization chamber. 
6. Close chamber, replace oxygen connection, and turn on pump for 1 minute. 
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7. Turn oxygen off. 
8. Turn plasma RF coil power on and set power level to high. 
9. Once chamber begins to glow purple, start timer. 
10. Sterilize for 3 minutes on the machine’s high power setting. 
11. After 3 minutes turn machine off, vent chamber and remove samples 
12. After sterilization, samples should be stored under sterile hood until use. 
 
V: Protocol for Measurement of 14C with Liquid Scintillation 
 Liquid scintillation counting (LSC) is used as a measurement of radioactivity. 
Beta particles emitted from radioactive material transfer energy in aromatic solvents. 
These solvents then produce photons, which can be detected using a scintillation 
counter. The following protocols are used for the determination of amounts of 
radioactivity in I-Dox-UCA, blood serum, and tissue samples. All three protocols 
should be performed using radiation safety approved safety measures. 
 
Determination of 14C in I-Dox-UCA 
1. Four milligrams of dry radioactive I-Dox-UCA are suspended in 10 mL of 
Ultima Gold scintillation cocktail (Perkin Elmer) within a 20 ml scintillation 
vial (Fisher Scientific) in triplicate. 
2. The samples are then vortexed for 5 minutes to ensure complete suspension of 
the UCA. 
3. After suspension, vials are read using a Packard 1900 CA scintillation counter 
for 2 minutes using the machines 14C protocol. 
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4. Results are automatically adjusted for quenching by the machine’s quenching 
algorithm and reported as disintegrations per minute (DPM).  
5. DPM can then be then converted to Cu using 1 Cu =2.22 E12 DPM. 
6. Vials should be stored as dry radioactive waste before being picked up by 
Drexel’s Radiation Safety Department. 
 
Determination of 14C in Blood Serum Samples 
1. Two hundred micro liters of blood serum is added to 0.5 ml of tissue solvent 
(Perkin Elmer) and 0.5 ml of isopropyl alcohol (Fisher Scientific) and 
incubated at 60oC for 30 minutes.  
2. After incubation, 0.2 ml hydrogen peroxide is added and shaken on a bench 
top shaker for 30 minutes. 
3. The samples are then incubated at 60oC for 30 minutes.  
4. Ten milliliters of scintillation cocktail (Ultima Gold, Perkin Elmer) are added 
to each vial and vortexed for 30 seconds.  
5. Scintillation vials should be allowed to adapt to light for one hour prior to 
being read. 
7. Vials are then read using a Packard 1900 CA scintillation counter for 2 
minutes using the machines 14C protocol. 
8. Results are automatically adjusted for quenching by the machine’s quenching 
algorithm and reported as disintegrations per minute (DPM).  
9. DPM can then be then converted to Cu using 1 Cu =2.22 E12 DPM. 
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10. Vials should be stored as dry radioactive waste before being picked up by 
Drexel’s Radiation Safety Department. 
 
Determination of 14C in Tissue Samples 
1. Harvested tissue samples (organs and tumor samples) should be cut into 50-
100 mg samples in triplicate and placed in 20 ml scintillation vials. 
2. Tissue samples are then mixed with 2 ml of tissue solvent (Perkin Elmer) and 
incubated at 60oC for 3 hours.  
3. After incubation, 0.2 ml of hydrogen peroxide is added and incubated for 30 
minutes at 60oC. 
6. Ten milliliters of scintillation cocktail (Ultima Gold, Perkin Elmer) are added 
to each vial and vortexed for 30 seconds.  
7. Scintillation vials should be allowed to adapt to light for one hour prior to 
being read. 
11. Vials are then read using a Packard 1900 CA scintillation counter for 2 
minutes using the machines 14C protocol. 
12. Results are automatically adjusted for quenching by the machine’s quenching 
algorithm and reported as disintegrations per minute (DPM).  
13. DPM can then be then converted to Cu using 1 Cu =2.22 E12 DPM. 
14. Vials should be stored as dry radioactive waste before being picked up by 
Drexel’s Radiation Safety Department. 
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